2019年，《Cell Research》发表甘露特钠疗效机制，研究者提出了一个全新假说：AD的发生与发展，源于肠道菌群紊乱—免疫失衡—神经炎症这一连锁反应；甘露特钠可通过调节肠道菌群，减少脑部炎症，从而改善认知功能，即“脑肠轴机制”。

这一发现引发国际关注，让世界重新认识了肠道菌群在中枢神经系统中的核心地位，至今已被引录1000余次。美国神经科学协会前主席、美国科学院院士、圣路易斯华盛顿大学David M. Holtzman 教授等发表述评认为，这一靶向肠道菌群治疗AD 的新策略为抗AD 药物的研发提供了全新思路。同年底甘露特钠发明人被《Nature》杂志评为5位“2020年关注人物”之一。

甘露特钠作用机制研究成果以封面文章的形式在《Cell Research》上发表

2021年， 《柳叶刀》（The Lancet）杂志发表AD综述，基于甘露特钠的作用机理和兼具改善症状和改变病程的特征，将甘露特钠归类为可抑制神经炎症的AD疾病修饰疗法。

《柳叶刀》将甘露特钠归类为可抑制神经炎症的AD疾病修饰疗法

2024年，美国圣路易斯华盛顿大学David M. Holtzman教授及芝加哥大学Sangram S. Sisodia教授共同通讯在《分子神经变性》（Molecular Neurodegeneration）发表脑肠轴重磅研究，背对背验证甘露特钠靶向菌群-胶质细胞-淀粉样蛋白轴，减轻神经炎症和Aβ斑块的作用机制。

国际权威专家独立验证甘露特钠作用机制

2024年，美国圣路易斯华盛顿大学David M. Holtzman教授于《实验与分子医学》（Experimental & Molecular Medicine）发表AD与肠道菌群专题综述，提出“健康脑肠轴”与“AD脑肠轴”概念，指出重塑菌群→神经炎症↓→神经元损伤↓是AD脑肠轴的重要干预策略。文中指出，甘露特钠可减少外周免疫细胞向大脑的浸润，抑制神经炎症，认为“调节肠道菌群可能是延缓AD进展的一个有前景的策略”。

David M. Holtzman教授提出“健康脑肠轴”与“AD脑肠轴”概念

以下为甘露特钠被提及/被引用的部分文献列表（后续不断更新中）：

1.  Wang X, Sun G, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression[J]. Cell Res, 2019, 29(10):787-803.

2.  Wang X, Xie Z, Yuan J, et al. Sodium oligomannate disrupts the adherence of Ribhigh bacteria to gut epithelia to block SAA-triggered Th1 inflammation in 5XFAD transgenic mice[J]. Cell Discov, 2024, 10(1):115.

3.  Bosch ME, Dodiya HB, Michalkiewicz J, et al. Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner[J]. Mol Neurodegener, 2024, 19(1):18.

4.  Gong H, Pan J, Guo F, et al. Sodium oligomannate activates the enteroendocrine-vagal afferent pathways in APP/PS1 mice[J]. Acta Pharmacologica Sinica, 2024, 45(9): 1821-1831.

5.  王玲玲, 杨娟, 王涛, 等. 甘露特钠胶囊改善阿尔兹海默病认知障碍并降低神经炎症的机制研究[J]. 河北医科大学学报, 2023, 44(06):629-634+639.

6.  Wang T, Kuang W, Chen W, et al. A phase II randomized trial of sodium oligomannate in Alzheimer's dementia[J]. Alzheimers Res Ther, 2020, 12(1):110. 

7.  Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia[J]. Alzheimers Res Ther, 2021, 13(1):62.

8.  CTAD 2024. LP021- Post-Marketing Study of Sodium Oligomannate: Long-Term Safety and Effectiveness of an Agent Targeting the Gut Microbiome for the Treatment of Alzheimer’s Disease.

9.  Zhang LF, Zhang YP, Lin PX, et al. Efficacy and safety of sodium oligomannate in the treatment of Alzheimer's disease[J]. Pak J Pharm Sci, 2022, 35(3):741-745.

10.  姚晓利,肖卫忠,李楠,等.多奈哌齐联合甘露特钠治疗轻中度阿尔茨海默病的疗效[J].中国新药与临床杂志, 2022, 41(07):412-417.

11.  史璐行,刘巧玲,钱雪芬,等. 甘露特钠联合多奈哌齐治疗轻度阿尔茨海默病的疗效[J]. 中国老年学杂志, 2022, 42(19):4695-4698.

12.  王云霞,李旺俊. 甘露特钠联合多奈哌齐治疗阿尔茨海默病的临床研究[J].现代药物与临床, 2022, 37(10):2258-2262.

13.  宋冬晶,刘斌,钟莺,等.甘露特钠胶囊联合盐酸多奈哌齐片治疗痴呆患者的临床疗效及安全性[J].阿尔茨海默病及相关病杂志, 2022, 5(04):295-299.

14.  王特,赵伟,刘艳,等.阿尔茨海默病采用甘露特钠配合多奈派齐治疗的效果[J].慢性病学杂志, 2023, 24(09):1425-1427.

15.  张黎军,王亚宇,李东丽,等. 甘露特钠联合多奈哌齐治疗阿尔茨海默病的效果及对患者认知功能的影响[J]. 中国实用医刊,2024,51(01)：82-85.

16.  魏红辉,孙宁宁,王越,等. 联用甘露特钠对轻中度阿尔茨海默病患者精神行为症状的疗效研究[J].中国新药与临床杂志, 2024, 43(09):691-695.

17.  钱群花,张群英.甘露特钠联合多奈哌齐治疗老年阿尔茨海默病患者疗效及对认知功能的影响研究[J].罕少疾病杂志,2024,31(06):18-19. 

18.  张颖,于小琪,卢福昌,等. 基于神经递质和肠道菌群探讨露甘露特钠胶囊联合盐酸多奈哌齐片治疗轻中度阿尔茨海默病的疗效[J].现代生物医学进展, 2024, 24(20):3870-3872.

19.  王少艾,曾又晓,黄丽虹.甘露特钠对老年阿尔茨海默病患者认知功能及对血清BDNF、IL-6的影响[J]. 深圳中西医结合杂志, 2024, 34(21):112-115.

20.  霍学智.甘露特钠治疗伴有认知障碍的老年阿尔茨海默病患者的疗效分析[J].中西医结合心血管病电子杂志, 2024, 12(05):33-35+8.

21.  敬泽慧,李晓平.甘露特钠联合盐酸美金刚治疗老年中度阿尔茨海默病的临床效果[J].中国老年学杂志,2024,44(18):4434-4438.

22.  Qi Wang, Wenqi Wu, Yue He, et al. Efficacy of Sodium Oligomannate Capsules Combined with Memantine Hydrochloride and Donepezil Hydrochloride in Treating Moderate Alzheimer’s Disease[J]. Journal of Clinical and Nursing Research, 2025, 9(1): 19-26.

23.  缪默然,袁文林,王立阳.美金刚分别联合甘露特钠与多奈哌齐治疗阿尔茨海默病对其认知功能的影响对比[J].中外医疗, 2024, 43(16):62-65.

24.  Jian Zhao, Xi Li, Xuelian Jia, et al. Clinical Study on the Treatment of Senile Alzheimer’s Dementia with Sodium Oligomannate Combined with Memantine Hydrochloride[J]. Journal of Clinical and Nursing Research, 2024, 8(10): 208-217.

25.  朱志全,李季.甘露特钠胶囊对轻中度阿尔茨海默病的临床疗效及肠道菌群的影响[J].吉林医学, 2025, 46(04):913-915.

26.  夏俊博,焦桂红,李宁,等.甘露特钠联合高频重复经颅磁刺激对阿尔茨海默病患者日常生活能力与智力水平的影响[J].新乡医学院学报, 2024, 41(08):755-761.

27.  罗倩,杨伟.脑深部电刺激联合甘露特钠治疗阿尔茨海默病的疗效及对血清趋化因子CX3CL1及ApoE4水平的影响[J].新疆医科大学学报, 2025, 48(04):482-486+493.

28.  黎晓艳,曾超胜.综合干预疗法联合甘露特钠治疗阿尔茨海默病的临床研究[J].中文科技期刊数据库（全文版）医药卫生, 2022(6):90-93.

29.  吴孟娇,王景信,邵芃,等.甘露特钠胶囊治疗卒中后认知障碍的临床疗效分析[J].航空航天医学杂志,2023,34(06):654-657.

30.  苏冉,郝丕达,王阳,等.甘露特钠联合多奈哌齐治疗卒中后认知障碍的效果观察[J].慢性病学杂志, 2024, 25(02):272-274.

31.  陈红艳,吴硕.甘露特钠联合加兰他敏治疗血管性痴呆的临床研究[J].现代药物与临床,2024,39(03):632-636.

32.  贺瑜,罗兴梅.甘露特钠治疗血管性痴呆1例[J].中国新药与临床杂志, 2022, 41(01):60-62.

33.  徐莉丝,汪子琪,蔡清艳,等. 阿尔茨海默病临床前期主观认知下降患者的诊治1例[J]. 中国临床案例成果数据库,2024,06(01)：E0057-E0057.

34.  翟万庆.甘露特钠改善高龄阿尔茨海默病患者认知功能及日常活动能力1例[J].中国新药与临床杂志, 2022, 41(06):383-384.

35.  邢梦娅.甘露特钠改善经皮冠状动脉介入治疗后急性进展的阿尔茨海默病1例[J].国际老年医学杂志,2023,44(01):121-124.

36.  高静,王伟.甘露特钠改善卵巢癌术后阿尔茨海默病患者认知功能、行为精神症状及生活功能1例[J].中国新药与临床杂志, 2021, 40(11):797-800. 

37.  赵娜,窦荣花. 甘露特钠胶囊联合舒肝解郁胶囊治疗轻度阿尔茨海默病1例. 每周文摘·养老周刊,2023(17):281-283.

38.  戚辰,冯海一,楼之茵.甘露特钠联合多奈哌齐治疗ApoEε3/ε4型阿尔茨海默病1例[J]. 中国新药与临床杂志, 2022, 41(03):189-192.

39.  陶卫群.甘露特钠联合抗精神病药治疗阿尔茨海默病性痴呆的行为精神症状1例[J].中国新药与临床杂志, 2022, 41(06):380-382.

40.  鞠彦秀,孔祥怡,王星懿,等.甘露特钠治疗轻度行为障碍1例[J]. 中国新药与临床杂志, 2022, 41(05):317-320.

41.  杜若南,蔡海鹏,王鑫,等. 以情绪低落、焦虑、夜眠差起病的阿尔茨海默病1例[J]. 中国临床案例成果数据库,2024,06(01)：E2556-E2556.

42.  赵文.甘露特钠治疗阿尔茨海默病伴肠易激综合征1例[J].中国新药与临床杂志,2021,40(10):734-736.

43.  宋冬晶,刘斌,牛剑明.甘露特钠联合多奈哌齐治疗阿尔茨海默病伴排尿障碍1例[J]. 国际老年医学杂志, 2022, 43(04):510-513.

44.  许欣茹,王治国,张国旭,等.甘露特钠联合美金刚、多奈哌齐治疗阿尔茨海默病合并糖尿病1例[J].国际老年医学杂志,2022,43(04):506-509.

45.  尤丰玲,夏高富,蔡静.甘露特钠治疗阿尔茨海默病源性轻度认知障碍合并甲状腺功能减退症-桥本氏甲状腺炎1例[J].国际老年医学杂志, 2023, 44(01):125-129.

46.  古媚,杨苗娟,赵臣勇,等. 甘露特钠治疗阿尔茨海默病伴干燥综合征1例[J]. 临床医药文献电子杂志,2023,10(29):18-21.

47.  孙文昊.甘露特钠联合左乙拉西坦治疗阿尔茨海默病伴发癫痫1例[J].中国新药与临床杂志,2021,40(12):861-864.

48.  贾伟丽,许岱昀,周国平.甘露特钠联合抗癫痫药物治疗阿尔茨海默病伴发癫痫及痴呆行为精神症状患者一例[J]. 脑与神经疾病杂志, 2024, 32(09):580-583.

49.  房立岩,尤丰玲,曹丽平等.甘露特钠联合美金刚和多奈哌齐治疗混合型痴呆1例.国际老年医学杂志,2022,43(06):772-775.

50.  胡秀秀,詹贞,吕冬俊,等.甘露特钠联合美金刚治疗行为变异型额颞叶痴呆1例[J]. 中国新药与临床杂志, 2022, 41(02):125-128.

51.  王文婷,毕新婕,陈鸿旭,等.甘露特钠联合利斯的明治疗路易体痴呆1例[J].国际老年医学杂志,2022,43(06):767-771.

52.  Wang YL, Zhang Y, Xu J. Sodium oligomannate combined with rivastigmine may improve cerebral blood flow and cognitive impairment following CAR-T cell therapy: A case report[J]. Front Oncol, 2022, 12:902301.

53.  谢懂君,吴旭玲,董楝,等.甘露特钠对慢性癫痫大鼠认知功能障碍的影响[J].中国神经精神疾病杂志,2023,49(06):351-356.

54.  Yang X, Zhangyi Z, Yu A, et al. GV-971 attenuates the progression of neuromyelitis optica in murine models and reverses alterations in gut microbiota and associated peripheral abnormalities[J]. CNS Neurosci Ther, 2024, 30(7):e14847.

55.  Chen X, Chen X, Yan D, et al. GV-971 prevents severe acute pancreatitis by remodeling the microbiota-metabolic-immune axis[J]. Nat Commun, 2024, 15(1):8278.

56.  Yu Z, Yang Y, Chan RB, et al. GV-971 attenuates α-Synuclein aggregation and related pathology[J]. CNS Neurosci Ther, 2024, 30(2):e14393.  

57.  Li Z, Liu Y, Wang Y, et al. Sodium oligomannate's amelioration of reproductive and metabolic phenotypes in a letrozole-induced PCOS-like mouse model depends on the gut microbiome[J]. Biol Reprod, 2024, 111(2):361-375.

58.  赵怡琳,李作孝. 甘露特钠对实验性自身免疫性脑脊髓炎小鼠的治疗作用及对肠道菌群和小胶质细胞极化的影响[J]. 中华医学杂志,2024,104(17)：1521-1528.

59.  王敏,韩彦青,高变芳,等.甘露特钠治疗进行性核上性麻痹1例[J].中国实用神经疾病杂志, 2024, 27(10):1311-1315.

60.  王云,柏燕燕,韩伯军. Tau蛋白病分析1例[J]. 中国临床案例成果数据库,2025,07(01)：E0587-E0587.

61.  马彩艳,叶鑫鑫,徐晓阳,等. 1例以精神病性症状为首发症状的抗NMDAR脑炎[J]. 临床医药文献电子杂志,2023,10(40):1-3,78.

62.  Lu J, Pan Q, Zhou J, et al. Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer's disease drug in China[J]. J Pharm Anal, 2022, 12(1):145-155.

63.  Zhang Z, Yang X, Zhang L,et al. Development and validation of LC-MS/MS method for quantitation of sodium oligomannate in human plasma, urine and feces[J]. Bioanalysis, 2023, 15(7):371-390.

64.  Syed YY. Sodium Oligomannate: First Approval[J]. Drugs, 2020, 80(4):441-444. 

65.  Jiang L, Sun Q, Li L, et al. Molecular Insights into the Inhibitory Effect of GV971 Components Derived from Marine Acidic Oligosaccharides against the Conformational Transition of Aβ42 Monomers[J]. ACS Chem Neurosci, 2021, 12(19):3772-3784. 

66.  Zhou C, Zhang J, Luo X, et al. Sodium Oligomannate Electrostatically Binds to Aβ and Blocks Its Aggregation[J]. J Phys Chem B, 2023, 127(9):1983-1994. 

67.  安娜, 聂颖兰, 朱法科, 等. 大麻二酚抗阿尔茨海默病活性研究进展 [J]. 药学进展, 2021, 45(7): 539-48.

68.  稗田宗太郎, 小野賢二郎. 認知症の治療の進歩 [J]. 神経治療学, 2022, 39(5): 756-9.

69.  陈士林, 孙奕, 万会花, 等. 中药与天然药物 2015~ 2020 年研究亮点评述 [J]. 药学学报, 2020, 55(12): 2751-76.

70.  陈杏雨, 李瑞娜, 谢少为, 等. 肠道微生物群与认知损害 [J]. 国际神经病学神经外科学杂志, 2023, 50(4): 90-4.

71.  程文彬, 陈晓晗, 孙文静, 等. 阿尔茨海默病精准诊断和药物研发的焦点与挑战 [J]. 海军军医大学学报, 2023, 44(9): 1013-25.

72.  方建, 李晓晖, 陈文武. 黄芪甲苷基于 MEK5/ERK5 信号通路对阿尔茨海默病大鼠小胶质细胞活性的影响 [J]. 上海中医药杂志, 2022, 55(10): 73-8.

73.  侯继文, 魏亚琳, 谭巧文, 等. 轻度认知障碍及其与生活方式的关系研究进展 [J]. Advances in Clinical Medicine, 2019, 9: 1387.

74.  黄龙舰, 赵春阳, 冯新红, 等. 抗阿尔茨海默病药物非临床药效学评价体系的探索 [J]. 药学学报, 2020, 55(5): 789-805.

75.  贾岳津, 马培, 吴柔燕, 等. “石菖蒲-远志” 防治痴呆探析 [J]. Modern Chinese, 2024, 31(2).

76.  雷梦瑶, 高佩佩, 龙建纲. 中药有效成分对 AD 相关认知功能的改善作用及其机制研究进展 [J]. 药学学报, 2022, 57(7): 1925-36.

77.  雷雯慧, 高婕, 徐鹏, 等. 阿尔茨海默病肠道细菌和真菌菌群结构和组成改变研究 [J]. 中国微生态学杂志, 2024, 36(5): 577-83.

78.  李晓峰, 司冰心, 王广才, 等. 阿尔茨海默病的临床研究进展 [J]. Advances in Clinical Medicine, 2020, 10: 2254.

79.  李学秀, 崔嗣庚, 吕运一. 红参松花粉片对阿尔茨海默症大鼠空间学习记忆能力及海马神经细胞凋亡的影响 [J]. 北京师范大学学报 (自然科学版), 2021, 57(6): 854-8.

80.  李颖, 王茵, 陈婷茹, 等. 海带高值化综合利用研究进展 [J]. 渔业研究, 2023, 45(2): 192-201.

81.  厉飘飘. 几种糖类物质的神经保护功能及其作用机制研究 [D]; 南昌大学, 2020.

82.  林逸君. 海洋抗肿瘤药物研发与产业化进展 [J]. 应用海洋学学报, 2025, 44(2): 376-87.

83.  刘冠辰, 乔志林, 陈晨. 异质性研发对区域创新发展的影响研究——基于省际面板数据的实证分析 [J]. 云南社会科学, 2021.

84.  刘妍妍, 刘建飞, 邢连喜, 等. 中药中寡糖分离分析方法研究进展 [J]. 天然产物研究与开发, 2022, 34(5): 887.

85.  卢志园, 王葆青, 赵晨怡, 等. 调心补肾方改善阿尔茨海默病小鼠前额皮质突触缺失和 tau 蛋白过度磷酸化的作用研究 [J]. 上海中医药杂志, 2022, 56(9): 76-81.

86.  陆守荣, 张云云, 郁洁, 等. 肠道菌群对阿尔茨海默病的影响 [J]. Chinese Journal of Clinical Healthcare, 2021, 24(6).

87.  罗勤. 治疗阿尔茨海默症新药——甘露特钠 GV-971 [J]. 健康生活, 2020.

88.  聂奕玮, 车土玲, 陈学权, 等. 基于脑–肠轴理论探析阿尔茨海默病作用机制 [J]. Hans Journal of Biomedicine, 2023, 13: 121.

89.  潘汉博, 林妙满, 龚一富, 等. 海洋天然产物对抗阿尔茨海默症的研究进展 [J]. 中国海洋药物, 2019, 38(2): 73-82.

90.  彭康雯, 何怡婧, 靳令经. 粪菌移植治疗中枢神经系统疾病的研究进展 [J]. Journal of International Neurology and Neurosurgery, 2020, 47(6): 645-9.

91.  山原直紀, 下畑享良. タウオパチーにおける抗タウ療法 [J]. 神経治療学, 2025, 42(2): 65-71.

92.  石丽霞, 李科, 焦思明, 等. 黄芪活性多糖 APS-II 的酸降解及其降解寡糖的结构和免疫活性研究 [J]. 药学学报, 2021, 56(8): 2266-75.

93.  孙蓉, 宋绍霏, 张通. 阿尔茨海默病药物治疗的现状及展望 [J]. Chinese Journal of Clinical Healthcare, 2020, 23(2).

94.  王浩, 黄晏, 张汉霆. 阿尔茨海默病: 与性别, 癌症, 饮食有关吗? [J]. 中国药理学与毒理学杂志, 2020, 34(1): 1-6.

95.  王佳杰, 王新童, 李远恒, 等. 用于改善认知障碍的靶向 α7 型尼古丁乙酰胆碱受体正向变构调节剂的研发现状 [J]. 药学进展, 2020, 44(8): 573-87.

96.  王欣. 人类何时战胜阿尔茨海默症 [J]. 科学 24 小时, 2020, (5): 34-5.

97.  魏伟. 解码 “蓝色药库” [J]. 走向世界, 2020, (10): 50-3.

98.  夏安琪, 李军, 岳玲, 等. 蒙特利尔认知评估量表在中国社区老人中的应用 [J]. 上海交通大学学报 (医学版), 2021, 41(12): 1662-7.

99.  肖雨薇, 胡伟强, 赵梦华, 等. 治疗阿尔茨海默病创新药物研发进展 [J]. 中国药理学与毒理学杂志, 2024, 38(4): 286.

100.  谢宗杰, 王静, 韩露, 等. 基于 LINCS 转录组数据以囊泡谷氨酸转运体 1 为靶点的抗阿尔茨海默病药物重定位# br [J]. 中国药理学与毒理学杂志, 2022, 36(9): 641-8.

101.  徐丹, 蔡铮, 贾彩, et al. 2009-2018 年国家自然科学基金在防治阿尔茨海默病药物药理学研究领域资助项目分析 [J]. 中国药理学与毒理学杂志, 2019, 33(5): 327-33.

102.  徐泽澳, 江海燕, 范潇予, 等. 抗神经退行性疾病复方药物研究进展 [J]. 中国药物警戒, 2024, 21(9): 967.

103.  颜潇娜, 王泽, 李荣芳. 藤茶黄酮对阿尔兹海默症作用机制的研究进展 [J]. Modern Food Science & Technology, 2023, 39(8).

104.  杨岩涛, 赵佳柱, 肖佳妹, 等. 人参皂苷治疗阿尔茨海默病的药理作用研究进展 [J]. 2021.

105.  杨志友, 马智慧, 张永平, 等. 岩藻多糖对 Aβ25-35 诱导神经元凋亡和突起萎缩的抑制作用 [J]. 广东海洋大学学报, 2021, 41(4): 77-83.

106.  野中さおり. 158. 歯周病による腸管バリア破綻がもたらす認知障害の機序 [J].

107.  扆雪涛, 于德志, 方选, 等. 抗阿尔茨海默症海藻天然产物及其药理机制研究进展 [J]. 中国海洋药物, 2020, 39(2): 93-100.

108.  袁子焰, 杜然然, 秦奕, 等. 党领导下的医学科技百年实践与新时期创新发展思考 [J]. 中国医药导报, 2021, 18(35): 4-7, 14.

109.  岳玲, 王涛, 肖世富. 阿尔茨海默病诊断与治疗研究进展 [J]. 收藏, 2019, 1.

110.  张平, 季晖, 胡庆华. 阿尔茨海默症的临床治疗和天然来源潜在药物的研究进展 [J]. 药学学报, 2022, 57(7): 1954-61.

111.  张颖, 于小琪, 卢福昌, 等. 基于神经递质和肠道菌群探讨露甘露特钠胶囊联合盐酸多奈哌齐片 治疗轻中度阿尔茨海默病的疗效 [J]. Progress in Modern Biomedicine, 2024, 24(20).

112.  章瑾, 王尚志, 杨明睿, 等. 褐藻多糖调控肠道微生态作用机制研究进展 [J]. 大连海洋大学学报, 2024, 39(2): 349-59.

113.  赵小亮, 王钰婷, 肖宁, 等. 海洋寡糖及其衍生物活性的研究进展 [J]. 生物技术进展, 2018, 8(6): 477.

114.  郑易林, 邵黎明. 展望 2019: 寻求中国生物医药企业生存与发展的新平衡点 [J]. PROGRESS IN PHARMACEUTICAL SCIENCES, 2019, 43(3): 191-3.

115.  郑易林, 谢琼, 肖立, 等. 抗阿尔茨海默病药物研发进展 [J]. 药学进展, 2019, 43(2): 100-10.

116.  周峰岩, 赵玉亮, 张文志, 等. 有机化学糖类化合物教学的思政案例设计与实践 [J]. 大学化学, 2021.

117.  AALDIJK E, VERMEIREN Y. The role of serotonin within the microbiota-gut-brain axis in the development of Alzheimer’s disease: A narrative review [J]. Ageing Research Reviews, 2022, 75: 101556.

118.  AARONS T. Investigating Small Extracellular Vesicle miRNA as Biomarkers for Alzheimers Disease [M]. University of Salford (United Kingdom), 2023.

119.  ABITBOL A, MALLARD B, TIRALONGO E, et al. Mushroom natural products in neurodegenerative disease drug discovery [J]. Cells, 2022, 11(23): 3938.

120.  ABUELEZZ N Z, NASR F E, GARCíA-AYLLóN M-S, et al. Advancements of Nanocarriers for Brain Targeting and Limitations in Clinical Translation [M]. Nanocarriers in Neurodegenerative Disorders. CRC Press. 2025: 282-93.

121.  ADIL N A, OMO-ERIGBE C, YADAV H, et al. The Oral–Gut Microbiome–Brain Axis in Cognition [J]. Microorganisms, 2025, 13(4): 814.

122.  ADLER G. Die Bedeutung des Darm-Mikrobioms für die Alzheimer-Demenz [J]. Nervenheilkunde, 2022, 41(09): 601-8.

123.  ADVERTISEMENTFEATURE A C C. EXPLORING THE FUTURE HEALTH OF RESEARCH [J].

124.  AHMAD M, UDDIN I, MURAD M, et al. Cholinesterase inhibitors for the treatment of Alzheimer’s disorder: Synthesis, biological analysis and molecular modelling studies of iso-quinoline derivatives [J]. Results in Chemistry, 2024, 9: 101661.

125.  AI X, NIU Q, LI S, et al. Eco-friendly ozonation of alginate: Physicochemical characterization and degradation mechanism exploration through mass spectrometry [J]. International Journal of Biological Macromolecules, 2024, 279: 135306.

126.  AKıNCıOĞLU H, AYDIN T, JAFAROVA S, et al. In Vitro and in Silico Investigation of Secondary Metabolites of Plantago Major L. Subsp. Major Leaves as New Drug Targets Against Neurodegenerative Diseases [J]. Subsp Major Leaves as New Drug Targets Against Neurodegenerative Diseases.

127.  AL-HUSSANIY H A, ALI A-S, HAJLEH M N A, et al. Selection and Progress of drugs for treating Dementia [J]. Research Journal of Pharmacy and Technology, 2024, 17(4): 1674-8.

128.  ALBERTINI C. Development of new chemical entities to target neuroinflammatory pathways [J]. 2022.

129.  ALBERTINI C, SALERNO A, DE SENA MURTEIRA PINHEIRO P, et al. From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology [J]. Medicinal Research Reviews, 2021, 41(5): 2606-33.

130.  ALFEI S, ZUCCARI G. Ellagic Acid (EA): A Green Multi-Target Weapon Reducing Oxidative Stress and Inflammation Thus Preventing and Ameliorating Alzheimer Disease (AD) Condition [J]. Int J Mol Sci, 2025, 26: 844.

131.  ALHAZMI H A, ALBRATTY M. An update on the novel and approved drugs for Alzheimer disease [J]. Saudi Pharmaceutical Journal, 2022, 30(12): 1755-64.

132.  ALMALKI W H. 4 Role of Gut Microbiome [J]. Gut Microbiome and Environmental Toxicants: Impact on Human Health, 2025: 64.

133.  ALMALKI W H. Role of Gut Microbiome on Human Health [M]. Gut Microbiome and Environmental Toxicants. CRC Press. 2025: 64-85.

134.  ALMASI F, ABBASLOO F, SOLTANI N, et al. Biology, Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson’s Disease: Advances and Challenges [J]. Molecular Neurobiology, 2025: 1-19.

135.  ALMEIDA Z L, VAZ D C, BRITO R M. Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s Pathogenesis [J]. Molecular Neurobiology, 2024: 1-29.

136.  AMARNANI B. Evaluation of Nanoformulation of Anti-Viral Drug In Alzheimer's Disease Induced Model of Rats [D]; Institute of Pharmacy, Nirma University, A'bad, 2020.

137.  AMERICANS A. ADAS-cog scale, 281, 282–283, 284–285, 455 ADCOMS score, 235, 461 ADNI see Alzheimer’s Disease Neuroimaging Initiative (ADNI) [J]. drug discovery, 34: 39.

138.  AN C, GAO L, XIANG L, et al. IGF-1 and Glucocorticoid Receptors Are Potential Target Proteins for the NGF-Mimic Effect of β-Cyclocitral from Lavandula angustifolia Mill. in PC12 Cells [J]. International Journal of Molecular Sciences, 2024, 25(18): 9763.

139.  ANDERSON C, BUCHOLC M, MCCLEAN P L, et al. The potential of a stratified approach to drug repurposing in Alzheimer’s disease [J]. Biomolecules, 2023, 14(1): 11.

140.  ANGELOVA V T, STOYANOV B P, SIMEONOVA R. New Insights into the Development of Donepezil-Based Hybrid and Natural Molecules as Multi-Target Drug Agents for Alzheimer’s Disease Treatment [J]. Molecules, 2024, 29(22): 5314.

141.  ANGIONI D, MIDDLETON L, BATEMAN R, et al. Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force [J]. The Journal of Prevention of Alzheimer's Disease, 2025: 100163.

142.  ANISHA P, BADAM R, KAZA V S. Addressing Overcrowding: A Plight for Smart Cities [J]. Smart Sensors for Industry 40: Fundamentals, Fabrication and IIoT Applications, 2025: 15-38.

143.  ANTAR A, SZALLASI A, IMATAKI O. Case reports in hematological malignancies: 2022 [Z]. Frontiers Media SA. 2023: 1272547

144.  ANTUNES E M, BEUKES D R, CARO-DIAZ E J, et al. Medicines from the sea [M]. Oceans and Human Health. Elsevier. 2023: 103-48.

145.  APTER J T, WHITE K M. New horizons in Alzheimer research from amyloid and beyond [J]. OBM Geriatrics, 2020, 4(2): 1-9.

146.  ARANDA-ABREU G E, ROJAS-DURáN F, HERNáNDEZ-AGUILAR M E, et al. Alzheimer’s Disease: Cellular and Pharmacological Aspects [J]. Geriatrics, 2024, 9(4): 86.

147.  ATHAR T, AL BALUSHI K, KHAN S A. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease [J]. Molecular biology reports, 2021, 48(7): 5629-45.

148.  AUSTAD S N, BALLINGER S, BUFORD T W, et al. Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease [J]. Acta Pharmaceutica Sinica B, 2022, 12(2): 511-31.

149.  AZIMI M, ATIQ M A. Why do we need new therapies for neurodegenerative disorders? [M]. Essential Guide to Neurodegenerative Disorders. Elsevier. 2025: 579-84.

150.  AZIZ N, WAL P, PATEL A, et al. A comprehensive review on the pharmacological role of gut microbiome in neurodegenerative disorders: potential therapeutic targets [J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397(10): 7307-36.

151.  AZIZOGLU U, THANKA P P, SUDARSANAN S E, et al. Genetically Modified Bacteria: History, Principle, and Utility [M]. Handbook of Molecular Biotechnology. CRC Press: 602-11.

152.  BACHURIN S, BOVINA E, USTYUGOV A. Current trends in the development of drugs for the treatment of Alzheimer’s disease and their clinical trials [J]. Biomedical Chemistry: Research and Methods, 2018, 1(3): e00015-e.

153.  BACHURIN S O, BOVINA E V, USTYUGOV A A. Drugs in clinical trials for Alzheimer's disease: the major trends [J]. Medicinal research reviews, 2017, 37(5): 1186-225.

154.  BAI H, FENG X-F. Searching for new drugs to treat Alzheimer’s disease dementia through multiple pathways [J]. World Journal of Clinical Cases, 2025, 13(1): 100833.

155.  BALKHI S, DI SPIRITO A, POGGI A, et al. Immune Modulation in Alzheimer’s Disease: From Pathogenesis to Immunotherapy [J]. Cells, 2025, 14(4): 264.

156.  BAO Q, LIU Y, ZHANG X, et al. Clinical observation and mechanism of acupuncture on amnestic mild cognitive impairment based on the gut-brain axis: study protocol for a randomized controlled trial [J]. Frontiers in Medicine, 2023, 10: 1198579.

157.  BARBOSA M, VALENTãO P, ANDRADE P B. Polyphenols from brown seaweeds (Ochrophyta, Phaeophyceae): Phlorotannins in the pursuit of natural alternatives to tackle neurodegeneration [J]. Marine Drugs, 2020, 18(12): 654.

158.  BARTOCHOWSKI Z, CONWAY J, WALLACH Y, et al. Dietary interventions to prevent or delay Alzheimer’s disease: what the evidence shows [J]. Current nutrition reports, 2020, 9: 210-25.

159.  BASAK J M, FERREIRO A, COHEN L S, et al. Bacterial sepsis increases hippocampal fibrillar amyloid plaque load and neuroinflammation in a mouse model of Alzheimer's disease [J]. Neurobiology of disease, 2021, 152: 105292.

160.  BATEMAN R J, SMITH J, DONOHUE M C, et al. Two phase 3 trials of gantenerumab in early Alzheimer’s disease [J]. New England Journal of Medicine, 2023, 389(20): 1862-76.

161.  BATOOL Z, CHEN J-H, GAO Y, et al. Natural Carotenoids as Neuroprotective Agents for Alzheimer’s Disease: An Evidence-Based Comprehensive Review [J]. Journal of Agricultural and Food Chemistry, 2022, 70(50): 15631-46.

162.  BAUER S, JIN W, ZHANG F, et al. The application of seaweed polysaccharides and their derived products with potential for the treatment of Alzheimer’s disease [J]. Marine drugs, 2021, 19(2): 89.

163.  BEERA A M, SEETHAMRAJU S M, NORI L P. Alzheimer’s disease: perspective on therapeutic options and recent hallmarks in clinical research [J]. International Journal of Pharmaceutical Research and Allied Sciences, 2021, 10(4-2021): 110-20.

164.  BEHERA A, SA N, PRADHAN S P, et al. Metal nanoparticles in Alzheimer’s disease [J]. Journal of Alzheimer's Disease Reports, 2023, 7(1): 791-810.

165.  BEHL C. The search for novel targets in Alzheimer's disease—The 90s redux [J]. Progress in Molecular Biology and Translational Science, 2021, 177: 123-35.

166.  BEITNERE U, VILANOVA-CUEVAS B, CHRISTIAN S G, et al. Unique features of the gut microbiome characterized in animal models of Angelman Syndrome [J]. Msystems, 2023, 8(1): e00608-22.

167.  BENICHOU HAZIOT C, BIRAK K S. Therapeutic potential of microbiota modulation in Alzheimer’s disease: a review of preclinical studies [J]. Journal of Alzheimer's Disease Reports, 2023, 7(1): 415-31.

168.  BERNOUDY G C. A Comparison Between Pharmaceutical Inhibitors of Amyloid Plaque and Monoclonal Antibodies Used in the Treatment of Alzheimer's Disease [D]; University of Bridgeport, 2024.

169.  BEŞARAT P. Effects of Enhanced Trkb Signaling in Mouse Embryonic Stem Cell-Derived Cortical Neurons Against Amyloid Beta 42-mediated Cellular Events [D]; Middle East Technical University (Turkey), 2023.

170.  BHATTACHARYA K, BHATTACHARJEE A. Computational and Experimental Studies in Alzheimer's Disease [M]. CRC Press, 2024.

171.  BHATTACHARYA R S, SINGH R, PANGHAL A, et al. Multi‐Targeting Phytochemicals for Alzheimer's Disease [J]. Phytotherapy Research, 2025.

172.  BI D, XIAO S, LIN Z, et al. Alginate-derived mannuronate oligosaccharide attenuates tauopathy through enhancing autophagy [J]. Journal of Agricultural and Food Chemistry, 2021, 69(15): 4438-45.

173.  BI D, YANG X, LU J, et al. Preparation and potential applications of alginate oligosaccharides [J]. Critical reviews in food science and nutrition, 2023, 63(29): 10130-47.

174.  BIAN Y, ZHAO C, LEE S M-Y. Neuroprotective potency of saffron against neuropsychiatric diseases, neurodegenerative diseases, and other brain disorders: From bench to bedside [J]. Frontiers in Pharmacology, 2020, 11: 579052.

175.  BIDZAN L. Farmakologiczne leczenie choroby Alzheimera—współczesne możliwości [J]. Psychiatria, 2020, 17(2): 87-94.

176.  BLAIKIE L, KAY G, MACIEL P, et al. Experimental modelling of Alzheimer's disease for therapeutic screening [J]. European Journal of Medicinal Chemistry Reports, 2022, 5: 100044.

177.  BLIVET G, ROMAN F, LELOUVIER B, et al. Photobiomodulation Therapy: A Novel Therapeutic Approach to Alzheimer's Disease Made Possible by the Evidence of a Brain–Gut Interconnection [J]. Journal of Integrative Neuroscience, 2024, 23(5): 92.

178.  BORA N S, SAHARIAH B J, DEVI C M, et al. Preclinical Approach: In vivo and In vitro Methods for Evaluating Anti-Alzheimer's Drugs [M]. Computational and Experimental Studies in Alzheimer's Disease. CRC Press. 2024: 15-34.

179.  BORSOM E. Dense, longitudinal sampling reveals key gut microbial communities associated with Alzheimer’s disease pathologies [D]; Northern Arizona University, 2022.

180.  BORSOM E M, CONN K, KEEFE C R, et al. Predicting neurodegenerative disease using prepathology gut microbiota composition: a longitudinal study in mice modeling Alzheimer’s disease pathologies [J]. Microbiology Spectrum, 2023, 11(2): e03458-22.

181.  BORSOM E M, LEE K, COPE E K. Do the bugs in your gut eat your memories? Relationship between gut microbiota and Alzheimer’s disease [J]. Brain Sciences, 2020, 10(11): 814.

182.  BOTCHWAY B O, LIU X, ZHOU Y, et al. Biometals in Alzheimer disease: emerging therapeutic and diagnostic potential of molybdenum and iodine [J]. Journal of Translational Medicine, 2023, 21(1): 351.

183.  BOTCHWAY B O, OKOYE F C, CHEN Y, et al. Alzheimer disease: recent updates on apolipoprotein E and gut microbiome mediation of oxidative stress, and prospective interventional agents [J]. Aging and disease, 2022, 13(1): 87.

184.  BOTELHO M J, MILINOVIC J, BANDARRA N M, et al. Alzheimer’s disease and toxins produced by marine dinoflagellates: An issue to explore [J]. Marine drugs, 2022, 20(4): 253.

185.  BOU ZERDAN M, HEBBO E, HIJAZI A, et al. The gut microbiome and alzheimer’s disease: A growing relationship [J]. Current Alzheimer Research, 2022, 19(12): 808-18.

186.  BRANDENBURG B. Ausgaben und Einnahmen der Gemeinden und Gemeindeverbände im Land Brandenburg Jahr 2006 [J]. 2006.

187.  BRENOWITZ W D, XIANG Y, MCEVOY C T, et al. Current Alzheimer disease research highlights: evidence for novel risk factors [J]. Chinese medical journal, 2021, 134(18): 2150-9.

188.  BREUKINK F. Immunotherapy as a treatment strategy for Alzheimer’s and Parkinson’s Disease [D], 2024.

189.  BULGART H R, NECZYPOR E W, WOLD L E, et al. Microbial involvement in Alzheimer disease development and progression [J]. Molecular neurodegeneration, 2020, 15: 1-12.

190.  BUTTON E B. VASOPROTECTIVE FUNCTIONS OF HIGH-DENSITY LIPOPROTEINS ON THE CEREBROVASCULATURE AND THEIR RELEVANCE FOR ALZHEIMER’S [D]; UNIVERSITY OF BRITISH COLUMBIA (Vancouver, 2020.

191.  BY S, KAHL A, COGSWELL P M. Alzheimer's Disease Clinical Trials: What Have We Learned From Magnetic Resonance Imaging [J]. Journal of Magnetic Resonance Imaging, 2025, 61(2): 579-94.

192.  CAI J, LIU Y, FAN H. Review on pathogenesis and treatment of Alzheimer's disease [J]. Developmental Dynamics, 2025, 254(4): 296-309.

193.  CAO C, FU G, XU R, et al. Coupling of Alzheimer’s Disease Genetic Risk Factors with Viral Susceptibility and Inflammation [J]. Aging and Disease, 2024, 15(5): 2028.

194.  CAO J, AMAKYE W K, QI C, et al. Bifidobacterium Lactis Probio-M8 regulates gut microbiota to alleviate Alzheimer’s disease in the APP/PS1 mouse model [J]. European Journal of Nutrition, 2021, 60: 3757-69.

195.  CAO J, HOU J, PING J, et al. Advances in developing novel therapeutic strategies for Alzheimer’s disease [J]. Molecular neurodegeneration, 2018, 13: 1-20.

196.  CAO W, ZHU B, LIU Z, et al. Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer’s disease: A systematic review and network meta-analysis [J]. Neuroscience, 2024.

197.  CAO X, DU X, JIAO H, et al. Carbohydrate-based drugs launched during 2000− 2021 [J]. Acta Pharmaceutica Sinica B, 2022, 12(10): 3783-821.

198.  CAO Y, LIU X, LIU J, et al. Clinical observation of warming needle therapy combined with Chinese medication in treating post-stroke cognitive impairment due to obstruction of wind-phlegm [J]. Journal of Acupuncture and Tuina Science, 2024, 22(4): 305-10.

199.  CAO Y, YU F, LYU Y, et al. Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China [J]. Frontiers in Neurology, 2022, 13: 1034243.

200.  CARLONI S, RESCIGNO M. The gut-brain vascular axis in neuroinflammation; proceedings of the Seminars in immunology, F, 2023 [C]. Elsevier.

201.  CASTRO C M, MOLINA C R, FERRáNDEZ F J V. Redirigiendo las estrategias terapéuticas en la Enfermedad de Alzheimer [J]. RESCIFAR Revista Española de Ciencias Farmacéuticas, 2020, 1(1): 18-33.

202.  CATANESI M, CAIONI G, CASTELLI V, et al. Benefits under the sea: The role of marine compounds in neurodegenerative disorders [J]. Marine drugs, 2021, 19(1): 24.

203.  CATUMBELA C S, GIRIDHARAN V V, BARICHELLO T, et al. Clinical evidence of human pathogens implicated in Alzheimer’s disease pathology and the therapeutic efficacy of antimicrobials: An overview [J]. Translational Neurodegeneration, 2023, 12(1): 37.

204.  CEPPA F A, IZZO L, SARDELLI L, et al. Human gut-microbiota interaction in neurodegenerative disorders and current engineered tools for its modeling [J]. Frontiers in cellular and infection microbiology, 2020, 10: 297.

205.  CHAKRABORTY K. Bioactive compounds and nutraceuticals from seaweeds [J]. 2024.

206.  CHAN H J, YANSHREE, ROY J, et al. Therapeutic potential of human stem cell implantation in alzheimer’s disease [J]. International Journal of Molecular Sciences, 2021, 22(18): 10151.

207.  CHANDRA S. Gut Microbiome Regulation of Reactive Astrocytosis in Alzheimer’s Disease [D]; Northwestern University, 2024.

208.  CHANDRA S, SISODIA S S, VASSAR R J. The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored [J]. Molecular neurodegeneration, 2023, 18(1): 9.

209.  CHANG T-F, LIN C-F, WU S-Y, et al. Antiviral effects of Sarcodia suae water extracts against vesicular stomatitis virus infection [J]. European Journal of Phycology, 2024, 59(4): 490-500.

210.  CHANU M T. Alzheimer’s Disease and Related Dementia Drug Trials, Failures and Progress: Data Update 2024 [J]. 2024.

211.  CHAURASIA R N, FAVAS T. Novel therapeutics for diverse neurodegenerative disorders [M]. A Review on Diverse Neurological Disorders. Elsevier. 2024: 553-71.

212.  CHEN D, CHEN Q, QIN X, et al. Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease [J]. Frontiers in Aging Neuroscience, 2023, 15: 1209863.

213.  CHEN H, ZENG Y, WANG D, et al. Neuroinflammation of microglial regulation in Alzheimer’s Disease: Therapeutic approaches [J]. Molecules, 2024, 29(7): 1478.

214.  CHEN K, YAO X, YU Y, et al. Safety and Toxicity of Qi‐Fu Yin, a Classical Traditional Chinese Medicine Prescription: A Nonclinical Research [J]. Journal of Applied Toxicology, 2025.

215.  CHEN L, CAO H, ZHANG X, et al. Antidepressant effects of sulforaphane (SFN) and its derivatives SLL-III-9 and SLL-III-120 and their potential underlying mechanisms based on the microbiota–gut–brain axis [J]. Food & Function, 2024, 15(20): 10539-52.

216.  CHEN M, HUANG N, LIU J, et al. AMPK: A bridge between diabetes mellitus and Alzheimer's disease [J]. Behavioural Brain Research, 2021, 400: 113043.

217.  CHEN S, LIU H, WANG S, et al. The neuroprotection of verbascoside in Alzheimer’s disease mediated through mitigation of neuroinflammation via blocking NF-κB-p65 signaling [J]. Nutrients, 2022, 14(7): 1417.

218.  CHEN S-L, SUN Y, WAN H-H, et al. Highlights on the progress of traditional Chinese medicine and natural drugs during 2015-2020 [J]. 2020.

219.  CHEN X, CHEN X, YAN D, et al. GV-971 prevents severe acute pancreatitis by remodeling the microbiota-metabolic-immune axis [J]. Nature communications, 2024, 15(1): 8278.

220.  CHEN Y, LAI M, TAO M. Evaluating the efficacy and safety of Alzheimer’s disease drugs: A meta-analysis and systematic review [J]. Medicine, 2024, 103(16): e37799.

221.  CHEN Y, LI Y, WU M, et al. Electroacupuncture improves cognitive function in APP/PS1 mice by inhibiting oxidative stress related hippocampal neuronal ferroptosis [J]. Brain Research, 2024, 1831: 148744.

222.  CHEN Y, YU Y. Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation [J]. Journal of neuroinflammation, 2023, 20(1): 165.

223.  CHEN Y, ZHOU J, WANG L. Role and mechanism of gut microbiota in human disease [J]. Frontiers in cellular and infection microbiology, 2021, 11: 625913.

224.  CHEN Z, MAQBOOL J, SAJID F, et al. Human gut microbiota and its association with pathogenesis and treatments of neurodegenerative diseases [J]. Microbial Pathogenesis, 2021, 150: 104675.

225.  CHENG G-L, LEI W, LIANG H-B, et al. Screening of active ingredients in Kaixin Powder for Alzheimer’s disease based on molecular docking [J]. 2022.

226.  CHENG H-R, WEN C-Y, ZHANG C, et al. The use of GV-971 induces liver injury in an Alzheimer's disease patient [J]. Authorea Preprints, 2020.

227.  CHENG Q, MA X, LIU J, et al. Pharmacological inhibition of the asparaginyl endopeptidase (AEP) in an Alzheimer’s disease model improves the survival and efficacy of transplanted neural stem cells [J]. International Journal of Molecular Sciences, 2023, 24(9): 7739.

228.  CHENG X, SONG C, DU Y, et al. Pharmacological treatment of alzheimer’s disease: insights from drosophila melanogaster [J]. International journal of molecular sciences, 2020, 21(13): 4621.

229.  CHENG Y, LIU J, LING Z. Short-chain fatty acids-producing probiotics: A novel source of psychobiotics [J]. Critical reviews in food science and nutrition, 2022, 62(28): 7929-59.

230.  CHHETRI J, CHAN P, VELLAS B, et al. Report from the first clinical trials on Alzheimer’s disease (CTAD) Asia-China 2018: bringing together global leaders [J]. The journal of prevention of Alzheimer's disease, 2019, 6: 144-7.

231.  CHI L. Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis [M]. University of Macau, 2020.

232.  CHIB S, SHARMA K, SINGH R. Interventions of cognitive impairment in older adults: a comprehensive review [J]. Aging and Health Research, 2025: 100223.

233.  CHIRIAPKIN A, KODONIDI I, POZDNYAKOV D, et al. Synthesis and QSAR of new azomethine derivatives as agents for the treatment of Alzheimer's disease [J]. Pharmacologyonline, 2021, 3: 563-84.

234.  CHIRIAPKIN A S, KODONIDI I P, POZDNYAKOV D I, et al. Synthesis, in vitro and docking studies of 2-substituted 5, 6, 7, 8-tetrahydrobenzo [4, 5] thieno [2, 3-d] pyrimidine-4 (3H)-one derivatives as agents for the treatment of Alzheimer's disease [J]. Chimica Techno Acta, 2022, 9(2): 20229204.

235.  CHIRIAPKIN A S, KODONIDI I P, POZDNYAKOV D I, et al. Chimica Techno Acta [J]. Chimica Techno Acta, 2022.

236.  CHO D. Molecular mechanism of Ramalin-mediated anti-Alzheimer's effects [J]. 2020.

237.  CHOI H, LEE D, MOOK-JUNG I. Gut microbiota as a hidden player in the pathogenesis of Alzheimer’s disease [J]. Journal of Alzheimer’s Disease, 2022, 86(4): 1501-26.

238.  CHOK K C, NG K Y, KOH R Y, et al. Role of the gut microbiome in Alzheimer’s disease [J]. Reviews in the Neurosciences, 2021, 32(7): 767-89.

239.  CHOWDHURY S R, XIE F, GU J, et al. Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug Development [J]. Pharmaceutical Fronts, 2019, 1(01): e22-e32.

240.  CHU J, ZHANG W, LIU Y, et al. Biomaterials-based anti-inflammatory treatment strategies for Alzheimer’s disease [J]. Neural Regeneration Research, 2024, 19(1): 100-15.

241.  CHUAN-BIN Z, MEI-JUAN G. Recent advance in relation between trimethylamine N-oxide metabolized by intestinal microbes and cognitive impairment [J]. Jie Fang Jun Yi Xue Za Zhi, 2023, 48(3): 339.

242.  COHEN J J. Der Einfluss häufig eingesetzter Medikamente auf das Demenzrisiko [D]; Universitäts-und Landesbibliothek Bonn, 2023.

243.  COIMBRA M L, DA SILVA E H F, DE ALENCAR FARIA I, et al. THERAPEUTIC OPTIONS UNDER TEST FOR THE TREATMENT OF ALZHEIMER'S DISEASE: A LITERATURE REVIEW [J]. CIPEEX, 2022, 3(1): 1-.

244.  CONSTANCE J. Pharm Exec’s 2020 Pipeline Report [J]. 2019.

245.  CONTI FILHO C E, LOSS L B, MARCOLONGO-PEREIRA C, et al. Advances in Alzheimer’s disease’s pharmacological treatment [J]. Frontiers in Pharmacology, 2023, 14: 1101452.

246.  CORDIANO R, GAMMERI L, DI SALVO E, et al. Pomegranate (Punica granatum L.) Extract effects on inflammaging [J]. Molecules, 2024, 29(17): 4174.

247.  COSTA M, PáEZ A. Emerging insights into the role of albumin with plasma exchange in Alzheimer’s disease management [J]. Transfusion and Apheresis Science, 2021, 60(3): 103164.

248.  COSTA M, SOARES C, SILVA A, et al. Optimization of Nanoencapsulation of Codium tomentosum Extract and Its Potential Application in Yogurt Fortification [J]. Marine Drugs, 2025, 23(4): 147.

249.  COSTANZO M, DE GIGLIO M A R, GILHEN-BAKER M, et al. The chemical basis of seawater therapies: A review [J]. Environmental Chemistry Letters, 2024, 22(4): 2133-49.

250.  COX L M, SCHAFER M J, SOHN J, et al. Calorie restriction slows age-related microbiota changes in an Alzheimer’s disease model in female mice [J]. Scientific reports, 2019, 9(1): 17904.

251.  CUI T, YU P, FENG X, et al. Elucidation of the inhibitory effects of Jiedu Yizhi formula on neuronal apoptosis in the treatment of Alzheimer’s disease based on network pharmacology and in vivo experiments [J]. Metabolic Brain Disease, 2025, 40(1): 1-17.

252.  CUMMINGS J. New approaches to symptomatic treatments for Alzheimer’s disease [J]. Molecular Neurodegeneration, 2021, 16: 1-13.

253.  CUMMINGS J. Drug development for psychotropic, cognitive-enhancing, and disease-modifying treatments for Alzheimer’s disease [J]. The Journal of neuropsychiatry and clinical neurosciences, 2021, 33(1): 3-13.

254.  CUMMINGS J, KINNEY J, FILLIT H. Alzheimer's Disease Drug Development: Research and Development Ecosystem [M]. Cambridge University Press, 2022.

255.  CUMMINGS J, LEE G, MORTSDORF T, et al. Alzheimer's disease drug development pipeline: 2017 [J]. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2017, 3(3): 367-84.

256.  CUMMINGS J, LEE G, NAHED P, et al. Alzheimer's disease drug development pipeline: 2022 [J]. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, 8(1): e12295.

257.  CUMMINGS J, LEE G, RITTER A, et al. Alzheimer's disease drug development pipeline: 2020 [J]. Alzheimer's & dementia: translational research & clinical interventions, 2020, 6(1): e12050.

258.  CUMMINGS J, LEE G, RITTER A, et al. Alzheimer's disease drug development pipeline: 2018 [J]. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2018, 4: 195-214.

259.  CUMMINGS J, LEE G, ZHONG K, et al. Alzheimer's disease drug development pipeline: 2021 [J]. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2021, 7(1): e12179.

260.  CUMMINGS J, MORSTORF T, LEE G. Alzheimer's drug-development pipeline: 2016 [J]. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2016, 2(4): 222-32.

261.  CUMMINGS J L. Translational scoring of candidate treatments for Alzheimer’s disease: a systematic approach [J]. Dementia and Geriatric Cognitive Disorders, 2020, 49(1): 22-37.

262.  D'ANTONIO F, KANE J P, IBAñEZ A, et al. Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group [J]. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021, 13(1): e12235.

263.  D’ALESSANDRO G, MARROCCO F, LIMATOLA C. Microglial cells: Sensors for neuronal activity and microbiota-derived molecules [J]. Frontiers in immunology, 2022, 13: 1011129.

264.  DA SILVA RIBEIRO A. Relatório de Estágio e Monografia Intitulada Doença de Alzheimer–Novo Olhar Farmacoterapêutico [D]; Universidade de Coimbra (Portugal), 2021.

265.  DAI B, MA X, TANG Y, et al. Design, synthesis, and biological activity of novel semicarbazones as potent Ryanodine receptor1 inhibitors of Alzheimer’s disease [J]. Bioorganic & Medicinal Chemistry, 2021, 29: 115891.

266.  DAI C-L, LIU F, IQBAL K, et al. Gut microbiota and immunotherapy for Alzheimer’s disease [J]. International Journal of Molecular Sciences, 2022, 23(23): 15230.

267.  DAI H, HAN J, WANG T, et al. Recent advances in gut microbiota-associated natural products: structures, bioactivities, and mechanisms [J]. Natural product reports, 2023, 40(6): 1078-93.

268.  DAI R, SUN Y, SU R, et al. Anti-Alzheimer's disease potential of traditional chinese medicinal herbs as inhibitors of BACE1 and AChE enzymes [J]. Biomedicine & Pharmacotherapy, 2022, 154: 113576.

269.  DAI Y, LEI C, ZHANG Z, et al. Amyloid-beta targeted therapeutic approaches for Alzheimer’s disease: long road ahead [J]. Current Drug Targets, 2022, 23(11): 1040-56.

270.  DAI Z, HU T, WEI J, et al. Network-based identification and mechanism exploration of active ingredients against Alzheimer’s disease via targeting endoplasmic reticulum stress from traditional chinese medicine [J]. Computational and Structural Biotechnology Journal, 2024, 23: 506-19.

271.  DALLEMAGNE P, ROCHAIS C. Facing the complexity of Alzheimer's disease [Z]. Taylor & Francis. 2020: 175-7

272.  DANTAS R L M, BARACHO N C, CAMINS A, et al. Pharmacological drug strategies in Alzheimer's Disease [J]. Revista Neurociências, 2021, 29.

273.  DAR G M, AHMAD E, ALI A, et al. Genetic aberration analysis of mitochondrial respiratory complex I implications in the development of neurological disorders and their clinical significance [J]. Ageing research reviews, 2023, 87: 101906.

274.  DAS S. Marine Plant Species: Nutritional and Medicinal Value for Brain Health [M]. Plant-based Foods and their Implications in Brain Health. CRC Press: 149-97.

275.  DAS S, BHARATI K. International Journal of Alzheimer's Disease Research [J].

276.  DATA S. Eugene B. Chang [J].

277.  DE CAMARGO JANGE L. Perspectivas sobre abordagens terapêuticas na Doença de Alzheimer [D]; Universidade de São Paulo, 2020.

278.  DE CASTRO VILANOVA J, DE MELO B R, DA ROCHA T H L, et al. A relação da disbiose e desenvolvimento de transtornos neurodegenerativos: uma revisão sistemática de literatura [J]. Research, Society and Development, 2023, 12(5): e3612541454-e.

279.  DE CERIO DíEZ M D. Tipología formal y función estilística de la referencia a la muerte en los epigramas funerarios de Ánite de Tegea [J]. Faventia, 1998, 20(1): 49-74.

280.  DE SIMONE A, TUMIATTI V, ANDRISANO V, et al. Glycogen synthase kinase 3β: a new gold rush in anti-Alzheimer’s disease Multitarget Drug Discovery? Miniperspective [J]. Journal of Medicinal Chemistry, 2020, 64(1): 26-41.

281.  DE SOUSA C N S, DA SILVA LEITE C M G, DA SILVA MEDEIROS I, et al. Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review [J]. Metabolic brain disease, 2019, 34: 39-52.

282.  DECOURT B, NOORDA K, NOORDA K, et al. Review of advanced drug trials focusing on the reduction of brain beta-amyloid to prevent and treat dementia [J]. Journal of experimental pharmacology, 2022: 331-52.

283.  DELRIEU J. Alzheimer's disease [J]. Pathy's Principles and Practice of Geriatric Medicine, 2022, 2: 794-807.

284.  DELRIEU J, OUSSET P-J. Quelles perspectives de traitements curatifs à court et à long terme pour la maladie d’Alzheimer? [J]. La Presse Médicale Formation, 2022, 3(1): 70-7.

285.  DEMUTH H-U, QIU Y, SHI J, et al. OPEN ACCESS EDITED BY Ju Gao, The University of Arizona, United States [J]. Reviews In Alzheimer's Disease and Related Dementias, 2023: 20.

286.  DEORE S L, BAVISKAR B, KIDE A A, et al. Modified Investigation Tools and Techniques Useful in Alzheimer’s Disease Research [M]. Deciphering Drug Targets for Alzheimer’s Disease. Springer. 2023: 41-67.

287.  DHANAWAT M, MALIK G, WILSON K, et al. The Gut Microbiota-Brain Axis: A New Frontier in Alzheimer's Disease Pathology [J]. CNS & Neurological Disorders-Drug Targets, 2025, 24(1): 7-20.

288.  DI MECO A, VASSAR R. Early detection and personalized medicine: future strategies against Alzheimer's disease [J]. Progress in molecular biology and translational science, 2021, 177: 157-73.

289.  DIAS C C. Doença de Alzheimer: o que há de novo? [D]; Universidade de Lisboa (Portugal), 2017.

290.  DíAZ G E F, CABODEVILLA R C V. Disbiosis intestinal en la enfermedad de Alzheimer [J]. Correo Científico Médico, 2023, 27(1).

291.  DISSANAYAKA D S, JAYASENA V, RAINEY-SMITH S R, et al. The role of diet and gut microbiota in Alzheimer’s disease [J]. Nutrients, 2024, 16(3): 412.

292.  DONG H, DONG S, ERIK HANSEN P, et al. Progress of bromophenols in marine algae from 2011 to 2020: Structure, bioactivities, and applications [J]. Marine drugs, 2020, 18(8): 411.

293.  DONG Y, LI X, CHENG J, et al. Drug development for Alzheimer’s disease: microglia induced neuroinflammation as a target? [J]. International Journal of Molecular Sciences, 2019, 20(3): 558.

294.  DORAISWAMY P M. Probing Gut-Brain Links in Alzheimer’s Disease with Rifaximin Paul V. Suhocki MDa James S. Ronald MDa, PhD Anna Mae E. Diehl MDa David M. Murdoch MD, MPHa [J]. Cell, 919: 880-6767.

295.  DORMAN G, FLORES I, GUTIéRREZ C, et al. Medicinal herbs and nutritional supplements for dementia therapy: potential targets and clinical evidence [J]. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders), 2022, 21(1): 26-51.

296.  DOS REIS LUíS J P. Targeting Neuroinflammation: From Target Validation to Rational Design of Selective Modulators [D]; Universidade de Coimbra (Portugal), 2021.

297.  DOS SANTOS G A A. Pharmacological Treatment of Alzheimer's Disease [J].

298.  DOU X, HUANG H, LI Y, et al. Multistage screening reveals 3-substituted indolin-2-one derivatives as novel and isoform-selective c-Jun N-terminal kinase 3 (JNK3) inhibitors: implications to drug discovery for potential treatment of neurodegenerative diseases [J]. Journal of Medicinal Chemistry, 2019, 62(14): 6645-64.

299.  DOU Y, ZHAO D. Targeting Emerging Pathogenic Mechanisms by Natural Molecules as Potential Therapeutics for Neurodegenerative Diseases. Pharmaceutics 2022, 14, 2287 [Z]. s Note: MDPI stays neu-tral with regard to jurisdictional claims in …. 2022

300.  DU X, LI X, LIU Q. Pathometallomics: Taking Neurodegenerative Disease as an Example [J]. Applied Metallomics: From Life Sciences to Environmental Sciences, 2024: 311-47.

301.  DUARTE R J G. Potencial Aplicação de Compostos Bioativos de Macroalgas Marinhas no Tratamento E/Ou Prevenção de Doenças Neurodegenerativas [D]; Universidade Fernando Pessoa (Portugal), 2023.

302.  DUGGAL P, MEHAN S. Neuroprotective approach of anti-cancer microtubule stabilizers against tauopathy associated dementia: Current status of clinical and preclinical findings [J]. Journal of Alzheimer's disease reports, 2019, 3(1): 179-218.

303.  DUNHAM S J, MCNAIR K A, ADAMS E D, et al. Longitudinal analysis of the microbiome and metabolome in the 5xfAD mouse model of Alzheimer’s disease [J]. MBio, 2022, 13(6): e01794-22.

304.  DURAI P, BEERAKA N M, RAMACHANDRAPPA H V, et al. Advances in PPARs molecular dynamics and glitazones as a repurposing therapeutic strategy through mitochondrial redox dynamics against neurodegeneration [J]. Current Neuropharmacology, 2022, 20(5): 893-915.

305.  ELROSASY A, RAMADAN A, ABDELHALIM N, et al. Sodium Oligomannate (GV-971) Safety and Efficacy in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials [J]. Cureus Journal of Medical Science, 2024, 16(7).

306.  ELROSASY A, ZEID M A, NEGIDA A. Sodium Oligomannate (GV-971) Safety and Efficacy in the Treatment of Alzheimer’s Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials (P11-9.005); proceedings of the Neurology, F, 2024 [C]. Lippincott Williams & Wilkins Hagerstown, MD.

307.  EROLTU K. Treatment options for Alzheimer’s Disease: An overview of the amyloid, tau, and alternate hypotheses [J]. Journal of High School Science, 2023, 7(4).

308.  ETTCHETO M, BUSQUETS O, CANO A, et al. Pharmacological strategies to improve dendritic spines in Alzheimer’s disease [J]. Journal of Alzheimer’s Disease, 2021, 82(s1): S91-S107.

309.  EVERETT B A, TRAN P, PRINDLE A. Toward manipulating serotonin signaling via the microbiota–gut–brain axis [J]. Current Opinion in Biotechnology, 2022, 78: 102826.

310.  EZGIN S. Effects of Enhanced TrkA Signaling in Mouse Embryonic Stem Cell-Derived Basal Forebrain Cholinergic Neurons Against the in Vitro Neurodegenerative Process of Alzheimer’s Disease [D]; Middle East Technical University (Turkey), 2022.

311.  FABRIZI E, ANCIDONI A, LOCURATOLO N, et al. The Italian guideline on diagnosis and treatment of dementia and mild cognitive impairment [J]. Age and Ageing, 2024, 53(11): afae250.

312.  FAN R. DESIGN, SYNTHESIS, AND EVALUATION OF 5-LIPOXYGENASE INHIBITOR PRODRUGS FOR ALZHEIMER’S DISEASE [D]; Temple University. Libraries, 2016.

313.  FAN X, LI J, DENG X, et al. Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation [J]. European Journal of Medicinal Chemistry, 2020, 193: 112217.

314.  FANG J, PIEPER A A, NUSSINOV R, et al. Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing [J]. Medicinal research reviews, 2020, 40(6): 2386-426.

315.  FANG X, ZHOU X, MIAO Y, et al. Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease [J]. Amb Express, 2020, 10: 1-13.

316.  FASINA O B, LI L, CHEN D, et al. Tetradecyl 2, 3-Dihydroxybenzoate Improves Cognitive Function in AD Mice by Modulating Autophagy and Inflammation Through IPA and Hsc70 Targeting [J]. International Journal of Molecular Sciences, 2024, 25(21): 11719.

317.  FENG Y, HAO F. Advances in natural polysaccharides in Alzheimer's disease and Parkinson's disease: Insights from the brain-gut axis [J]. Trends in Food Science & Technology, 2024: 104678.

318.  FENG Y, LI X, JI D, et al. Functionalised penetrating peptide-chondroitin sulphate‑gold nanoparticles: Synthesis, characterization, and applications as an anti-Alzheimer's disease drug [J]. International Journal of Biological Macromolecules, 2023, 230: 123125.

319.  FERRARI C, SORBI S. The complexity of Alzheimer’s disease: an evolving puzzle [J]. Physiological reviews, 2021, 101(3): 1047-81.

320.  FERREIRO A L, CHOI J, RYOU J, et al. Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease [J]. Science translational medicine, 2023, 15(700): eabo2984.

321.  FILLIT H, CUMMINGS J. Drug Disease: Development An Historical for Perspective Alzheimer’s [J]. Alzheimer's Disease Drug Development: Research and Development Ecosystem, 2022: 25.

322.  FILLIT H, CUMMINGS J. Drug Development for Alzheimer’s Disease: An Historical Perspective [J]. Alzheimer's Disease Drug Development: Research and Development Ecosystem, 2022: 25.

323.  FLORES-CUADRA J A, MADRID A, FERNáNDEZ P L, et al. Critical review of the Alzheimer’s disease non-transgenic models: Can they contribute to disease treatment? [J]. Journal of Alzheimer’s Disease, 2021, 82(s1): S227-S50.

324.  FRANCISCO T N, MALAFAIA D, MELO L, et al. Recent advances in fluorescent theranostics for Alzheimer’s disease: A comprehensive survey on design, synthesis, and properties [J]. ACS omega, 2024, 9(12): 13556-91.

325.  FRANZONI F, CAMMISULI D, SCARFò G, et al. Exploring Neurocognitive Deterioration in Alzheimer’s Disease. Biology 2023, 12, 343 [Z]. 2023

326.  FRANZONI F, CAMMISULI D M, SCARFò G, et al. Exploring Neurocognitive Deterioration in Alzheimer’s Disease [Z]. Multidisciplinary Digital Publishing Institute. 2023: 343

327.  FRöLICH L, HAUSNER L. Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit [J]. Der Nervenarzt, 2021, 92(12): 1239.

328.  FU X, ZHENG Y, LIN C, et al. An evaluation of the coupling coordination of technological innovation system in China’s marine biopharmaceutical industry [J]. Journal of Ocean University of China, 2023, 22(1): 271-84.

329.  FU Y, GU Z, CAO H, et al. The role of the gut microbiota in neurodegenerative diseases targeting metabolism [J]. Frontiers in Neuroscience, 2024, 18: 1432659.

330.  FüLöP T, MUNAWARA U, LARBI A, et al. Targeting infectious agents as a therapeutic strategy in Alzheimer’s disease [J]. CNS drugs, 2020, 34: 673-95.

331.  FULOP T, TRIPATHI S, RODRIGUES S, et al. Targeting impaired antimicrobial immunity in the brain for the treatment of Alzheimer’s disease [J]. Neuropsychiatric disease and treatment, 2021: 1311-39.

332.  GADHAVE K, KUMAR D, UVERSKY V N, et al. A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy [J]. Medicinal research reviews, 2021, 41(5): 2689-745.

333.  GAO D, LI P, GAO F, et al. Preparation and multitarget anti‐AD activity study of chondroitin sulfate lithium in AD mice induced by combination of D‐gal/AlCl3 [J]. Oxidative Medicine and Cellular Longevity, 2022, 2022(1): 9466166.

334.  GAO F, CHEN J, ZHOU Y, et al. Recent progress of small-molecule-based theranostic agents in Alzheimer's disease [J]. RSC Medicinal Chemistry, 2023, 14(11): 2231-45.

335.  GAO F, ZHAO J, LIU P, et al. Preparation and in vitro evaluation of multi-target-directed selenium-chondroitin sulfate nanoparticles in protecting against the Alzheimer's disease [J]. International journal of biological macromolecules, 2020, 142: 265-76.

336.  GAO H, FANG B, SUN Z, et al. Effect of human milk oligosaccharides on learning and memory in mice with Alzheimer’s disease [J]. Journal of Agricultural and Food Chemistry, 2023, 72(2): 1067-81.

337.  GAO M, DUAN X, LIU X-R, et al. Modulatory effects of Huoxiang Zhengqi oral liquid on gut microbiome homeostasis based on healthy adults and antibiotic-induced gut microbial dysbiosis mice model [J]. Frontiers in Pharmacology, 2022, 13: 841990.

338.  GAO W, DONG Q, WU X, et al. Bifunctional Inhibitor Lentinan Inhibits Fibrillogenesis of Amyloid-β Protein and α-Synuclein and Alleviates Their Cytotoxicity: In Vitro and In Vivo Studies [J]. ACS Chemical Neuroscience, 2024, 15(19): 3437-48.

339.  GAO Y, XU Y, YIN J. Selenomethionine ameliorates cognitive impairment, decreases hippocampal oxidative stress and attenuates dysbiosis in D-galactose-treated mice [J]. Antioxidants, 2022, 11(1): 111.

340.  GAO Y, ZHANG L, JIAO W. Marine glycan-derived therapeutics in China [J]. Progress in Molecular Biology and Translational Science, 2019, 163: 113-34.

341.  GAO Z, HOU R, QIAN C. Functional Proteins/Peptides Targeting to Clear Amyloid‐β for Alzheimer's Disease Therapy [J]. ChemBioChem, 2025, 26(4): e202400912.

342.  GATES E J, BERNATH A K, KLEGERIS A. Modifying the diet and gut microbiota to prevent and manage neurodegenerative diseases [J]. Reviews in the Neurosciences, 2022, 33(7): 767-87.

343.  GEBEL S. THERAPIE BEI DEMENZEN–GAMECHANGER ODER DEADEND? [J].

344.  GENG M. Causal communication between gut microbiota dysbiosis and neuroinflammation in Alzheimer’s disease and therapeutic intervention by oligomannate: Microbiome in Alzheimer’s disease: Pathogenesis and treatment implications [J]. Alzheimer's & Dementia, 2020, 16: e044151.

345.  GHAZNAVI G, HASHEMI S, ABOLHOSSEINI M M, et al. New insights into the role of nanotechnology in Bifidobacterium biomedical applications [J]. Advances in Natural Sciences: Nanoscience and Nanotechnology, 2024, 15(2): 023001.

346.  GIOVANNINI M G, LANA D, TRAINI C, et al. The microbiota–gut–brain axis and Alzheimer disease. From dysbiosis to neurodegeneration: Focus on the central nervous system glial cells [J]. Journal of Clinical Medicine, 2021, 10(11): 2358.

347.  GONCALVES P B, SODERO A C R, CORDEIRO Y. Green tea epigallocatechin-3-gallate (EGCG) targeting protein misfolding in drug discovery for neurodegenerative diseases [J]. Biomolecules, 2021, 11(5): 767.

348.  GONG B, JI W, CHEN X, et al. Recent advancements in strategies for abnormal protein clearance in Alzheimer's disease [J]. Mini Reviews in Medicinal Chemistry, 2022, 22(17): 2260-70.

349.  GONG C-X, DAI C-L, LIU F, et al. Multi-targets: An unconventional drug development strategy for Alzheimer’s disease [J]. Frontiers in aging neuroscience, 2022, 14: 837649.

350.  GONG H, HAN D, LUO Z, et al. Xiangshao Decoction alleviates gastric mucosal injury through NRF2 signaling pathway and reduces neuroinflammation in gastric ulcer rats [J]. Phytomedicine, 2023, 118: 154954.

351.  GOODHART C, PRADHAN M, GOODHART C, et al. Dependency, dementia and the coming crisis of caring [J]. The Great Demographic Reversal: Ageing Societies, Waning Inequality, and an Inflation Revival, 2020: 53-68.

352.  GOUILLY D, RAFIQ M, NOGUEIRA L, et al. Beyond the amyloid cascade: an update of Alzheimer's disease pathophysiology [J]. Revue Neurologique, 2023, 179(8): 812-30.

353.  GRAUL A, PINA P, TRACY M, et al. The year's new drugs and biologics 2019 [J]. Drugs Today, 2020, 56(1): 47.

354.  GRAUL A, PINA P, TRACY M, et al. A Report of New Drugs Research and Development in 2019 (IV) [J]. Progress in Pharmaceutical Sciences, 2020, 44(12): 954-64.

355.  GRAUL A, PINA P, TRACY M, et al. 2019 年全球新药研发报告 (Ⅳ) [J]. 药学进展, 2020, 44(12): 954-64.

356.  GRIEHL C, SCHMID A, WILHELM C. Meilensteine in der Algenbiotechnologie [J]. BIOspektrum, 2023, 29(3): 306-9.

357.  GRIMMER T. Therapieentwicklungen bei der Alzheimer-Krankheit [J]. Fortschritte der Neurologie· Psychiatrie, 2022, 90(07/08): 352-60.

358.  GU X, ZHOU J, ZHOU Y, et al. Huanglian Jiedu decoction remodels the periphery microenvironment to inhibit Alzheimer’s disease progression based on the “brain-gut” axis through multiple integrated omics [J]. Alzheimer's Research & Therapy, 2021, 13: 1-18.

359.  GU Y. ROS scavenging based multifunctional nanoparticles for neurological disorders therapy [J]. 2024.

360.  GUO X, GAO L, JIN J, et al. Knowledge of the public about the role of lumbar puncture in the diagnosis of Alzheimer's disease in China [J]. 2022.

361.  GUO X, GAO L, LIU J, et al. Public acceptability of lumbar puncture in the diagnosis of Alzheimer’s disease: a questionnaire-based single center study in China [J]. American Journal of Translational Research, 2023, 15(6): 4179.

362.  GUO Y, XU Y, LIN X, et al. Creutzfeldt-Jakob disease: alterations of gut microbiota [J]. Frontiers in neurology, 2022, 13: 832599.

363.  GUPTA A, SHARMA V, SINGH N. Ongoing clinical trials of new drugs for Alzheimer’s disease: A review article [J]. 2021.

364.  GUPTA B, ROHATGI K. Neuropharmacology in Alzheimer and Huntington Disease [M]. Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches. Bentham Science Publishers. 2022: 218-60.

365.  GUPTA R, RAGHUWANSHI S. Designer probiotics in metabolic disorders [M]. Probiotic Research in Therapeutics: Volume 5: Metabolic Diseases and Gut Bacteria. Springer. 2022: 241-60.

366.  HAFEZ GHORAN S, KIJJOA A. Marine-derived compounds with anti-Alzheimer’s disease activities [J]. Marine Drugs, 2021, 19(8): 410.

367.  HAGER K. Alzheimer's disease-Which substances are at present in phase III studies? [J]. Der Nervenarzt, 2022, 93(10): 1028-34.

368.  HAMMOND T C, LIN A-L. Glucose metabolism is a better marker for predicting clinical Alzheimer’s disease than amyloid or tau [J]. Journal of cellular immunology, 2022, 4(1): 15.

369.  HAN N, WEN Y, LIU Z, et al. Advances in the roles and mechanisms of lignans against Alzheimer’s disease [J]. Frontiers in Pharmacology, 2022, 13: 960112.

370.  HAN W, ZHOU Q, WANG M-W. Current challenges and future perspectives of drug discovery in China [J]. Expert Opinion on Drug Discovery, 2025, (just-accepted).

371.  HANNAN M A, DASH R, HAQUE M N, et al. Neuroprotective potentials of marine algae and their bioactive metabolites: Pharmacological insights and therapeutic advances [J]. Marine drugs, 2020, 18(7): 347.

372.  HAO C, HAN M, WANG W, et al. The neuroprotective effects of peracetylated chitosan oligosaccharides against β-amyloid-induced cognitive deficits in rats [J]. Marine life science & technology, 2023, 5(2): 211-22.

373.  HAO Z, LI L, NING Z, et al. Growth phase-dependent responses of an in vitro gut microbiome to metformin [J]. bioRxiv, 2020: 2020.02. 05.936500.

374.  HASSANZADEH A, YEGDANEH A, RABBANI M. Effects of hydroalcoholic, methanolic, and hexane extracts of brown algae Sargassum angustifolium on scopolamine-induced memory impairment and learning deficit in rodents [J]. Research in Pharmaceutical Sciences, 2023, 18(3): 292-302.

375.  HE F. Drug Discovery based on Oxidative Stress and HDAC6 for Treatment of Neurodegenerative Diseases [M]. Bayerische Julius-Maximilians-Universitaet Wuerzburg (Germany), 2021.

376.  HE J, SUN S, WANG H, et al. Triple-Target Inhibition of Cholinesterase, Amyloid Aggregation, and GSK3β to Ameliorate Cognitive Deficits and Neuropathology in the Triple-Transgenic Mouse Model of Alzheimer’s Disease [J]. Neuroscience Bulletin, 2025: 1-16.

377.  HE J, TAM K Y. Current mouse models of Alzheimer’s disease for investigating therapeutic agents [M]. Handbook of Animal Models in Neurological Disorders. Elsevier. 2023: 31-41.

378.  HE J, TAM K Y. Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer’s disease [J]. Drug discovery today, 2024, 29(4): 103914.

379.  HE X, YOUNG S-H, SCHWEGLER-BERRY D, et al. Multiwalled carbon nanotubes induce a fibrogenic response by stimulating reactive oxygen species production, activating NF-κB signaling, and promoting fibroblast-to-myofibroblast transformation [J]. Chemical research in toxicology, 2011, 24(12): 2237-48.

380.  HE Y, LI B, SUN D, et al. Gut microbiota: Implications in Alzheimer’s disease [J]. Journal of clinical medicine, 2020, 9(7): 2042.

381.  HE Z, LI X, WANG Z, et al. Esculentoside A alleviates cognitive deficits and amyloid pathology through peroxisome proliferator-activated receptor γ-dependent mechanism in an Alzheimer's disease model [J]. Phytomedicine, 2022, 98: 153956.

382.  HELGUDóTTIR S S, MøRKHOLT A S, LICHOTA J, et al. Rethinking neurodegenerative diseases: neurometabolic concept linking lipid oxidation to diseases in the central nervous system [J]. Neural Regeneration Research, 2024, 19(7): 1437-45.

383.  HENDRIX J A, BATEMAN R J, BRASHEAR H R, et al. Challenges, solutions, and recommendations for Alzheimer's disease combination therapy [J]. Alzheimer's & Dementia, 2016, 12(5): 623-30.

384.  HERNANDEZ A R, HOFFMAN J M, HERNANDEZ C M, et al. Reuniting the body “neck up and neck down” to understand cognitive aging: the nexus of geroscience and neuroscience [J]. The Journals of Gerontology: Series A, 2022, 77(1): e1-e9.

385.  HOLE K L, WILLIAMS R J. Flavonoids as an intervention for Alzheimer’s disease: progress and hurdles towards defining a mechanism of action 1 [J]. Brain Plasticity, 2020, 6(2): 167-92.

386.  HOMOLAK J. Patofiziološke promjene probavnog sustava u životinjskim modelima Alzheimerove i Parkinsonove bolesti [D]; University of Zagreb. School of Medicine, 2023.

387.  HOSSAIN S J, JYOTI M A, ISLAM M R, et al. Comparison in Nutrient and Bioactivities of Carbohydrate and Ethanol-methanol Extracts of Aegiceras corniculatum (L.) Fruit [J]. Khulna University Studies, 2024: 67-72.

388.  HOU J, WEI Y, TAN Q, et al. Research Progress on Mild Cognitive Impairment and Its Relationship with Lifestyle [J]. 2019.

389.  HU C, JIANG L, TANG L, et al. Design, synthesis and biological evaluation of 2-styryl-5-hydroxy-4-pyrone derivatives and analogues as multiple functional agents with the potential for the treatment of Alzheimer’s disease [J]. Bioorganic & Medicinal Chemistry, 2021, 44: 116306.

390.  HU D, JIN Y, HOU X, et al. Application of marine natural products against Alzheimer’s disease: past, present and future [J]. Marine Drugs, 2023, 21(1): 43.

391.  HU H, MENG J, ZHENG H, et al. Relief effect of biochar on continuous cropping of tobacco through the reduction of p-hydroxybenzoic acid in soil [J]. Heliyon, 2024, 10(12).

392.  HU L, TAO Y, JIANG Y, et al. Recent progress of nanomedicine in the treatment of Alzheimer’s disease [J]. Frontiers in Cell and Developmental Biology, 2023, 11: 1228679.

393.  HU S, YANG C, LUO H. Current trends in blood biomarker detection and imaging for Alzheimer’s disease [J]. Biosensors and Bioelectronics, 2022, 210: 114278.

394.  HUANG C, ZHANG Z, CUI W. Marine-derived natural compounds for the treatment of Parkinson’s disease [J]. Marine drugs, 2019, 17(4): 221.

395.  HUANG H, SHARMA H S, CHEN L, et al. Neurorestoratology: new advances in clinical therapy [J]. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders), 2023, 22(7): 1031-8.

396.  HUANG H, XIAO Z, LUO T, et al. CO87 Lifetime Cumulative Risk of Bone Fracture in Chinese Male Patients with Osteoporosis: A Model Simulation Study [J]. Value in Health, 2023, 26(12): S29-S30.

397.  HUANG J, HUANG N, CUI D, et al. Clinical antidiabetic medication used in Alzheimer’s disease: From basic discovery to therapeutics development [J]. Frontiers in Aging Neuroscience, 2023, 15: 1122300.

398.  HUANG J, HUANG N, MAO Q, et al. Natural bioactive compounds in Alzheimer's disease: From the perspective of type 3 diabetes mellitus [J]. Frontiers in aging neuroscience, 2023, 15: 1130253.

399.  HUANG J, QIN T-S, BO Y, et al. The Role of the Intestinal Flora and Its Derivatives in Neurocognitive Disorders: A Narrative Review from Surgical Perspective [J]. Molecular Neurobiology, 2025, 62(2): 1404-14.

400.  HUANG K-Y, TANG X-Y, YANG L, et al. Inactive bowel movement and stroke are associated with increased risks of mild cognitive impairment among community-living Singapore elderly [J]. Aging (Albany NY), 2020, 12(17): 17257.

401.  HUANG L, ZENG Y, LI Y, et al. Distribution in rat blood and brain of TDMQ20, a copper chelator designed as a drug-candidate for Alzheimer’s disease [J]. Pharmaceutics, 2022, 14(12): 2691.

402.  HUANG L-K, CHAO S-P, HU C-J. Clinical trials of new drugs for Alzheimer disease [J]. Journal of biomedical science, 2020, 27: 1-13.

403.  HUANG L-K, KUAN Y-C, LIN H-W, et al. Clinical trials of new drugs for Alzheimer disease: A 2020–2023 update [J]. Journal of biomedical science, 2023, 30(1): 83.

404.  HUANG W, ZHOU Y, TU L, et al. TDP-43: from Alzheimer’s disease to limbic-predominant age-related TDP-43 encephalopathy [J]. Frontiers in Molecular Neuroscience, 2020, 13: 26.

405.  HUANG X, ZHANG X, LI X, et al. Network Pharmacology-Based Analysis on the Mechanism of Drug Pair of Astragalus Membranaceus and Acorus Tatarinowii in the Treatment of Alzheimer’s Disease [M]. Computer Methods in Medicine and Health Care. IOS Press. 2021: 115-27.

406.  HUSSEIN A I H. ALZHEIMER: SFIDE DIAGNOSTICHE, TERAPIE EMERGENTI E PROSPETTIVE FUTURE [J]. 2023.

407.  IBRAHIM M M A. Mild cognitive impairment in older adults: Predictors, diagnosis, and management [J]. IJPS, 2025, 7(1): 36-45.

408.  ILIĆOVá M. Alzheimerova choroba-pokroky v léčbě a diagnostice [J]. 2021.

409.  IMBIMBO B P, LOZUPONE M, WATLING M, et al. Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives [J]. Expert opinion on investigational drugs, 2020, 29(9): 919-33.

410.  ISKALA S. Suolistomikrobiomin vaikutus Alzheimerin taudin kehitykseen [D]; S. Iskala, 2023.

411.  ISLAM A U, HADNI H, ALI F, et al. Synthesis, antimicrobial activity, molecular docking, molecular dynamics simulation, and ADMET properties of the mannopyranoside derivatives as antimicrobial agents [J]. Journal of Taibah University for Science, 2024, 18(1): 2327101.

412.  ISLAM M R, RABBI M A, HOSSAIN T, et al. Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review [J]. ACS Chemical Neuroscience, 2024, 15(20): 3589-614.

413.  ITZHAKI R F. Hypothesis: Does the apparent protective action of Green Valley’s drug GV971 against cognitive decline result from antiviral action against Herpes Simplex Virus type 1 in brain? [Z]. SAGE Publications Sage UK: London, England. 2020: 85-7

414.  ITZHAKI R F. Antivirals against SARS-CoV2: relevance to the treatment of Alzheimer’s disease [J]. Journal of Alzheimer’s Disease, 2020, 78(3): 905-6.

415.  ITZHAKI R F. Overwhelming evidence for a major role for herpes simplex virus type 1 (HSV1) in Alzheimer’s disease (AD); underwhelming evidence against [J]. Vaccines, 2021, 9(6): 679.

416.  JADHAV D, SARASWAT N, VYAWAHARE N, et al. Targeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy [J]. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2024, 60(1): 7.

417.  JALALI D, GUEVARRA J A, MARTINEZ L, et al. Nutraceutical and probiotic approaches to examine molecular interactions of the amyloid precursor protein APP in Drosophila models of alzheimer’s disease [J]. International Journal of Molecular Sciences, 2021, 22(13): 7022.

418.  JANNAT K, BALAKRISHNAN R, HAN J-H, et al. The neuropharmacological evaluation of seaweed: A potential therapeutic source [J]. Cells, 2023, 12(22): 2652.

419.  JANSSENS Y, DEBUNNE N, DE SPIEGELEER A, et al. PapRIV, a BV-2 microglial cell activating quorum sensing peptide [J]. Scientific reports, 2021, 11(1): 10723.

420.  JARAMILLO-JIMENEZ A, YING Y, REN P, et al. Prodromal dementia with Lewy bodies and recurrent panic attacks as the first symptom: a case report [J]. Frontiers in Neurology, 2022, 13: 839539.

421.  JARNE-FERRER J, GRIñáN-FERRé C, BELLVER-SANCHIS A, et al. A Combined Chronic Low-Dose Soluble Epoxide Hydrolase and Acetylcholinesterase Pharmacological Inhibition Promotes Memory Reinstatement in Alzheimer’s Disease Mice Models [J]. Pharmaceuticals, 2022, 15(8): 908.

422.  JEREMIC D, JIMéNEZ-DíAZ L, NAVARRO-LóPEZ J D. Targeting epigenetics: a novel promise for Alzheimer’s disease treatment [J]. Ageing Research Reviews, 2023, 90: 102003.

423.  JI D, WU X, LI D, et al. Protective effects of chondroitin sulphate nano-selenium on a mouse model of Alzheimer's disease [J]. International journal of biological macromolecules, 2020, 154: 233-45.

424.  JI J, WANG D, ZHANG Y. Marine biopharmaceutical industrial policies in China: Evolution, characteristics, and challenges [J]. Ocean & Coastal Management, 2022, 225: 106224.

425.  JI S, WU Y, ZHU R, et al. Novel Phenylethanoid glycosides improve hippocampal synaptic plasticity via the cyclic adenosine monophosphate-CREB-brain-derived neurotrophic growth factor pathway in APP/PS1 transgenic mice [J]. Gerontology, 2023, 69(9): 1065-75.

426.  JI X, LI P, GUO Q, et al. Salivary microbiome profiles for different clinical phenotypes of pituitary adenomas by single-molecular long-read sequencing [J]. Microbiology Spectrum, 2023, 11(6): e00234-23.

427.  JIA C, CHAI J, ZHANG S, et al. The Advancements of Marine Natural Products in the Treatment of Alzheimer’s Disease: A Study Based on Cell and Animal Experiments [J]. Marine Drugs, 2025, 23(3): 91.

428.  JIAJIE W, XINTONG W, YUANHENG L, et al. Current Landscape for Research and Development of α7-Nicotine Acetylcholine Receptor Targeting Positive Allosteric Modulators for Improvement of Cognitive Impairment [J]. Progress in Pharmaceutical Sciences, 2020, 44(8): 573-87.

429.  JIAN Y. Chemical glycobiology drives the discovery of carbohydrate-based drugs [Z]. 2020: 721-2

430.  JIAO J-J, HU Y, CUI Y-J, et al. Anisomycin alleviates cognitive impairments and pathological features in 3xTg-AD mice [J]. Neuropharmacology, 2024, 261: 110159.

431.  JIAO R, ZHANG D, ZHU W, et al. Preparation of polyhydroxy hydrophilic chromatographic stationary phases for alginate oligosaccharide separation [J]. European Polymer Journal, 2025, 232: 113949.

432.  JIAQI S, JING L, JIAYING L, et al. Cluster analysis method of bacterial 16S rRNA gene sequencing: research progress [J]. Chinese Journal of Microecology, 2023, 35(7): 864-8.

433.  JIE S, GUIHUA X. Research progress in the relationship between Alzheimer's disease and blood-brain barrier [J]. Journal of Practical Medicine/Shiyong Yixue Zazhi, 2024, 40(11).

434.  JIMENEZ‐GARCíA A M, VILLARINO M, ARIAS N. A systematic review and meta‐analysis of basal microbiota and cognitive function in Alzheimer's disease: A potential target for treatment or a contributor to disease progression? [J]. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2024, 16(4): e70057.

435.  JIN S, LU W, ZHANG J, et al. The mechanisms, hallmarks, and therapies for brain aging and age-related dementia [J]. Science Bulletin, 2024.

436.  JIN Z, ZHANG C, LIU M, et al. Synthesis, biological activity, molecular docking studies of a novel series of 3-Aryl-7 H-thiazolo [3, 2-b]-1, 2, 4-triazin-7-one derivatives as the acetylcholinesterase inhibitors [J]. Journal of Biomolecular Structure and Dynamics, 2021, 39(7): 2478-89.

437.  JINGJING M, BOZUN W. Alzheimer's drug wins quick approval [J]. Global Times Business, 2019: NA-NA.

438.  JOLY P, LABSY R, SILVIN A. Aging and neurodegeneration: when systemic dysregulations affect brain macrophage heterogeneity [J]. The Journal of Immunology, 2025, 214(5): 880-8.

439.  JONES G H, PINJARI O F, VECERA C M, et al. The role of the gut microbiome in bipolar disorder and its common medical comorbidities [J]. Frontiers in Neuroendocrinology, 2023, 70: 101078.

440.  JUN L, LING Y, BO H, et al. Application of Montreal Cognitive Assessment Scale to the elderly in Chinese community [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021, 41(12): 1662-7.

441.  KADIAN M, RAWAT N, TAINGURIYA H, et al. Accelerating Alzheimer s Disease Research by Pharmacologic, Genetic, and Computational Based Animal Models [M]. Animal Models for Neurological Disorders. Bentham Science Publishers. 2021: 1-51.

442.  KAMALJEET P R. ISAR Journal of Applied Medical Sciences [J].

443.  KANG N, LUAN Y, JIANG Y, et al. Neuroprotective effects of oligosaccharides in rehmanniae radix on transgenic caenorhabditis elegans models for alzheimer’s disease [J]. Frontiers in Pharmacology, 2022, 13: 878631.

444.  KARAMAN R. Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6 [J]. 2019.

445.  KARDAM S, AMBASTA R K, KUMAR P. Overview of pro-inflammatory and pro-survival components in neuroinflammatory signalling and neurodegeneration [J]. Ageing Research Reviews, 2024: 102465.

446.  KASSAB A E, GEDAWY E M, SAYED A S. Fused thiophene as a privileged scaffold: a review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation [J]. International Journal of Biological Macromolecules, 2024: 131018.

447.  KATSOULAKI E-E, DIMOPOULOS D, HADJIPAVLOU-LITINA D. Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases [J]. Pharmaceuticals, 2025, 18(6): 831.

448.  KAUR N, KUMAR V, MAHENDER T, et al. Nanomedical drug delivery for neurodegenerative disease [M]. Nanomedical Drug Delivery for Neurodegenerative Diseases. Elsevier. 2022: 67-79.

449.  KAUR P, KHERA A, ALAJANGI H K, et al. Role of tau in various tauopathies, treatment approaches, and emerging role of nanotechnology in neurodegenerative disorders [J]. Molecular Neurobiology, 2023, 60(3): 1690-720.

450.  KAURA N, KUMARA V, MAHENDERA T, et al. Nanomedical drug delivery for neurodegenerative disease [J]. Nanomedical Drug Delivery for Neurodegenerative Diseases, 2022: 67.

451.  KAZZI C, KUZNETSOVA V, SIRIRATNAM P, et al. Cognition following chimeric antigen receptor T-cell therapy: A systematic review [J]. Journal of Autoimmunity, 2023, 140: 103126.

452.  KE-WU Z. Annual advances of integrative pharmacology in 2019 [J]. Traditional Medicine Research, 2020, 5(2): 74.

453.  KEEP B. An associative analysis of recognition memory [D]; University of Nottingham, 2023.

454.  KESHAVARZIAN A, SISODIA S S. Gut microbiota dysbiosis and neurologic diseases: New Horizon with potential diagnostic and therapeutic impact [J]. Neurotherapeutics, 2024, 21(6).

455.  KHAIBRAKHMANOVA D R, KUZIVANOVA P R, GAINUTDINOV B R, et al. The Contrasting Effect of Sodium Alginate on Lysozyme and Albumin Denaturation and Fibril Formation [J]. Biophysica, 2024, 4(4): 651-66.

456.  KHALIFA K, BERGLAND A K, SOENNESYN H, et al. Effects of purified anthocyanins in people at risk for dementia: study protocol for a phase II randomized controlled trial [J]. Frontiers in Neurology, 2020, 11: 916.

457.  KHAN M A, ASHFAQ Q U A, ABBAS D, et al. Exploring Immunotherapeutic Approaches for Alzheimer’s Disease [J]. 2025.

458.  KHATSURIA F, MCMULLAN C, AIYEGBUSI O L, et al. Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies [J]. The Lancet Oncology, 2024, 25(10): e476-e88.

459.  KHEZRI M R, ESMAEILI A, GHASEMNEJAD-BERENJI M. Role of Bmal1 and gut microbiota in Alzheimer’s disease and Parkinson’s disease pathophysiology: the probable effect of melatonin on their association [J]. ACS Chemical Neuroscience, 2023, 14(21): 3883-93.

460.  KHOURY R, GALLOP A, ROBERTS K, et al. Pharmacotherapy for Alzheimer’s disease: what’s new on the horizon? [J]. Expert Opinion on Pharmacotherapy, 2022, 23(11): 1305-23.

461.  KHOURY R, GROSSBERG G T. Deciphering Alzheimer’s disease: Predicting new therapeutic strategies via improved understanding of biology and pathogenesis [J]. Expert opinion on therapeutic targets, 2020, 24(9): 859-68.

462.  KIM C K, LEE Y R, ONG L, et al. Alzheimer’s disease: key insights from two decades of clinical trial failures [J]. Journal of Alzheimer’s Disease, 2022, 87(1): 83-100.

463.  KIM J, JEON H, YUN KIM H, et al. Failure, success, and future direction of Alzheimer drugs targeting amyloid‐β cascade: pros and cons of chemical and biological modalities [J]. ChemBioChem, 2023, 24(19): e202300328.

464.  KIM N, DO J, JU I G, et al. Picrorhiza kurroa prevents memory deficits by inhibiting NLRP3 inflammasome activation and BACE1 expression in 5xFAD mice [J]. Neurotherapeutics, 2020, 17: 189-99.

465.  KINNEY J, SALAZAR A. Biobanking Chapter and Biomarkers in the Alzheimer’s Disease Drug-Development [J]. Alzheimer's Disease Drug Development: Research and Development Ecosystem, 2022: 123.

466.  KINNEY J, SALAZAR A. Biobanking and Biomarkers in the Alzheimer’s Disease Drug-Development Ecosystem [J]. Alzheimer's Disease Drug Development: Research and Development Ecosystem, 2022: 123.

467.  KLEINOVá L, CERMAN J, HLáVKA J, et al. Nové farmakologické možnosti v léčbě Alzheimerovy nemoci [J]. Česká a Slovenská Neurologie a Neurochirurgie, 2022, 85(6).

468.  KLOSE J, GRIEHL C, ROßNER S, et al. Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease [J]. 2022.

469.  KLOSE J, GRIEHL C, ROßNER S, et al. Natural products from plants and algae for treatment of Alzheimer’s disease: A review [J]. Biomolecules, 2022, 12(5): 694.

470.  KLOSE J, GRIEHL C, ROßNER S, et al. Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review. Biomolecules 2022, 12, 694 [Z]. s Note: MDPI stays neutral with regard to jurisdictional claims in published …. 2022

471.  KONECNY J, MISIACHNA A, HRABINOVA M, et al. Pursuing the complexity of Alzheimer’s disease: discovery of fluoren-9-amines as selective butyrylcholinesterase inhibitors and N-methyl-d-aspartate receptor antagonists [J]. Biomolecules, 2020, 11(1): 3.

472.  KORáBEČNý J. Multipotentní sloučeniny v terapii Alzheimerovy choroby [J]. 2020.

473.  KOTHA S, KULKARNI V M, S R S. An in-silico approach: identification of PPAR-γ agonists from seaweeds for the management of Alzheimer’s Disease [J]. Journal of Biomolecular Structure and Dynamics, 2021, 39(6): 2210-29.

474.  KUBISTA M, PEREZ MEEK G, SRAMEK K, et al. Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease [J]. Psychiatric Times, 2024, 41(2).

475.  KUHN J S, GARNER B A. The rules of golf in plain English [M]. University of Chicago Press, 2016.

476.  KULKARNI R, KUMARI S, DHAPOLA R, et al. Association Between the Gut Microbiota and Alzheimer’s Disease: An Update on Signaling Pathways and Translational Therapeutics [J]. Molecular Neurobiology, 2024: 1-21.

477.  KUMAR A. Animal Models for Neurological Disorders [M]. Bentham Science Publishers, 2021.

478.  KUMAR B, THAKUR A, DWIVEDI A R, et al. Multi-target-directed ligands as an effective strategy for the treatment of Alzheimer’s disease [J]. Current Medicinal Chemistry, 2022, 29(10): 1757-803.

479.  KUMAR S, MAHAJAN A, AMBATWAR R, et al. Recent Advancements in the Treatment of Alzheimer's Disease: A Multitarget-directed Ligand Approach [J]. Current Medicinal Chemistry, 2024, 31(37): 6032-62.

480.  KUMARI M, SADHU P, SHAH N, et al. Marine Pharmacognosy [J]. Pharmacognosy and Phytochemistry: Principles, Techniques, and Clinical Applications, 2025: 371-94.

481.  KUŹNIAR J, KOZUBEK P, CZAJA M, et al. Correlation between Alzheimer’s Disease and Gastrointestinal Tract Disorders [J]. Nutrients, 2024, 16(14): 2366.

482.  LAI H-Y, SHEN T. Gut Microbiota, Alzheimer and Psychiatric Diseases: Unveiling the Relationships and Treatment Options [M]. Gut Microbiota in Aging and Chronic Diseases. Springer. 2023: 279-333.

483.  LALHMANGAIHZUALA S, VANLALDINPUIA K, KHIANGTE V, et al. Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement [J]. Molecular Diversity, 2024: 1-27.

484.  LAM S. Transmission of Alzheimer pathology in murine and primate models: from proteinopathies to neuronal and cognitive impairments [D]; Université Paris-Saclay, 2021.

485.  LANFRANCHI F. ALTERAZIONI DEL METABOLISMO DEL RAME NELLE DIVERSE FASI DELLA MALATTIA DI ALZHEIMER. STUDIO SPERIMENTALE COMPARATIVO [J].

486.  LANTHIER C. Conception, synthèse et évaluation de nouveaux composés à dualité d'action agoniste des récepteurs 5-HT4 et antioxydante, d'intérêt thérapeutique pléiotrope dans la maladie d'Alzheimer [D]; Normandie Université, 2020.

487.  LEANDRO A, PACHECO D, GARCíA-POZA S, et al. Macroalgae: Current Applications in Daily Life and Prospects for the Future [J]. Algal Metabolites, 2023: 205-50.

488.  LEE J Y, WONG C Y, KOH R Y, et al. Natural bioactive compounds from macroalgae and microalgae for the treatment of Alzheimer’s disease: A review [J]. The Yale Journal of Biology and Medicine, 2024, 97(2): 205.

489.  LEE S, LI L, DENG J, et al. The Importance of Cooperating with China in the Global Health System [J]. Rotas a Oriente Revista de estudos sino-portugueses, 2022, (2): 127-47.

490.  LEI K, ZHOU L, DAN M, et al. Trojan Horse Delivery Strategies of Natural Medicine Monomers: Challenges and Limitations in Improving Brain Targeting [J]. Pharmaceutics, 2025, 17(3): 280.

491.  LENKA A, JANKOVIC J. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson’s disease? [J]. Expert Review of Neurotherapeutics, 2023, 23(2): 107-22.

492.  LEYHE T, JUCKER M, NEF T, et al. Conference report: dementia research and care and its impact in Switzerland [J]. Swiss medical weekly, 2020, 150(w20376): w20376.

493.  LI B, LI J, HAO Y, et al. Yuanzhi Powder inhibits tau pathology in SAMP8 mice: mechanism research of a traditional Chinese formula against Alzheimer's disease [J]. Journal of Ethnopharmacology, 2023, 311: 116393.

494.  LI C, LIU K, ZHU J, et al. High Plasma Levels of Aβ1-42 Affect Monocytes and Macrophages via Biphasic Effects on Myeloid-Derived Suppressor Cells and Granulocyte-Monocyte Progenitors in Mouse Models of Alzheimer’s Disease [J]. 2021.

495.  LI C, LIU K, ZHU J, et al. The effects of high plasma levels of Aβ [J]. 2023.

496.  LI C, LIU K, ZHU J, et al. The effects of high plasma levels of Aβ1-42 on mononuclear macrophage in mouse models of Alzheimer’s disease [J]. Immunity & Ageing, 2023, 20(1): 39.

497.  LI D, LI Y, ZHANG Z. Research progress in relationship between gut microbiota and Alzheimer’s disease; proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023), F, 2023 [C]. SPIE.

498.  LI G, ZHOU Y, YANG W-Y, et al. Inhibitory effects of sulfated polysaccharides from the sea cucumber cucumaria frondosa against Aβ40 aggregation and cytotoxicity [J]. ACS Chemical Neuroscience, 2021, 12(11): 1854-9.

499.  LI H, ZHENG C, ZHENG Y, et al. Distinct functional diversity of branched oligosaccharides as chaperones and inhibitory-binding partners of amyloid beta-protein and its aggregates [J]. Neuropharmacology, 2024, 261: 110141.

500.  LI H-Y, YI Y-L, GUO S, et al. Isolation, structural characterization and bioactivities of polysaccharides from Laminaria japonica: A review [J]. Food Chemistry, 2022, 370: 131010.

501.  LI J. APS celebrates the 90th anniversary of SIMM [J]. Acta Pharmacologica Sinica, 2022, 43(12): 3013-4.

502.  LI J, CAI C, YANG C, et al. Recent advances in pharmaceutical potential of brown algal polysaccharides and their derivatives [J]. Current Pharmaceutical Design, 2019, 25(11): 1290-311.

503.  LI J, HAO Y, WANG S, et al. Yuanzhi powder facilitated Aβ clearance in APP/PS1 mice: Target to the drainage of glymphatic system and meningeal lymphatic vessels [J]. Journal of Ethnopharmacology, 2024, 319: 117195.

504.  LI J, LIAO X, YIN X, et al. Gut microbiome and serum metabolome profiles of capsaicin with cognitive benefits in APP/PS1 mice [J]. Nutrients, 2022, 15(1): 118.

505.  LI J, MOU H, YAO R. Gut-Brain Axis and a Systematic Approach to Alzheimer’s Disease Therapies [J]. Brain Science Advances, 2025, 11(1): BSA. 2024.9050031.

506.  LI J, SHAO M, LIU H, et al. Lithium Coupled with C6-Carboxyl Improves the Efficacy of Oligoguluronate in DSS-Induced Ulcerative Colitis in C57BL/6J Mice [J]. Marine Drugs, 2024, 22(12): 573.

507.  LI J, ZOU B, CHENG X-Y, et al. Therapeutic effects of total saikosaponins from Radix bupleuri against Alzheimer’s disease [J]. Frontiers in Pharmacology, 2022, 13: 940999.

508.  LI K, GAO Y, LIU M, et al. Advances in Alzheimer's Disease Biomarkers [J]. Current Alzheimer Research, 2024.

509.  LI L, JIANG J, YAO Z, et al. Recent advances in the production, properties and applications of alginate oligosaccharides-a mini review [J]. World Journal of Microbiology and Biotechnology, 2023, 39(8): 207.

510.  LI L, YAN S, LIU S, et al. In-depth insight into correlations between gut microbiota and dietary fiber elucidates a dietary causal relationship with host health [J]. Food Research International, 2023, 172: 113133.

511.  LI L, ZHU B, YAO Z, et al. Directed preparation, structure–activity relationship and applications of alginate oligosaccharides with specific structures: A systematic review [J]. Food Research International, 2023, 170: 112990.

512.  LI M, CHEN W-D, WANG Y-D. The roles of the gut microbiota–miRNA interaction in the host pathophysiology [J]. Molecular Medicine, 2020, 26: 1-9.

513.  LI M, TONG F, WU B, et al. Radiation-Induced Brain Injury: Mechanistic Insights and the Promise of Gut–Brain Axis Therapies [J]. Brain Sciences, 2024, 14(12): 1295.

514.  LI R, MIAO Z, LIU Y E, et al. The brain–gut–bone axis in neurodegenerative diseases: insights, challenges, and future prospects [J]. Advanced Science, 2024, 11(38): 2307971.

515.  LI R, ZHUO Z, YAO Z, et al. Neuroimaging analysis reveals distinct cerebral perfusion responses to fasting‐postprandial metabolic switching in Alzheimer's disease patients [J]. CNS Neuroscience & Therapeutics, 2024, 30(9): e70014.

516.  LI S, WANG L, LIU B, et al. Unsaturated alginate oligosaccharides attenuated obesity-related metabolic abnormalities by modulating gut microbiota in high-fat-diet mice [J]. Food & function, 2020, 11(5): 4773-84.

517.  LI S, WEI Y, LIANG Z, et al. Review on dietary supplements as an effective improvement of Alzheimer’s disease: Focus on structures and mechanisms [J]. Food Science and Human Wellness, 2024, 13(4): 1787-805.

518.  LI X, LI Y, MA Z, et al. The Role of Gut Microbiota in the Mechanism of Cognitive Impairment in the Elderly [J]. Open Journal of Modern Neurosurgery, 2022, 12(4): 197-215.

519.  LI X, WANG D, ZHANG P, et al. Recent advances in the chemical synthesis of marine acidic carbohydrates [J]. Current Organic Chemistry, 2021, 25(4): 507-18.

520.  LI Y, CHEN Y, JIANG L, et al. Intestinal inflammation and Parkinson’s disease [J]. Aging and disease, 2021, 12(8): 2052.

521.  LI Y, LIU A, CHEN L, et al. Lactobacillus plantarum WSJ-06 alleviates neurobehavioral injury induced by lead in mice through the gut microbiota [J]. Food and Chemical Toxicology, 2022, 167: 113308.

522.  LI Z, LI Y, ZHANG J, et al. Serum metabolomics combined with gut microbiota reveals the effects of Polygala tenuifolia polysaccharide on the metabolic and microbial profiles in SAMP8 mouse [J]. Journal of Pharmaceutical and Biomedical Analysis, 2024, 251: 116442.

523.  LI Z, MA J-L, YANG J, et al. Discovery of Atractylenolide Derivatives as Novel LSD1 Inhibitors for the Treatment of Alzheimer’s Disease [J]. Journal of Agricultural and Food Chemistry, 2025.

524.  LI Z, ZHANG Z, YU B. Unlocking the Therapeutic Potential of Natural Products for Alzheimer’s Disease [J]. Journal of Medicinal Chemistry, 2025.

525.  LI Z H, JIANG Y Y, LONG C Y, et al. The gut microbiota‐astrocyte axis: implications for type 2 diabetic cognitive dysfunction [J]. CNS Neuroscience & Therapeutics, 2023, 29: 59-73.

526.  LIANG J, WANG Y, LIU B, et al. Deciphering the intricate linkage between the gut microbiota and Alzheimer's disease: Elucidating mechanistic pathways promising therapeutic strategies [J]. CNS Neuroscience & Therapeutics, 2024, 30(4): e14704.

527.  LIANG P, WANG Y, LIU J, et al. Identification and Exploration of Immunity‐Related Genes and Natural Products for Alzheimer's Disease Based on Bioinformatics, Molecular Docking, and Molecular Dynamics [J]. Immunity, Inflammation and Disease, 2025, 13(4): e70166.

528.  LIAO W, CAO D, WANG Y, et al. 1, 3-and 1, 4-linked Polysaccharides Uptake in Intestinal Cells Relies on Clathrin/Dynamin 1/Rab5-dependent Endocytosis [J]. bioRxiv, 2025: 2025.01. 02.631151.

529.  LIN C, ZHAO S, ZHU Y, et al. Microbiota-gut-brain axis and toll-like receptors in Alzheimer’s disease [J]. Computational and structural biotechnology journal, 2019, 17: 1309-17.

530.  LING-LING W, JUAN Y, TAO W, et al. The mechanism of GV-971 improving cognitive impairment and reducing neuroinflammation in Alzheimer′ s disease [J]. Journal of Hebei Medical University, 2023, 44(6): 629.

531.  LIU D, CAO M, WU S, et al. Inflammatory bowel disease and dementia: evidence triangulation from a meta-analysis of observational studies and Mendelian randomization study [J]. Biomedical and Environmental Sciences, 2025, 38(1): 56-66.

532.  LIU F, ZHAO W, ZHAO F, et al. Dual effect of the acidic polysaccharose ulvan on the inhibition of amyloid-β protein fibrillation and disintegration of mature fibrils [J]. ACS Applied Materials & Interfaces, 2020, 12(37): 41167-76.

533.  LIU J, TING J P, AL-AZZAM S, et al. Therapeutic advances in diabetes, autoimmune, and neurological diseases [J]. International Journal of Molecular Sciences, 2021, 22(6): 2805.

534.  LIU M, GUO H, LI Z, et al. Molecular level insight into the benefit of myricetin and dihydromyricetin uptake in patients with Alzheimer’s diseases [J]. Frontiers in Aging Neuroscience, 2020, 12: 601603.

535.  LIU M, LI S, CAO S, et al. Let food be your medicine–dietary fiber [J]. Food & Function, 2024, 15(15): 7733-56.

536.  LIU M-M, ZHOU N, JIANG N, et al. Neuroprotective effects of oligosaccharides from periplaneta americana on parkinson’s disease models In vitro and In vivo [J]. Frontiers in Pharmacology, 2022, 13: 936818.

537.  LIU N, HAZIYIHAN A, ZHAO W, et al. Trajectory of brain-derived amyloid beta in Alzheimer’s disease: where is it coming from and where is it going? [J]. Translational Neurodegeneration, 2024, 13(1): 42.

538.  LIU P, WANG Y, SUN Y, et al. Neuroinflammation as a potential therapeutic target in Alzheimer’s disease [J]. Clinical Interventions in Aging, 2022: 665-74.

539.  LIU P-P, XIE Y, MENG X-Y, et al. History and progress of hypotheses and clinical trials for Alzheimer’s disease [J]. Signal transduction and targeted therapy, 2019, 4(1): 29.

540.  LIU Q. Sylvia. Academic integrity disputes in China: a narrative case study [J]. Hist Philos Med, 2022, 4(2): 12.

541.  LIU Q, RUAN K, AN Z, et al. Updated review of research on the role of the gut microbiota and microbiota-derived metabolites in acute pancreatitis progression and inflammation-targeted therapy [J]. International Journal of Biological Sciences, 2025, 21(3): 1242.

542.  LIU S, FAN M, XU J-X, et al. Protective Effect of Exosomes Derived from Bone Marrow Mesenchymal Stem Cells Against AD-Like Behaviors in Mice: Involvement with Regulating Glial Activation and its Associated Neuroinflammation and BDNF-Related Neuropathological Changes in the Hippocampus [J]. 2021.

543.  LIU S, FAN M, ZHENG Q, et al. MicroRNAs in Alzheimer's disease: potential diagnostic markers and therapeutic targets [J]. Biomedicine & Pharmacotherapy, 2022, 148: 112681.

544.  LIU S, GAO J, ZHU M, et al. Gut microbiota and dysbiosis in Alzheimer’s disease: implications for pathogenesis and treatment [J]. Molecular neurobiology, 2020, 57: 5026-43.

545.  LIU S, LI X, FAN P, et al. The potential role of transcription factor sterol regulatory element binding proteins (SREBPs) in Alzheimer's disease [J]. Biomedicine & Pharmacotherapy, 2024, 180: 117575.

546.  LIU W, CHENG X, ZHANG Y, et al. Effect of transcranial direct current stimulation combined with transcutaneous auricular vagus nerve stimulation on poststroke cognitive impairment: a study protocol for a randomised controlled trial [J]. BMJ open, 2024, 14(4): e082764.

547.  LIU W, HE K, WU D, et al. Natural dietary compound xanthohumol regulates the gut microbiota and its metabolic profile in a mouse model of Alzheimer’s disease [J]. Molecules, 2022, 27(4): 1281.

548.  LIU X, HE CUI J, LUAN C, et al. Repurposing pharmaceuticals for Alzheimer's treatment via adjusting the lactoferrin interacting proteins [J]. International Journal of Biological Macromolecules, 2025: 144230.

549.  LIU X, LIU Y, LIU J, et al. Correlation between the gut microbiome and neurodegenerative diseases: a review of metagenomics evidence [J]. Neural Regeneration Research, 2024, 19(4): 833-45.

550.  LIU X, QIU X, YANG Y, et al. Alteration of gut microbiome and metabolome by Clostridium butyricum can repair the intestinal dysbiosis caused by antibiotics in mice [J]. Iscience, 2023, 26(3).

551.  LIU X, SHE W, SUNG H H-Y, et al. Tau-aggregation inhibitors derived from Streptomyces tendae MCCC 1A01534 protect HT22 cells against okadaic acid-induced damage [J]. International Journal of Biological Macromolecules, 2023, 231: 123170.

552.  LIU X, YU C, YAO Y, et al. Novel neuroprotective pyromeconic acid derivatives with concurrent anti-Aβ deposition, anti-inflammatory, and anti-oxidation properties for treatment of Alzheimer's disease [J]. European Journal of Medicinal Chemistry, 2023, 248: 115120.

553.  LIU Y. Nanobiomedical engineering strategies for aging-associated brain diseases therapy [D]; Macquarie University, 2021.

554.  LIU Y, CONG L, HAN C, et al. Recent progress in the drug development for the treatment of Alzheimer’s Disease especially on inhibition of Amyloid-peptide aggregation [J]. Mini Reviews in Medicinal Chemistry, 2021, 21(8): 969-90.

555.  LIU Y, ECHEVERRIA V, XU Y. Medicinal Plants for Cardiovascular and Neurodegenerative Aging-Related Diseases: From Bench to Bedside [J]. Frontiers in Pharmacology, 2020, 11: 585155.

556.  LIU Y, HAN C, DAI R, et al. Rational design, synthesis and activities of hydroxylated chalcones as highly potent dual functional agents against Alzheimer's disease [J]. Bioorganic Chemistry, 2022, 122: 105662.

557.  LIU Y, SONG J, LIU S, et al. A universal method for profiling and characterization of oligosaccharides in traditional Chinese medicines [J]. Journal of Pharmaceutical and Biomedical Analysis, 2024, 244: 116129.

558.  LIU Y, TANG C, WEI K, et al. Transcranial alternating current stimulation combined with sound stimulation improves the cognitive function of patients with Alzheimer's disease: A case report and literature review [J]. Frontiers in Neurology, 2022, 13: 962684.

559.  LIU Z, SHI Y, ZHANG X, et al. Discovery of novel 3-butyl-6-benzyloxyphthalide Mannich base derivatives as multifunctional agents against Alzheimer's disease [J]. Bioorganic & Medicinal Chemistry, 2022, 58: 116660.

560.  LO T Y, CHAN A S L, CHEUNG S T, et al. Multi-target regulatory mechanism of Yang Xin Tang− a traditional Chinese medicine against dementia [J]. Chinese Medicine, 2023, 18(1): 101.

561.  LOPEZ-IBAñEZ J, PAZOS F, CHAGOYEN M. MBROLE3: improved functional enrichment of chemical compounds for metabolomics data analysis [J]. Nucleic acids research, 2023, 51(W1): W305-W9.

562.  LóPEZ-VILLODRES J A, ESCAMILLA A, MERCADO-SáENZ S, et al. Microbiome alterations and Alzheimer’s disease: Modeling strategies with transgenic mice [J]. Biomedicines, 2023, 11(7): 1846.

563.  LOU Y, SUN S, TAN J. Pathogenesis of Alzheimer’s disease and its treatments: A systematic review; proceedings of the E3S Web of Conferences, F, 2021 [C]. EDP Sciences.

564.  LOUREIRO J C, DE ALMEIDA LIMA E SILVA L F, PAIS M V, et al. New Perspectives for Treatment in Alzheimer’s Disease [M]. Pharmacological Treatment of Alzheimer's Disease: Scientific and Clinical Aspects. Springer. 2022: 199-225.

565.  LOUREIRO J C, PAIS M V, STELLA F, et al. Passive antiamyloid immunotherapy for Alzheimer's disease [J]. Current opinion in psychiatry, 2020, 33(3): 284-91.

566.  LOZUPONE M, BERARDINO G, MOLLICA A, et al. ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease [J]. Expert opinion on investigational drugs, 2022, 31(8): 759-71.

567.  LOZUPONE M, SOLFRIZZI V, D’URSO F, et al. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs [J]. Expert Opinion on Emerging Drugs, 2020, 25(3): 319-35.

568.  LU M-H, JI W-L, CHEN H, et al. Intranasal transplantation of human neural stem cells ameliorates Alzheimer's disease-like pathology in a mouse model [J]. Frontiers in Aging Neuroscience, 2021, 13: 650103.

569.  LU S, NA K, WEI J, et al. Alginate oligosaccharide structures differentially affect DSS-induced colitis in mice by modulating gut microbiota [J]. Carbohydrate Polymers, 2023, 312: 120806.

570.  LU S, NA K, WEI J, et al. Alginate oligosaccharides: The structure-function relationships and the directional preparation for application [J]. Carbohydrate Polymers, 2022, 284: 119225.

571.  LU S, TAO Z, WANG G, et al. Mannuronate Oligosaccharides Ameliorate Experimental Colitis and Secondary Neurological Dysfunction by Manipulating the Gut–Brain Axis [J]. Journal of Agricultural and Food Chemistry, 2025.

572.  LU W-Y, LI H-J, WU Y-C. Marine Polysaccharides from Algae: Bioactivities and Application in Drug Research [M]. Marine Biochemistry. CRC Press. 2022: 85-109.

573.  Lü Y, CUI X, YUE C. Molecular diagnosis and drug development in both Alzheimer's and Parkinson's diseases [J]. Journal of Biotech Research [ISSN: 1944-3285], 2020, 11: 141-54.

574.  LUE J K Y, JING S N B C. Study on an innovative natural drug for Alzheimer's disease reported as a sham [J].

575.  LUE J K Y, JING S N B C. Editor Group of Traditional Medicine Research [J].

576.  LUíS J P D R. Targeting Neuroinflammation: from target validation to rational design of selective modulators [D]; 00500:: Universidade de Coimbra, 2022.

577.  LUO S, ZHANG X, HUANG S, et al. A monomeric polysaccharide from Polygonatum sibiricum improves cognitive functions in a model of Alzheimer's disease by reshaping the gut microbiota [J]. International journal of biological macromolecules, 2022, 213: 404-15.

578.  LUO W, SRINIVASULU C, HAO X, et al. The increasing impact of Chinese innovative drug research on the global stage with a focus on drug discovery [J]. Expert Opinion on Drug Discovery, 2020, 15(10): 1115-20.

579.  LYNCH M A. A case for seeking sex-specific treatments in Alzheimer’s disease [J]. Frontiers in Aging Neuroscience, 2024, 16: 1346621.

580.  MA L, JIANG X, HUANG Q, et al. Traditional Chinese medicine for the treatment of Alzheimer's disease: a focus on the microbiota–gut–brain axis [J]. Biomedicine & Pharmacotherapy, 2023, 165: 115244.

581.  MA L, YANG C, ZHENG J, et al. Non-polyphenolic natural inhibitors of amyloid aggregation [J]. European journal of medicinal chemistry, 2020, 192: 112197.

582.  MA X, SHIN Y-J, JANG H-M, et al. Lactobacillus rhamnosus and Bifidobacterium longum alleviate colitis and cognitive impairment in mice by regulating IFN-γ to IL-10 and TNF-α to IL-10 expression ratios [J]. Scientific reports, 2021, 11(1): 20659.

583.  MA X, ZHU K, WANG K, et al. Improvement of Catalytic Activity and Thermostability of Alginate Lyase VxAly7B-CM via Rational Computational Design Strategies [J]. Marine Drugs, 2025, 23(5): 198.

584.  MADDIBOYINA B, VANAMAMALAI H K, ROY H, et al. Food and drug industry applications of microalgae Spirulina platensis: A review [J]. Journal of basic microbiology, 2023, 63(6): 573-83.

585.  MAHER P. Inhibitors of Oxytosis/Ferroptosis: A New Class of Therapeutics for Alzheimer’s [J]. Ferroptosis in Health and Disease: 461.

586.  MAHER P. Inhibitors of Oxytosis/Ferroptosis: A New Class of Therapeutics for Alzheimer’s Disease [M]. Ferroptosis in Health and Disease. Springer. 2023: 461-90.

587.  MAK S H. Pharmacological characterizations of novel anti-dementia NMDA receptor antagonist memantine nitrates via multiple targets [J]. 2019.

588.  MAKSYMOWYCH W, THOM H, MøRUP M, et al. CO88 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Radiographic Axial Spondyloarthritis [J]. Value in Health, 2023, 26(12): S30.

589.  MALAN A, CHOUDHARY M, KAUR BAMRAH P, et al. Potential benefits of marine-derived compounds for slowing the advancement of Alzheimer’s disease [J]. Journal of Asian Natural Products Research, 2025, 27(4): 479-504.

590.  MAO Z, LIU Y. Yang Liu, Can Tang, Kailun Wei, Di Liu, Keke Tang, Meilian Chen, Xuewei Xia* and Zhiqi Mao [J]. Dementia and Neurodegenerative Diseases–Case Report Collection 2022, 2023: 61.

591.  MARRANDETTE D. Can I Get A Ruling: Golf Rules Revealed Through Others' Mistakes [M]. Turner Publishing Company, 2004.

592.  MARTENS N, SCHEPERS M, ZHAN N, et al. 24 (S)-Saringosterol prevents cognitive decline in a mouse model for Alzheimer’s disease [J]. Marine Drugs, 2021, 19(4): 190.

593.  MARTINS B, VIEIRA M, DELERUE-MATOS C, et al. Biological potential, gastrointestinal digestion, absorption, and bioavailability of algae-derived compounds with neuroprotective activity: A comprehensive review [J]. Marine Drugs, 2022, 20(6): 362.

594.  MARTINS M, SILVA R, MM PINTO M, et al. Marine natural products, multitarget therapy and repurposed agents in Alzheimer’s disease [J]. Pharmaceuticals, 2020, 13(9): 242.

595.  MARZOUK M M, FARID M M, HEGAZI N M, et al. Drug Discovery from Medicinal Plants against Alzheimer's Disease [J]. Phytochemical Drug Discovery for Central Nervous System Disorders: Biochemistry and Therapeutic Effects, 2023: 43-80.

596.  MASTIKHINA L, COPE S, MARSHALL T, et al. CO91 Association Between Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM) [J]. Value in Health, 2023, 26(12): S30-S1.

597.  MATHEW A, BALAJI E V, PAI S R K, et al. Current drug targets in Alzheimer’s associated memory impairment: A comprehensive review [J]. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders), 2023, 22(2): 255-75.

598.  MATTKE S, YOONG J, YEUN K-H, et al. China's Healthcare System's Readiness to Provide High-Quality Memory Care and Access to a Disease-Modifying Alzheimer's Treatment [J]. CESR-Schaeffer Working Paper, 2023, (2025_001).

599.  MD S, ALHAKAMY N A, ALFALEH M A, et al. Mechanisms involved in microglial-interceded Alzheimer’s disease and nanocarrier-based treatment approaches [J]. Journal of Personalized Medicine, 2021, 11(11): 1116.

600.  MENG-JIE L, LI-NA Z, SHANG Y-H, et al. Application progress of induced pluripotent stem cells in Alzheimer's disease [J]. Jie Fang Jun Yi Xue Za Zhi, 2021, 46(2): 193.

601.  MEZEIOVA E, PRCHAL L, HRABINOVA M, et al. Morphing cholinesterase inhibitor amiridine into multipotent drugs for the treatment of Alzheimer's disease [J]. Biomedicine & Pharmacotherapy, 2024, 173: 116399.

602.  MINCHAO H, YUHONG W. Relations Between Four Assessment Scales and Improved Medication Adherence in Alzheimer’s Disease Population [J]. 2022.

603.  MINCIC A M, ANTAL M, FILIP L, et al. Modulation of gut microbiome in the treatment of neurodegenerative diseases: A systematic review [J]. Clinical Nutrition, 2024.

604.  MINGXIA S, HONG Z, MENG W, et al. Exploration and practice of ideological and political education reform in pharmaceutical chemistry course [J]. Medical Education Management, 2024, 10(2): 192.

605.  MISHRA A, KRISHNAMURTHY S. Recent advancements in the role of phytochemicals and Medicinal plants in prophylaxis and management of Alzheimer’s disease [J]. Iranian Journal of Basic Medical Sciences, 2024, 27(11): 1357.

606.  MISRA S K, KUMAR A, SINGH S, et al. Application of carbohydrates as renewable feedstocks for the synthesis of bioactive compounds [J]. Carbohydrates in Chemistry and Biology: Decorated Compounds, Bioconjugates and Catalysts, 2025, 9: 251.

607.  MOHAMED E M, H. ELMAIDOMY A, ALAAELDIN R, et al. Anti-alzheimer potential of a New (+)-Pinitol Glycoside isolated from Tamarindus indica pulp: in vivo and in Silico evaluations [J]. Metabolites, 2023, 13(6): 732.

608.  MOHAMMADIAN F, MOHEBBI N. Symptomatic and Promising Disease-Modifying Treatments for Dementia Syndromes [J]. Journal of Pharmaceutical Care, 2022: 94-6.

609.  MOHAMMED M, JABBER H, JABBAR F A. Biomedical Applications of Alginate Oligosaccharides: Exploring Their Therapeutic Potential and Modification Techniques [J]. Trends in Pharmaceutical Biotechnology, 2024, 2(1): 22-34.

610.  MOHAPATRA L, MISHRA D, TRIPATHI A S, et al. Immunosenescence as a convergence pathway in neurodegeneration [J]. International Immunopharmacology, 2023, 121: 110521.

611.  MOHAPATRA T K, NAYAK R R, GANESHPURKAR A, et al. Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions [J]. Ibrain, 2025.

612.  MONROY-GARCíA I N, TORRES-ROMERO S, CASTRO-OCHOA L D, et al. Bioactive Compounds from Marine Macroalgae: A Natural Defense Against Oxidative Stress-Related Diseases [J]. Stresses, 2025, 5(1): 22.

613.  MORALES M, CUERVO-ZANATTA D, HERNANDEZ-ACOSTA J, et al. The Gut microbiota and Alzheimer’s [J].

614.  MORALES M, CUERVO-ZANATTA D, HERNANDEZ-ACOSTA J, et al. The Gut microbiota and Alzheimer's disease [M]. Diet and Nutrition in Neurological Disorders. Elsevier. 2023: 41-68.

615.  MORATó X, PYTEL V, JOFRESA S, et al. Symptomatic and disease-modifying therapy pipeline for Alzheimer’s disease: Towards a personalized polypharmacology patient-centered approach [J]. International Journal of Molecular Sciences, 2022, 23(16): 9305.

616.  MORAVCOVá Z. Syntéza nových derivátů 7-aryl takrinů jako potenciálních multipotentních terapeutik pro léčbu Alzheimerovy nemoci [J]. 2024.

617.  MORLEY J E. Management of cognitive dysfunction [Z]. Springer. 2021: 819-20

618.  MOTA I F, DE LIMA L S, SANTANA B D M, et al. Alzheimer’s disease: innovative therapeutic approaches based on peptides and nanoparticles [J]. The Neuroscientist, 2023, 29(1): 78-96.

619.  MUGNAINI C, BRIZZI A, PAOLINO M, et al. Novel Dual-Acting Hybrids Targeting Type-2 Cannabinoid Receptors and Cholinesterase Activity Show Neuroprotective Effects In Vitro and Amelioration of Cognitive Impairment In Vivo [J]. ACS Chemical Neuroscience, 2024, 15(5): 955-71.

620.  MURAKAMI K, IRIE K. Three structural features of functional food components and herbal medicine with amyloid β42 anti-aggregation properties [J]. Molecules, 2019, 24(11): 2125.

621.  NAGATA T, SHINAGAWA S, NAKAJIMA S, et al. Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease [J]. Expert Opinion on Pharmacotherapy, 2022, 23(6): 727-37.

622.  NAIK B, RICHA S, BHARADWAJ S, et al. Utilizing marine algal metabolites to fight neurodegenerative diseases [J]. Frontiers in Marine Science, 2024, 11: 1370839.

623.  NAKATSU D, KUNISHIGE R, TAGUCHI Y, et al. BMP4-SMAD1/5/9-RUNX2 pathway activation inhibits neurogenesis and oligodendrogenesis in Alzheimer’s patients’ iPSCs in senescence-related conditions [J]. Stem cell reports, 2023, 18(3): 688-705.

624.  NARENGAOWA, KONG W, LAN F, et al. The oral-gut-brain AXIS: the influence of microbes in Alzheimer’s disease [J]. Frontiers in cellular neuroscience, 2021, 15: 633735.

625.  NASCIMENTO A, FERNANDES R, CARVALHO A, et al. Insights for Alzheimer's disease pharmacotherapy and current clinical trials [J]. Neurochemistry International, 2022, 159: 105401.

626.  NASCIMENTO I C, SILVA R C D. Oligomanato de sódio remodelador da microbiota intestinal e o tratamento do Alzheimer: solução ou fakenews? [J]. 2022.

627.  NASKAR R, GHOSH A, BHATTACHARYA R, et al. A critical appraisal of geroprotective activities of flavonoids in terms of their bio-accessibility and polypharmacology [J]. Neurochemistry International, 2024: 105859.

628.  NAVOLOKIN N, ADUSHKINA V, ZLATOGORSKAYA D, et al. Promising strategies to reduce the SARS-CoV-2 amyloid deposition in the brain and prevent COVID-19-exacerbated dementia and Alzheimer’s disease [J]. Pharmaceuticals, 2024, 17(6): 788.

629.  NEGM A. MASTERARBEIT/MASTER’S THESIS [J]. 2022.

630.  NEMATSWERANI R. Design and synthesis of benzazole ureas as proposed irreversible GSK-3β inhibitors [D], 2021.

631.  NGAH W Z W, AHMAD H F, ANKASHA S J, et al. Dietary Strategies to Mitigate Alzheimer’s Disease: Insights into Antioxidant Vitamin Intake and Supplementation with Microbiota–Gut–Brain Axis Cross-Talk [J]. Antioxidants, 2024, 13(12): 1504.

632.  NGU E-L, TAN C-Y, LAI N J-Y, et al. Spirulina platensis suppressed iNOS and proinflammatory cytokines in lipopolysaccharide-induced BV2 microglia [J]. Metabolites, 2022, 12(11): 1147.

633.  NI J, WU Z. Inflammation spreading: negative spiral linking systemic inflammatory disorders and Alzheimer’s disease [J]. Frontiers in Cellular Neuroscience, 2021, 15: 638686.

634.  NIE T, YOU L, TANG F, et al. Microbiota-Gut-Brain Axis in Age-Related Neurodegenerative Diseases [J]. Current Neuropharmacology, 2024.

635.  NIU T-T, YIN H, XU B-L, et al. Protective effects of ginkgolide on a cellular model of Alzheimer’s disease via suppression of the NF-κ B signaling pathway [J]. Applied Biochemistry and Biotechnology, 2022, 194(6): 2448-64.

636.  NIU T-T, YUAN B-Y, LIU G-Z. Ginkgolides and bilobalide for treatment of Alzheimer’s disease and COVID-19: potential mechanisms of action [J]. European Review for Medical & Pharmacological Sciences, 2022, 26(24).

637.  NOURELDEN A Z, KAMAL I, TAWFIK A G, et al. Safety and efficacy of sodium oligomannate in patients with Alzheimer’s disease: a systematic review and meta-analysis [J]. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023, 59(1): 82.

638.  NOWAK D, SŁUPSKI W, RUTKOWSKA M. Nowe strategie terapeutyczne choroby Alzheimera [J]. Advances in Hygiene & Experimental Medicine/Postepy Higieny i Medycyny Doswiadczalnej, 2021, 75(1).

639.  NYS K, AGOSTINIS P, VERMEIRE S. Autophagy: a new target or an old strategy for the treatment of Crohn's disease? [J]. Nature Reviews Gastroenterology & Hepatology, 2013, 10(7): 395-401.

640.  NYSTUEN K L, MCNAMEE S M, AKULA M, et al. Alzheimer’s disease: Models and molecular mechanisms informing disease and treatments [J]. Bioengineering, 2024, 11(1): 45.

641.  OJEDA J, ÁVILA A, VIDAL P M. Gut microbiota interaction with the central nervous system throughout life [J]. Journal of clinical medicine, 2021, 10(6): 1299.

642.  OLLOQUEQUI J, CANO A, SANCHEZ-LóPEZ E, et al. Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders [J]. Biomedicine & Pharmacotherapy, 2022, 155: 113709.

643.  OLLOQUEQUI J, ETTCHETO M, CANO A, et al. Impact of new drugs for therapeutic intervention in Alzheimer’s disease [J]. Frontiers in Bioscience-Landmark, 2022, 27(5): 146.

644.  OSLé FERNáNDEZ C. La microbiota intestinal, un universo de beneficios [J]. 2021.

645.  OUMATA N, LU K, TENG Y, et al. Molecular mechanisms in Alzheimer's disease and related potential treatments such as structural target convergence of antibodies and simple organic molecules [J]. European Journal of Medicinal Chemistry, 2022, 240: 114578.

646.  PAINULI S, SEMWAL P, ZAM W, et al. NMDA inhibitors: a potential contrivance to assist in management of Alzheimer’s disease [J]. Combinatorial Chemistry & High Throughput Screening, 2023, 26(12): 2099-112.

647.  PAIS M V, FORLENZA O V. New Perspectives for Treatment in Alzheimer’s Disease [J]. Pharmacological Treatment of Alzheimer's Disease: 199.

648.  PAIS M V, FORLENZA O V. New Perspectives for Treatment [J]. Pharmacological Treatment of Alzheimer's Disease: Scientific and Clinical Aspects, 2022: 199.

649.  PAL T, DAS M. Review of Alzheimer’s Disease’s Animal Model with it’s Pathophysiology and Drug Discovery [J]. 2024.

650.  PALRAJ P, PARANTHAMAN S. Bioactive Compounds of Algae: Potential Neuroprotective Agents in Neurodegenerative Disorders [J]. Neuroprotective Effects of Phytochemicals in Brain Ageing: 257.

651.  PAN L, CAI C, LIU C, et al. Recent progress and advanced technology in carbohydrate-based drug development [J]. Current Opinion in Biotechnology, 2021, 69: 191-8.

652.  PAN L, XIE L, YANG W, et al. The role of the gut microbiome and brain-liver-gut Axis in neurological disorders [J]. Burns & Trauma, 2025: tkaf011.

653.  PAN Z, WU N, JIN C. Intestinal Microbiota Dysbiosis Promotes Mucosal Barrier Damage and Immune Injury in HIV‐Infected Patients [J]. Canadian Journal of Infectious Diseases and Medical Microbiology, 2023, 2023(1): 3080969.

654.  PANCHAL S K, JOHN O D, MATHAI M L, et al. Anthocyanins in chronic diseases: The power of purple [J]. Nutrients, 2022, 14(10): 2161.

655.  PANDA S P, DHURANDHAR Y, AGRAWAL M. The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches [J]. Mitochondrion, 2022, 66: 27-37.

656.  PANDEY P, PAWAR D, DHAYALAN S, et al. CO89 Efficacy of Anti-Alzheimer’S (AD) Drugs in Cognitive Improvement: A Network Meta-Analysis (NMA) of Randomized Controlled Trials (RCTS) [J]. Value in Health, 2023, 26(12): S30.

657.  PANEYALA S, YAMBAO P E L, SYED J M, et al. Clinical trials for neurodegenerative diseases [M]. The Neurodegeneration Revolution. Elsevier. 2025: 499-526.

658.  PAPIRI G, LUZZI S, MARCUCCI M, et al. Vasoactive neuropeptides and Alzheimer’s disease: a systematic review focusing on calcitonin gene-related peptide [J]. Journal of Integrative Neuroscience, 2021, 20(4): 1059-65.

659.  PARANTHAMAN S, PALRAJ P. Bioactive Compounds of Algae: Potential Neuroprotective Agents in Neurodegenerative Disorders [M]. Neuroprotective Effects of Phytochemicals in Brain Ageing. Springer. 2024: 257-88.

660.  PARIKH N H, PARIKH P K, RAO H J, et al. Current trends and updates in the treatment of Alzheimer's disease [M]. Alzheimer's Disease and Advanced Drug Delivery Strategies. Elsevier. 2024: 373-90.

661.  PARK S, CHANG H, SOHN H, et al. Systemic literature review study on the efficacy and safety of novel Alzheimer’s disease treatments [J]. Korean Journal of Clinical Pharmacy, 2023, 33(4): 290-304.

662.  PATEL B, WALKER R, CAPó M, et al. A Review of Alzheimer’s Disease and Inflammation: Pathogenesis, Inflammatory Processes, and Novel Insights from the Artificial Intelligence Perspective [J]. Medical Research Archives, 2023, 11(7.2).

663.  PATEL S, VYAS N, PATEL A, et al. Comprehensive Review of Ethnopharmacological and Phytochemical Aspects of Nutraceuticals in Psychiatric Disorders [J]. Current Psychopharmacology, 2022, 11(1): 30-42.

664.  PAUL P, BHATTACHARJEE A, BORDOLOI S K, et al. The evolution of alzheimer’s disease therapies: A comprehensive review [J]. Annals of Medical Science & Research, 2024, 3(1): 11-9.

665.  PENG D, LIU T, LU H, et al. Intranasal delivery of engineered extracellular vesicles loaded with miR-206-3p antagomir ameliorates Alzheimer's disease phenotypes [J]. Theranostics, 2024, 14(19): 7623.

666.  PENG D, XU S, ZOU T, et al. Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study [J]. BMC medicine, 2023, 21(1): 459.

667.  PENG G, LI M, MENG Z. Polysaccharides: Potential bioactive macromolecules for Alzheimer’s disease [J]. Frontiers in Nutrition, 2023, 10: 1249018.

668.  PENG Y, TAO H, WANG S, et al. Dietary intervention with edible medicinal plants and derived products for prevention of Alzheimer's disease: A compendium of time-tested strategy [J]. Journal of Functional Foods, 2021, 81: 104463.

669.  PéREZ-AREALES F J, SAMPIETRO A, MARTíNEZ P, et al. Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis [J]. 2022.

670.  PERKOVIĆ R, HRVOIĆ L, GUDELJ E, et al. Nove terapije u liječenju Alzheimerove bolesti [J]. Medicina Fluminensis: Medicina Fluminensis, 2023, 59(1): 4-15.

671.  PERONE R, ALBERTINI C, ULIASSI E, et al. Turning Donepezil into a Multi‐Target‐Directed Ligand through a Merging Strategy [J]. ChemMedChem, 2021, 16(1): 187-98.

672.  PILLAJO M B, CORREA M S, MENDOZA M M J. 4. DELIRIUM (SÍNDROME CONFUSIONAL AGUDO) [J]. APORTES Y DEBATES DESDE LA ACADEMIA PARA EL FOMENTO A LA CALIDAD Y CALIDEZ EN EL CUIDADO Y ATENCIÓN A LAS PERSONAS ADULTAS MAYORES.

673.  PINILLA CABRERA M. Fármacos derivados de carbohidratos [J]. 2024.

674.  PLASCENCIA-VILLA G, PERRY G. Alzheimer’s disease pharmacology [J]. 2022.

675.  PLEEN J, TOWNLEY R. Alzheimer’s disease clinical trial update 2019–2021 [J]. Journal of neurology, 2022, 269(2): 1038-51.

676.  POKRZYK J, KULCZYŃSKA-PRZYBIK A, GUZIK-MAKARUK E, et al. Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer’s Disease [J]. International Journal of Molecular Sciences, 2025, 26(5): 1935.

677.  POO M-M. New light on the horizon of Alzheimer's disease [Z]. Oxford University Press. 2020: 831-

678.  POON C H, WANG Y, FUNG M-L, et al. Rodent models of amyloid-beta feature of Alzheimer’s disease: Development and potential treatment implications [J]. Aging and disease, 2020, 11(5): 1235.

679.  POOR S R, ETTCHETO M, CANO A, et al. Metformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment [J]. Pharmaceuticals, 2021, 14(9): 890.

680.  POZDNYAKOV D, CHIRYAPKIN A, KODONIDI I. Novel 6, 7-dimethoxyquinazolin-4 (3H)-one derivatives as promising compounds for the therapy of alzheimer's disease [J]. Problems of Biological Medical and Pharmaceutical Chemistry, 2023, 26(4): 23-7.

681.  POZDNYAKOV D I, ZOLOTYCH D S, RUKOVITSYNA V M, et al. Chromone derivatives suppress neuroinflammation and improve mitochondrial function in the sporadic form of Alzheimer’s disease under experimental conditions [J]. Iranian Journal of Basic Medical Sciences, 2022, 25(7): 871.

682.  PRAJAPATI S K, PATHAK A, SAMAIYA P K. Alzheimer’s disease: from early pathogenesis to novel therapeutic approaches [J]. Metabolic Brain Disease, 2024, 39(6): 1231-54.

683.  PRAJAPATI S K, SHAH R, ALFORD N, et al. The triple alliance: microbiome, mitochondria, and metabolites in the context of age-related cognitive decline and Alzheimer’s disease [J]. The Journals of Gerontology: Series A, 2023, 78(12): 2187-202.

684.  PRITCHARD M F, POWELL L C, ADAMS J Y, et al. Structure–activity relationships of low molecular weight alginate oligosaccharide therapy against Pseudomonas aeruginosa [J]. Biomolecules, 2023, 13(9): 1366.

685.  PURANIK N, SONG M. Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer’s Disease, a Potential Therapeutic Target [J]. Molecules, 2024, 29(23): 5744.

686.  QI C-C, CHEN X-X, GAO X-R, et al. Impaired learning and memory ability induced by a bilaterally hippocampal injection of streptozotocin in mice: involved with the adaptive changes of synaptic plasticity [J]. Frontiers in aging neuroscience, 2021, 13: 633495.

687.  QI J, ZHENG Z, LI J, et al. Nonfamilial early-onset Alzheimer's disease associated with de novo PSEN1 mutation: A case report and review of the literature [J]. 2024.

688.  QIAO O, JI H, ZHANG Y, et al. New insights in drug development for Alzheimer's disease based on microglia function [J]. Biomedicine & Pharmacotherapy, 2021, 140: 111703.

689.  QIN P, SUN Y, LI L. Mitochondrial dysfunction in chronic neuroinflammatory diseases [J]. International Journal of Molecular Medicine, 2024, 53(5): 47.

690.  QORRI B, TSAY M, AGRAWAL A, et al. Using machine intelligence to uncover Alzheimers disease progression heterogeneity [J]. Exploration of Medicine, 2020, 1(6): 377-95.

691.  RABIEI POOR S, ETTCHETO ARRIOLA M, CANO FERNáNDEZ A, et al. Promising application of metformin in Alzheimer's disease [J]. Pharmaceuticals, 2021, vol 14, num 9, 2021.

692.  RABIEIPOOR S. Study on Effects of Metformin and Transplantation of NPCs Separately and in Combination on Restores Cognitive Dysfunction and Histopathological Deficits in Mouse Model of Sporadic Alzheimer’s Disease [J]. 2024.

693.  RAJENDRAN K, KRISHNAN U M. Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease [J]. Ageing Research Reviews, 2024: 102309.

694.  RAJENDRAN K, SUKUMAR A J, KRISHNAN U M. Emerging paradigms in Alzheimer’s Therapy [J]. European Journal of Pharmacology, 2024: 176872.

695.  RAJPUT S, MALVIYA R, BAHADUR S, et al. Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease [J]. Current Pharmaceutical Design, 2023, 29(35): 2802-13.

696.  RAMESH M, GOVINDARAJU T. Multipronged diagnostic and therapeutic strategies for Alzheimer's disease [J]. Chemical science, 2022, 13(46): 13657-89.

697.  RAO Y. Omission of previous publications by an author should be corrected [J]. Cell Research, 2020, 30(9): 819-.

698.  RAO Y, SU R, WU C, et al. Marine fungus Aspergillus c1. sp metabolite activates the HSF1/PGC-1α axis, inducing a thermogenic program for treating obesity [J]. Frontiers in Pharmacology, 2024, 15: 1320040.

699.  RAPAKA D, SANIOTIS A, MOHAMMADI K, et al. From ambiguity to accuracy: A review of Alzheimer’s disease diagnostic errors and the need for non-invasive biomarkers [J]. Journal of Neurosciences in Rural Practice, 2025, 16(1): 14-21.

700.  RASHID S M, RAZAK R, TANTRAY A K, et al. Unraveling Alzheimer’s: Exploring the Gut Microbiota–Brain Axis as a New Frontier in Understanding [J]. Journal of Dementia and Alzheimer's Disease, 2024, 1(1): 22-47.

701.  RASMUSSEN P. Seaweed: So much more than a sushi wrap [J].

702.  REN B, GUO C, LIU R-Z, et al. Imidazolylacetophenone oxime-based multifunctional neuroprotective agents: Discovery and structure-activity relationships [J]. European journal of medicinal chemistry, 2022, 228: 114031.

703.  REN R, QI J, LIN S, et al. The China alzheimer report 2022 [J]. General psychiatry, 2022, 35(1): e100751.

704.  REUBEN D B. Clinica de nutrición Madrid [J].

705.  RIBEIRO A D S. Relatório de Estágio e Monografia intitulada “Doença de Alzheimer–Novo Olhar Farmacoterapêutico” [D], 2021.

706.  RICHING A S, MAJOR J L, LONDONO P, et al. The brain–heart axis: alzheimer’s, diabetes, and hypertension [J]. ACS Pharmacology & Translational Science, 2019, 3(1): 21-8.

707.  RICHTER L. Screeningová studie různých rostlinných taxonů a jejich vliv na lidské enzymatické systémy II [J]. 2022.

708.  RINGMAN J M, FRAUTSCHY S A, TENG E, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study [J]. Alzheimer's research & therapy, 2012, 4: 1-8.

709.  RISSARDO J, CAPRARA A F. Oligomannate and aducanumab: Novel drugs for alzheimer disease [J]. Ibnosina Journal of Medicine and Biomedical Sciences, 2020, 12(04): 327-8.

710.  RIZVANI K. Le basi neurobiologiche del Disturbo Neurocognitivo maggiore e lieve [J].

711.  RODRIGUES L. Isolation of Marine Natural Products and Synthesis of Bioactive Molecules Using Chiron Approach [D]; Goa University, 2023.

712.  ROSSI B, SANTOS-LIMA B, TERRABUIO E, et al. Common peripheral immunity mechanisms in multiple sclerosis and Alzheimer's disease [J]. Frontiers in immunology, 2021, 12: 639369.

713.  ROSSI M, FRESCHI M, DE CAMARGO NASCENTE L, et al. Sustainable drug discovery of multi-target-directed ligands for Alzheimer’s disease [J]. Journal of medicinal chemistry, 2021, 64(8): 4972-90.

714.  RUNFOLA M. Drug development of new diphenylmethane scaffold-based compounds for the treatment of neurodegenerative disorders [J]. 2021.

715.  RUTSCH A, KANTSJö J B, RONCHI F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology [J]. Frontiers in immunology, 2020, 11: 604179.

716.  S SHARMA H, D SKAPER S, SHARMA A. Conference Report: 7th Clinical Trials on Alzheimer’s Disease Annual Conference, Philadelphia, PA, USA Nov 20-22, 2014 [J]. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 2015, 14(1): 7-10.

717.  SAAMA P M, PATEL O V, BETTEGOWDA A, et al. Novel algorithm for transcriptome analysis [J]. Physiological genomics, 2006, 28(1): 62-6.

718.  SAFDAR A, GHANI M U, SABAR M F, et al. Advancement in the Treatment of ALZHEIMER'S Disease, 2023 [J]. Amyloid, 2024, 5: 6.

719.  SAHA S, SINGH S, PRASAD S, et al. Gut microbiota and Alzheimer’s disease: experimental evidence and clinical reality [J]. Current Alzheimer Research, 2021, 18(10): 787-801.

720.  SAHLGREN BENDTSEN K M, HALL V J. The breakthroughs and caveats of using human pluripotent stem cells in modeling Alzheimer’s disease [J]. Cells, 2023, 12(3): 420.

721.  SAINI A. Novel Approaches for Feature Extraction and Representation Learning of Alzheimer's Biomarkers [M]. Deep Generative Models for Integrative Analysis of Alzheimer's Biomarkers. IGI Global. 2025: 313-40.

722.  SAIYASIT N, BUTLIG E-A R, CHANEY S D, et al. Neurovascular Dysfunction in Diverse Communities with Health Disparities—Contributions to Dementia and Alzheimer’s Disease [J]. Frontiers in Neuroscience, 2022, 16: 915405.

723.  SAMANTA S, RAMESH M, KUMAR A, et al. The Role of Gut Microbiome in Alzheimer's Disease and Therapeutic Strategies [J]. 2022.

724.  SAMPIETRO A, PéREZ-AREALES F J, MARTíNEZ P, et al. Unveiling the multitarget anti-Alzheimer drug discovery landscape: A bibliometric analysis [J]. Pharmaceuticals, 2022, 15(5): 545.

725.  SAMPIETRO PIFARRE A, PéREZ AREALES F J, MARTíNEZ P, et al. Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis [J]. Pharmaceuticals, 2022, vol 15, num 5, p 545, 2022.

726.  SANG Z, HUANG L. Alzheimer's disease therapeutics: current strategies and future directions [M]. Privileged Scaffolds in Drug Discovery. Elsevier. 2023: 405-73.

727.  SANTANGELO M C, IACOPINI D, FAVERO L, et al. One-Pot Stereospecific Synthesis of 1, 4-Oligosaccharides by Glycal-Derived Vinyl Epoxides Assembly [J]. ACS omega, 2024, 9(45): 45047-52.

728.  SANTOS A M D S. Internship Reports and Monograph Entitled" Neuroprotective activity of compounds extracted from algae in the treatment of Alzheimer's Disease" [D], 2024.

729.  SãO PEDRO A F A. Estudo dos efeitos de compostos de origem marinha no crescimento de microrganismos da pele [D]; Instituto Politecnico de Leiria (Portugal), 2024.

730.  SATAPATHY T, KUMAR D. A comprehensive review and recent advancement in the application of tannins for treating Parkinson disease [J]. Pharmacological Research-Modern Chinese Medicine, 2024: 100499.

731.  SATHASIVAN S, ANNAMALAI J, BATHCHA S K S, et al. Nanotechnology Based Drug Delivery and Marine Diet Derived Compounds in Alpha-Synuclein-Linked Parkinson’s Disease [J]. Junior Researchers, 2025, 3(2): 212-26.

732.  SCARANO N. Druggable targets to contrast Alzheimer's disease: molecular modelling approaches for the drug design process [J]. 2025.

733.  SCASSELLATI C, GALOFORO A C, ESPOSITO C, et al. Promising intervention approaches to potentially resolve neuroinflammation and steroid hormones alterations in Alzheimer’s disease and its neuropsychiatric symptoms [J]. Aging and disease, 2021, 12(5): 1337.

734.  SCHäCHTLE M A, ROSSHART S P. The microbiota-gut-brain axis in health and disease and its implications for translational research [J]. Frontiers in cellular neuroscience, 2021, 15: 698172.

735.  SCHAIBLE P, HENSCHEL J, ERNY D. How the gut microbiota impacts neurodegenerative diseases by modulating CNS immune cells [J]. Journal of Neuroinflammation, 2025, 22(1): 60.

736.  SCHEINER M, HOFFMANN M, HE F, et al. Selective pseudo-irreversible butyrylcholinesterase inhibitors transferring antioxidant moieties to the enzyme show pronounced neuroprotective efficacy in vitro and in vivo in an Alzheimer’s disease mouse model [J]. Journal of Medicinal Chemistry, 2021, 64(13): 9302-20.

737.  SEO D-O, BOROS B D, HOLTZMAN D M. The microbiome: A target for Alzheimer disease? [J]. Cell research, 2019, 29(10): 779-80.

738.  SEO D-O, HOLTZMAN D M. Gut microbiota: from the forgotten organ to a potential key player in the pathology of Alzheimer’s disease [J]. The Journals of Gerontology: Series A, 2020, 75(7): 1232-41.

739.  SEO D-O, HOLTZMAN D M. Current understanding of the Alzheimer’s disease-associated microbiome and therapeutic strategies [J]. Experimental & molecular medicine, 2024, 56(1): 86-94.

740.  SERAFIN P, ZAREMBA M, SULEJCZAK D, et al. Air pollution: a silent key driver of dementia [J]. Biomedicines, 2023, 11(5): 1477.

741.  SHA S, REN L, XING X, et al. Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease [J]. Neural Regeneration Research, 2016: 10.4103.

742.  SHA S, REN L, XING X, et al. 针对 Aβ 和 tau 免疫治疗阿尔茨海默病的进展 [J]. 中国神经再生研究 (英文版), 2026, 21(2): 577.

743.  SHAIK S M, CAO Y, GOGOLA J V, et al. Translational profiling identifies sex-specific metabolic and epigenetic reprogramming of cortical microglia/macrophages in APPPS1-21 mice with an antibiotic-perturbed-microbiome [J]. Molecular Neurodegeneration, 2023, 18(1): 95.

744.  SHAN M, BAI Y, FANG X, et al. American ginseng for the treatment of Alzheimer’s disease: a review [J]. Molecules, 2023, 28(15): 5716.

745.  SHAO L, LI X, XIAO T, et al. Variations in microbial assemblage between rhizosphere and root endosphere microbiomes contribute to host plant growth under cadmium stress [J]. Applied and Environmental Microbiology, 2023, 89(11): e00960-23.

746.  SHAO X, XU P, YU B. Chemical Synthesis of β‐(1, 4)‐d‐Oligomannurarates with Purported Anti‐Alzheimer Activity [J]. European Journal of Organic Chemistry, 2025, 28(4): e202401125.

747.  SHARMA A, IM S-H. Special issue on the human microbiome: from symbiosis to therapy [J]. Experimental & Molecular Medicine, 2020, 52(9): 1361-3.

748.  SHARMA C, MAZUMDER A. A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease [J]. Central Nervous System Agents in Medicinal ChemistryChemistry-Central Nervous System Agents), 2024, 24(1): 45-56.

749.  SHARMA H S, CHOPP M, CHEN L, et al. The 2021 yearbook of neurorestoratology [J]. Journal of Neurorestoratology, 2022, 10(3): 100008.

750.  SHARMA P, PAL R, SHARMA A K, et al. Current Bioactive Compounds in the Treatment of Alzheimer's Disease [J]. Current Bioactive Compounds, 2024.

751.  SHEMTOV S J, EMANI R, BIELSKA O, et al. The intestinal immune system and gut barrier function in obesity and ageing [J]. The FEBS journal, 2023, 290(17): 4163-86.

752.  SHEN H, LIU K, KONG F, et al. Strategies for measuring concentrations and forms of amyloid-β peptides [J]. Biosensors and Bioelectronics, 2024: 116405.

753.  SHEN Y, LI H. General information on clinical psychopharmacology in China [J]. Journal of Clinical Psychopharmacology, 2018, 38(2): 107-10.

754.  SHEN Y, LIU F, ZHANG M. Therapeutic potential of plant-derived natural compounds in Alzheimer’s disease: Targeting microglia-mediated neuroinflammation [J]. Biomedicine & Pharmacotherapy, 2024, 178: 117235.

755.  SHENHAV O. Next generation in Alzheimer's therapeutic strategies [D]; University of Zagreb. School of Medicine. Department of Neurology, 2024.

756.  SHI J. Dear Dr. Abbasi: We would like to thank the editorial office and reviewers for their constructive comments. We have addressed them point by point as the following. Thank you for your time. Sincerely [J].

757.  SHI J, SABBAGH M N, VELLAS B. Alzheimer’s disease beyond amyloid [J]. BMJ: British Medical Journal, 2020, 371: 1-4.

758.  SHI J, SABBAGH M N, VELLAS B. Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions [J]. Bmj, 2020, 371.

759.  SHI J, TOUCHON J, MIDDLETON L T, et al. Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer’s disease [J]. Science Bulletin, 2024, 69(23): 3777-84.

760.  SHI X, HE W, GUPTA A, et al. Extracellular vesicles as drug and gene delivery vehicles in central nervous system diseases [J]. Biomaterials Science, 2025.

761.  SHIBAO T, HASE H, MIZOKAMI K, et al. CGRPβ suppresses the pathogenesis of ulcerative colitis via the immunoproteasome [J]. Scientific Reports, 2025, 15(1): 7224.

762.  SHIVANI S, CHATTOPADHYAY A, CHUANG E Y. Targeting the gut microbiome for non-communicable diseases: present and future [J]. Annals of Translational Medicine, 2021, 9(5): 361.

763.  SHOME A, JHA K T, CHAWLA V, et al. An Insight into Medicinal Chemistry and SAR Studies of Cholinesterase and BACE-1 Inhibitors for Alzheimer's Disease [J]. CNS & neurological disorders drug targets, 2024.

764.  SHRESTHA S, CHOI J S, ZHANG W, et al. Neuroprotective activity of macroalgal fucofuroeckols against amyloid β peptide-induced cell death and oxidative stress [J]. International Journal of Food Science and Technology, 2022, 57(7): 4286-95.

765.  SHRESTHA S, ZHANG W, BEGBIE A J, et al. Ecklonia radiata extract containing eckol protects neuronal cells against Aβ 1–42 evoked toxicity and reduces aggregate density [J]. Food & Function, 2020, 11(7): 6509-16.

766.  SHUKLA R, SINGH T R. Identification of Novel Inhibitors and Biomarkers for Alzheimer's Disease using Computational Systems Polypharmacology and Machine Learning Approach [D]; Jaypee University of Information Technology, Solan, HP, 2022.

767.  SHUXIAN L, YING L, WEN Q, et al. Research on the Bacterial Community Structure and Functions in the Intestine of Pomacea maculata [J].

768.  SIDDIQI M K, MAJID N, MALIK S. Amyloid Oligomers, Protofibrils [J]. Macromolecular Protein Complexes II: Structure and Function, 2020, 93: 471.

769.  SIGHENCEA M G, POPESCU R Ș, TRIFU S C. From Fundamentals to Innovation in Alzheimer’s Disease: Molecular Findings and Revolutionary Therapies [J]. International Journal of Molecular Sciences, 2024, 25(22): 12311.

770.  SINGH H, CHAWLA V, BALA R, et al. Current and Future of Alzheimer's Therapy with the best Approach [J]. CNS & Neurological Disorders-Drug Targets-CNS & Neurological Disorders), 2020, 19(9): 691-7.

771.  SINGH P, KARWASRA R, SHARMA A, et al. A REVIEW ON ACETYLCHOLINESTERASE INHIBITING THERAPEUTICS AND RECENT BREAKTHROUGHS IN THE FIELD OF ALZHEIMERS DISEASE [J].

772.  SKYLYNN T, LEE C, ELENA M, et al. A Review of Recent Advances in the Management of Alzheimer’s Disease [J]. Cureus, 2024, 16(4).

773.  SMERALDA W. Membranes biomimétiques pour la caractérisation de nouveaux agents thérapeutiques: application à la maladie d'Alzheimer [D]; Normandie Université, 2019.

774.  SOCHOCKA M, OCHNIK M. Sobczy nski [Z]. M. 2021: 111352

775.  SOCHOCKA M, OCHNIK M, SOBCZYŃSKI M, et al. Ginkgo biloba leaf extract improves an innate immune response of peripheral blood leukocytes of Alzheimer’s disease patients [J]. Nutrients, 2022, 14(10): 2022.

776.  SONG C, SHI J, ZHANG P, et al. Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond [J]. Translational neurodegeneration, 2022, 11(1): 18.

777.  SONG M, FAN X. Systemic metabolism and mitochondria in the mechanism of Alzheimer’s disease: finding potential therapeutic targets [J]. International Journal of Molecular Sciences, 2023, 24(9): 8398.

778.  SONI T, JAWANDA I K, KUMARI S, et al. Insights in the Cross-Talk Between Microbiota-Gut-Brain Axis: A Focus on Alzheimer’s Disease [J]. Role of Microbes in Sustainable Development: Human Health and Diseases, 2023: 487-508.

779.  SöNMEZ G, YAZARKAN Y, AKI Ö E, et al. Unraveling the Enigma: Exploring the Periphery’s Influence in Alzheimer’s Pathophysiology—Cause or Consequence? [J]. The Eurasian Journal of Medicine, 2025, 57(1): e24592.

780.  SORRENTI V, CASTAGNA D A, FORTINGUERRA S, et al. Spirulina microalgae and brain health: A scoping review of experimental and clinical evidence [J]. Marine drugs, 2021, 19(6): 293.

781.  SOSA S, BRINGAS G, URRUTIA N, et al. NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial [J]. Alzheimer's Research & Therapy, 2023, 15(1): 215.

782.  ȘOVREA A S, BOȘCA A B, DRONCA E, et al. Non-Drug and Non-Invasive Therapeutic Options in Alzheimer’s Disease [J]. Biomedicines, 2025, 13(1): 84.

783.  STRAUS M. 2022 Pipeline Report: Capitalizing on Opportunity [J]. 2021.

784.  STRONGYLI E, EVANGELIDIS P, SAKELLARI I, et al. Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb [J]. Pharmaceuticals, 2024, 17(5): 591.

785.  STRüBING A, MCKIBBON C, RUAN H, et al. CO90 Augmenting Synthetic Control Arms Using Bayesian Borrowing: A Case Study in First-Line Non-Small Cell Lung Cancer [J]. Value in Health, 2023, 26(12): S30.

786.  SU Y, LIU N, SUN R, et al. Radix Rehmanniae Praeparata (Shu Dihuang) exerts neuroprotective effects on ICV-STZ-induced Alzheimer’s disease mice through modulation of INSR/IRS-1/AKT/GSK-3β signaling pathway and intestinal microbiota [J]. Frontiers in Pharmacology, 2023, 14: 1115387.

787.  SU Y, LIU N, WANG P, et al. Proteomic analysis and experimental validation reveal the blood–brain barrier protective of Huanshaodan in the treatment of SAMP8 mouse model of Alzheimer’s disease [J]. Chinese Medicine, 2024, 19(1): 137.

788.  SUGIMOTO A, ONO K. Basics of amyloid β-protein in Alzheimer’s disease [M]. Autophagy Dysfunction in Alzheimer's Disease and Dementia. Elsevier. 2022: 73-89.

789.  SUHOCKI P V, RONALD J S, DIEHL A M E, et al. Probing gut‐brain links in Alzheimer's disease with rifaximin [J]. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022, 8(1): e12225.

790.  SUN D, QIAO Y, JIANG X, et al. Multiple antigenic peptide system coupled with amyloid beta protein epitopes as an immunization approach to treat alzheimer’s disease [J]. ACS Chemical Neuroscience, 2019, 10(6): 2794-800.

791.  SUN F, ZHAO J, ZHANG H, et al. Proteomics evidence of the role of TDMQ20 in the cholinergic system and synaptic transmission in a mouse model of Alzheimer’s disease [J]. ACS Chemical Neuroscience, 2022, 13(21): 3093-107.

792.  SUN H-H, YANG G-S, CHENG Y-M, et al. Progress in understanding the biological activities of marine oligosaccharides [J]. 2022.

793.  SUN L, XU M, SHI Y, et al. Decoding psychosis: from national genome project to national brain project [J]. General Psychiatry, 2022, 35(4): e100889.

794.  SUN M, MA K, WEN J, et al. A review of the brain-gut-microbiome axis and the potential role of microbiota in Alzheimer’s disease [J]. Journal of Alzheimer’s disease, 2020, 73(3): 849-65.

795.  SUN S, GAO Z, WANG M, et al. Chemical Constituents of the Marine Traditional Chinese Medicine of Pegasus laternarius Cuvier (Hai-E Yu) [J]. Pharmaceutical Fronts, 2024, 6(02): e149-e54.

796.  SUSANTO E, PUTRA Y, PANGESTUTI R. Industrial Potential of Seaweeds in Biomedical Applications: Current Trends and Future Prospects [M]. Sustainable Global Resources of Seaweeds Volume 2: Food, Pharmaceutical and Health Applications. Springer. 2022: 433-40.

797.  SVOB STRAC D, KONJEVOD M, SAGUD M, et al. Personalizing the care and treatment of Alzheimer’s disease: an overview [J]. Pharmacogenomics and personalized medicine, 2021: 631-53.

798.  SVOBODOVA B, MORAVCOVA Z, MISIACHNA A, et al. Novel Tacrine-Based Compounds: Bridging Cholinesterase Inhibition and NMDAR Antagonism [J]. 2025.

799.  SVOBODOVA B, PULKRABKOVA L, PANEK D, et al. Structure-Guided Design of N-Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer’s Disease [J]. International Journal of Molecular Sciences, 2023, 24(11): 9124.

800.  SWATHI M, HAZRA A, DHANU A, et al. Exploring the Interplay Between Gut Microflora and Parkinson’s [M]. Gut Microbiome and Brain Ageing: Brain Aging. Springer. 2024: 307-33.

801.  SZALLASI A, ANTAR A, IMATAKI O. Case Reports in Hematological Malignancies: 2022 [M]. Frontiers Media SA, 2023.

802.  TAN W, QI L, HU X, et al. Research progress in traditional Chinese medicine in the treatment of Alzheimer’s disease and related dementias [J]. Frontiers in pharmacology, 2022, 13: 921794.

803.  TANAKA M, TöRöK N, VéCSEI L. Novel pharmaceutical approaches in dementia [J]. NeuroPsychopharmacotherapy, 2020: 1-18.

804.  TANAKA M, TöRöK N, VéCSEI L. Novel pharmaceutical approaches in dementia [M]. NeuroPsychopharmacotherapy. Springer. 2022: 2803-20.

805.  TANG L, JIANG J, SONG G, et al. Design, synthesis, and biological evaluation of novel urolithins derivatives as potential phosphodiesterase II inhibitors [J]. Scientific Reports, 2021, 11(1): 23792.

806.  TANVEER L. Investigating the Protective Effects of Phototherapy and various drugs in Alzheimer Disease [D]; School of Mechanical & Manufacturing Engineering (SMME), NUST, 2024.

807.  TAO Z, LEI Z, RUI Z, et al. Novel Mechanisms of Some Traditional Chinese Medicine for the Therapy of Neurocognitive Disorders [J]. PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2020, 47(8): 729-42.

808.  TARAWNEH R, PENHOS E. The gut microbiome and Alzheimer’s disease: Complex and bidirectional interactions [J]. Neuroscience & Biobehavioral Reviews, 2022, 141: 104814.

809.  TARı Ö, YAĞMURTAŞAN R. Alzheimer hastalığı ve anti-Alzheimer etkili bileşiklerin yapılarının araştırılması [J]. Hacettepe University Journal of the Faculty of Pharmacy, 2023, 43(2): 150-73.

810.  TENG K-C, TSENG K-Y, TZENG Z-H, et al. A concise synthesis of l-gulose and its C-6 derivatives [J]. Bioorganic & Medicinal Chemistry, 2022, 73: 117029.

811.  THAKUR S, DHAPOLA R, SARMA P, et al. Neuroinflammation in Alzheimer’s disease: current progress in molecular signaling and therapeutics [J]. Inflammation, 2023, 46(1): 1-17.

812.  THAMBI A, CHAKRABORTY K. Brown and red marine macroalgae as novel bioresources of promising medicinal properties [J]. Journal of Aquatic Food Product Technology, 2022, 31(3): 227-41.

813.  THANGWARITORN S, LEE C, METCHIKOFF E, et al. A review of recent advances in the management of Alzheimer’s disease [J]. Cureus, 2024, 16(4).

814.  THAPLIYAL A, SINGH M B, KUMARI K, et al. Identification of novel inhibitors of microglia-specific proteins responsible for neuroinflammatory response by molecular docking and simulation studies [J]. International Journal of Modelling and Simulation, 2025: 1-15.

815.  THEISLER C. Adjuvant medical care [M]. CRC Press, 2022.

816.  TIKHONOVA M A, CHANG H-M, SINGH S K, et al. Experimental and Innovative Approaches to Multi-Target Treatment of Parkinson's and Alzheimer's Diseases [Z]. Frontiers Media SA. 2022: 910020

817.  TIWARI S S, GATTANI S G, SHARMA B, et al. Carbohydrate-based therapeutics: evolution from wellness pursuit to medical treatment [M]. Polysaccharides. CRC Press. 2023: 109-23.

818.  TONG Y, LU G, GUO J, et al. A New Intestinal Supplement Synbiotics Therapeutically Regulates Gut Microbiota and Activates Ppars Pathway to Inhibit Alzheimer’s Disease Progression in Mouse Models [J]. New Microbiol, 2024, 47: 68-79.

819.  TRAMONTIN N D S. Efeito do tratamento com ultrassom pulsado de baixa intensidade transcraniano sobre parâmetros cerebrais em um modelo de doença de Alzheimer induzida por beta amiloide [J]. 2022.

820.  TRISAL A, SINGH I, GARG G, et al. Gut–brain axis and brain health: modulating neuroinflammation, cognitive decline, and neurodegeneration [J]. 3 Biotech, 2025, 15(1): 25.

821.  TSOLAKI M, ARCAN C, ZAHID S. The role of natural products in neurological disorders [Z]. Frontiers Media SA. 2023: 1163282

822.  UDDIN M S, KABIR M T, JEANDET P, et al. Novel Anti‐Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing [J]. Oxidative Medicine and Cellular Longevity, 2020, 2020(1): 7039138.

823.  UGBAJA S C. Multidimensional Computational Modeling of Potent BACE1 (β-Secretase) Inhibitors Towards Alzheimer’s Disease Treatment [D]; School of Laboratory Medicine & Medical Sciences, University of Kwa-Zulu Natal, 2021.

824.  UGBAJA S C, LAWAL I A, KUMALO H M, et al. Alzheimer's disease and β-secretase inhibition: an update with a focus on computer-aided inhibitor design [J]. Current drug targets, 2022, 23(3): 266-85.

825.  ULIASSI E, DE OLIVEIRA A S, DE CAMARGO NASCENTE L, et al. Cashew nut shell liquid (CNSL) as a source of drugs for Alzheimer’s disease [J]. Molecules, 2021, 26(18): 5441.

826.  VALDIVIESO CASTRO M P. El rol del intestino como diana con papel terapéutico en personas con enfermedades neurodegenerativas [J]. 2023.

827.  VANDEN EYNDE J J, MANGONI A A, RAUTIO J, et al. Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes–6 [Z]. MDPI. 2019: 119

828.  VECCHIO I, SORRENTINO L, PAOLETTI A, et al. The state of the art on acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease [J]. Journal of Central nervous system disease, 2021, 13: 11795735211029113.

829.  VELLAS B, BAIN L, TOUCHON J, et al. Advancing Alzheimer's disease treatment: lessons from CTAD 2018 [J]. The Journal of Prevention of Alzheimer's Disease, 2019, 6(3): 198-203.

830.  VENTER J. Design, synthesis and biological activity studies of 1-aryl-3-(4-methoxybenzyl) ureas as proposed irreversible GSK-3 inhibitors in Alzheimer’s disease therapeutic development [D]; Stellenbosch: Stellenbosch University, 2019.

831.  VERY W, HAVE Y T. Alzheimer’s drug trial explores gut-brain link [J].

832.  VIAYNA E, SOLA I, BARTOLINI M, et al. Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents [J]. Journal of Medicinal Chemistry, 2014, 57(6): 2549-67.

833.  VON ADUCANUMAB S. Alzheimer-Medikamente: aktuelle Phase-3-Studien [J]. Omega, 2021.

834.  WANG C, CAI X, WANG R, et al. Neuroprotective effects of verbascoside against Alzheimer’s disease via the relief of endoplasmic reticulum stress in Aβ-exposed U251 cells and APP/PS1 mice [J]. Journal of neuroinflammation, 2020, 17: 1-16.

835.  WANG C, CHEN S, GUO H, et al. Forsythoside A mitigates Alzheimer's-like pathology by inhibiting ferroptosis-mediated neuroinflammation via Nrf2/GPX4 axis activation [J]. International journal of biological sciences, 2022, 18(5): 2075.

836.  WANG C, HAO J, LIU X, et al. Isoforsythiaside attenuates Alzheimer’s disease via regulating mitochondrial function through the PI3K/AKT pathway [J]. International journal of molecular sciences, 2020, 21(16): 5687.

837.  WANG C, SHEN Z, YU J, et al. Protective effects of enzyme degradation extract from Porphyra yezoensis against oxidative stress and brain injury in d-galactose-induced ageing mice [J]. British Journal of Nutrition, 2020, 123(9): 975-86.

838.  WANG C, WU C, SONG L. TRPA1-Activated Peptides from Saiga Antelope Horn: Screening, Interaction Mechanism, and Bioactivity [J]. International Journal of Molecular Sciences, 2025, 26(5): 2119.

839.  WANG H, HUANG H T, SADEGHI B, et al. frontiers ORIGINAL RESEARCH in Microbiology published: 11 February 2022 [J]. The role of gut microbiota and probiotics in modulating gut-brain axis of humans and animals, 2023: 29.

840.  WANG H, WANG T, XIAO S, et al. Globalization of Alzheimer’s Disease Clinical Trials [J]. Alzheimer's Disease Drug Development: Research and Development Ecosystem, 2022: 275.

841.  WANG H, WANG T, XIAO S, et al. Chapter Globalization of Alzheimer's Disease [J]. Alzheimer's Disease Drug Development: Research and Development Ecosystem, 2022: 275.

842.  WANG H, ZHU B. Directed preparation of algal oligosaccharides with specific structures by algal polysaccharide degrading enzymes [J]. International Journal of Biological Macromolecules, 2024: 134093.

843.  WANG J. Characterization of neurochemical activities through inhibition of CDK5 or AChE by dimers of tacrine and neostigmine respectively [J]. 2021.

844.  WANG J, ZHANG Y, LU Q, et al. Exploring carbohydrates for therapeutics: A review on future directions [J]. Frontiers in pharmacology, 2021, 12: 756724.

845.  WANG K, NA L, DUAN M. The pathogenesis mechanism, structure properties, potential drugs and therapeutic nanoparticles against the small oligomers of amyloid-β [J]. Current Topics in Medicinal Chemistry, 2021, 21(2): 151-67.

846.  WANG L, LU Y, LIU J, et al. Gegen Qinlian tablets delay Alzheimer's disease progression via inhibiting glial neuroinflammation and remodeling gut microbiota homeostasis [J]. Phytomedicine, 2024, 128: 155394.

847.  WANG L, SUN T, WANG Z, et al. Design, Synthesis, and Proof of Concept of Balanced Dual Inhibitors of Butyrylcholinesterase (BChE) and Histone Deacetylase 6 (HDAC6) for the Treatment of Alzheimer’s Disease [J]. ACS chemical neuroscience, 2023, 14(17): 3226-48.

848.  WANG M, AMAKYE W K, CAO J, et al. Non-uinform gut microbiota alteration patterns associated with therapeutic outcomes in an Alzheimer's disease animal model [J]. 2019.

849.  WANG M, CAO J, AMAKYE W K, et al. Mid infrared light treatment attenuates cognitive decline and alters the gut microbiota community in APP/PS1 mouse model [J]. Biochemical and Biophysical Research Communications, 2020, 523(1): 60-5.

850.  WANG M, CAO J, GONG C, et al. Exploring the microbiota-Alzheimer’s disease linkage using short-term antibiotic treatment followed by fecal microbiota transplantation [J]. Brain, Behavior, and Immunity, 2021, 96: 227-38.

851.  WANG M, LI Z-L, FENG L-R, et al. Tβ4 and PDTC displayed recovery on the glial and neuronal alterations in an early Alzheimer’s disease model [J]. 2022.

852.  WANG M, ZHANG H, LIANG J, et al. Exercise suppresses neuroinflammation for alleviating Alzheimer’s disease [J]. Journal of neuroinflammation, 2023, 20(1): 76.

853.  WANG N, WANG X, HE M, et al. Ginseng polysaccharides: A potential neuroprotective agent [J]. Journal of Ginseng Research, 2021, 45(2): 211-7.

854.  WANG S. Intertwined relationship among ROS, mitochondria and APOE4 during the onset of Alzheimer's disease; proceedings of the AIP Conference Proceedings, F, 2022 [C]. AIP Publishing.

855.  WANG T, JIA H. The sigma receptors in Alzheimer’s disease: New potential targets for diagnosis and therapy [J]. International Journal of Molecular Sciences, 2023, 24(15): 12025.

856.  WANG W, JU Y, LIU N, et al. Structural characteristics of microbial exopolysaccharides in association with their biological activities: A review [J]. Chemical and Biological Technologies in Agriculture, 2023, 10(1): 137.

857.  WANG W, WANG X, GAO W, et al. Ulvan inhibits α-synuclein fibrillation and disrupts the mature fibrils: in vitro and in vivo studies [J]. International Journal of Biological Macromolecules, 2022, 211: 580-91.

858.  WANG X, LI Z, SUN R, et al. Zunyimycin C enhances immunity and improves cognitive impairment and its mechanism [J]. Frontiers in Cellular and Infection Microbiology, 2022, 12: 1081243.

859.  WANG X-C. Advances in Drug Therapy for Alzheimer’s Disease [J].

860.  WANG X-S, LI J-J, WANG Y-S, et al. Acupuncture and related therapies for the cognitive function of Alzheimer’s disease: a network meta-analysis [J]. Iranian Journal of Public Health, 2021, 50(12): 2411.

861.  WANG Y, WANG D, LV H, et al. Modulation of the gut microbiota and glycometabolism by a probiotic to alleviate amyloid accumulation and cognitive impairments in AD rats [J]. Molecular Nutrition & Food Research, 2022, 66(19): 2200265.

862.  WANG Y, WANG K, YAN J, et al. Recent progress in research on mechanisms of action of natural products against Alzheimer’s disease: Dietary plant polyphenols [J]. International Journal of Molecular Sciences, 2022, 23(22): 13886.

863.  WASéN C, SIMONSEN E, EKWUDO M N, et al. The emerging role of the microbiome in Alzheimer's disease [M]. International review of neurobiology. Elsevier. 2022: 101-39.

864.  WEI B, ZHANG B, DU A-Q, et al. Saccharina japonica fucan suppresses high fat diet-induced obesity and enriches fucoidan-degrading gut bacteria [J]. Carbohydrate Polymers, 2022, 290: 119411.

865.  WEI C, ZHANG G, FU X, et al. Apolipoprotein E ε4-Specific Relationship Between Serum Olfactomedin 4 and Alzheimer’s Disease [J]. Molecular Neurobiology, 2025: 1-12.

866.  WEI M, LIU H, WANG Y, et al. Mechanisms of male reproductive sterility triggered by Dysbiosis of intestinal microorganisms [J]. Life, 2024, 14(6): 694.

867.  WEI R, HE J-Q, CHEN W-H, et al. Evaluations of the neuroprotective effects of a dual-target isoquinoline inhibitor in the triple transgenic mouse model of Alzheimer's disease [J]. Neuroscience Letters, 2023, 802: 137166.

868.  WEI Y-D, CHEN X-X, YANG L-J, et al. Resveratrol ameliorates learning and memory impairments induced by bilateral hippocampal injection of streptozotocin in mice [J]. Neurochemistry International, 2022, 159: 105385.

869.  WENCEL P L. Udział polimerazy poli (ADP-rybozy)-1 oraz bioaktywnych sfingolipidów w toksyczności peptydów amyloidu beta w doświadczalnych modelach choroby Alzheimera [J]. 2019.

870.  WENHUI L, JIE G, PENG X, et al. Gut bacteriome and mycobiome dysbiosis in patients with Alzheimer's disease [J]. Chinese Journal of Microecology, 2024, 36(5): 577-83.

871.  WIĘCEK M, PIOTROWSKA D G, KOŁODZIEJCZYK M, et al. Choroba Alzheimera–przegląd substancji leczniczych i ich pochodnych [J]. Farm Pol, 2023, 79(12): 789-800.

872.  WILSON J. Therapeutic Implications of the Gut-CNS Axis in Promoting Recovery Following Cervical Spinal Cord Injury [J]. 2023.

873.  WOJTANIA M A, MAJEWSKA E M, DUDA W. Importance of gut microbiome in Alzheimer's disease [J]. Medycyna Środowiskowa, 2024, 27(2): 60-5.

874.  WONG-GUERRA M, CALFIO C, MACCIONI R B, et al. Revisiting the neuroinflammation hypothesis in Alzheimer’s disease: A focus on the druggability of current targets [J]. Frontiers in Pharmacology, 2023, 14: 1161850.

875.  WORCESTER S. MDedge Psychiatry [J].

876.  WU H, ZHOU S, NING W, et al. Major royal-jelly proteins intake modulates immune functions and gut microbiota in mice [J]. Food Science and Human Wellness, 2024, 13(1): 444-53.

877.  WU J, WANG C, ZHANG T, et al. Synthesis of mannan oligosaccharide-sialic acid conjugates and its inhibition on Aβ42 aggregation [J]. Carbohydrate Research, 2023, 531: 108891.

878.  WU J, WU M, ZHANG H, et al. An oligomannuronic acid-sialic acid conjugate capable of inhibiting Aβ42 Aggregation and alleviating the inflammatory response of BV-2 microglia [J]. International Journal of Molecular Sciences, 2021, 22(22): 12338.

879.  WU J, ZHU Y, ZHOU L, et al. Parasite-derived excretory-secretory products alleviate gut microbiota dysbiosis and improve cognitive impairment induced by a high-fat diet [J]. Frontiers in immunology, 2021, 12: 710513.

880.  WU J-J, YANG Y, WAN Y, et al. New insights into the role and mechanisms of ginsenoside Rg1 in the management of Alzheimer’s disease [J]. Biomedicine & pharmacotherapy, 2022, 152: 113207.

881.  WU J-S, MENG Q-Y, SHI X-H, et al. The oxygenated products of cryptotanshinone by biotransformation with Cunninghamella elegans exerting anti-neuroinflammatory effects by inhibiting TLR 4-mediated MAPK signaling pathway [J]. Bioorganic Chemistry, 2020, 104: 104246.

882.  WU M, LI Y, MIAO Y, et al. Exploring the efficient natural products for Alzheimer’s disease therapy via Drosophila melanogaster (fruit fly) models [J]. Journal of Drug Targeting, 2023, 31(8): 817-31.

883.  WU P-N, XIONG S, ZHONG P, et al. Global trends in research on irritable bowel syndrome and the brain–gut axis: Bibliometrics and visualization analysis [J]. Frontiers in pharmacology, 2022, 13: 956204.

884.  WU Q, LI Q, ZHANG X, et al. Treatment with Bifidobacteria can suppress Aβ accumulation and neuroinflammation in APP/PS1 mice [J]. PeerJ, 2020, 8: e10262.

885.  WU S, LIU X, JIANG R, et al. Roles and mechanisms of gut microbiota in patients with Alzheimer’s disease [J]. Frontiers in aging neuroscience, 2021, 13: 650047.

886.  WU S, LIU X, JIANG R, et al. Roles and Mechanisms of Gut Microbiota in Patients With [J]. Progress of Translational Medicine in Alzheimer's Disease, 2022: 712545080.

887.  WU X, CAI H, PAN L, et al. Small molecule natural products and Alzheimer’s disease [J]. Current topics in medicinal chemistry, 2019, 19(3): 187-204.

888.  WU Y, GUO S, WANG K, et al. The interaction of peptide inhibitors and Aβ protein: Binding mode analysis, inhibition of the formation of Aβ aggregates, and then exert neuroprotective effects [J]. Frontiers in Aging Neuroscience, 2023, 15: 1139418.

889.  WU Z, ZHANG T, MA X, et al. Recent advances in anti-inflammatory active components and action mechanisms of natural medicines [J]. Inflammopharmacology, 2023, 31(6): 2901-37.

890.  XIA Z-D, MA R-X, WEN J-F, et al. Pathogenesis, animal models, and Drug Discovery of Alzheimer’s Disease [J]. Journal of Alzheimer’s Disease, 2023, 94(4): 1265-301.

891.  XIAO Q-Y, YE T-Y, WANG X-L, et al. Effects of Qi-Fu-Yin on aging of APP/PS1 transgenic mice by regulating the intestinal microbiome [J]. Frontiers in cellular and infection microbiology, 2023, 12: 1048513.

892.  XIAO S. A phase II clinical trial on GV-971 in patients with Alzheimer’s [abstract no. OC 3] [J]. J Prev Alz Dis, 2014, 1: 214-96.

893.  XIAO S, ZHANG Z, GENG M, et al. Phase 3 Clinical trial of a novel and multi-targeted oligosaccharide in patients with mildmoderate ad in china [J]. Clinical Trials on Alzheimer’s Disease, 2018.

894.  XIAO Y, LI K, BIAN J, et al. Urolithin A protects neuronal cells against stress damage and apoptosis by Atp2a3 inhibition [J]. Molecular Nutrition & Food Research, 2023, 67(21): 2300146.

895.  XIAOJUAN L, HONGMEI L, ZHUXIN W, et al. Exploration of the pharmacological components and therapeutic mechanisms in treatment of Alzheimer's disease with Polygonati Rhizoma and its processed product using combined analysis of metabolomics, network pharmacology, and gut microbiota [J]. Heliyon, 2024, 10(15).

896.  XIE J, ZHONG C, WANG T, et al. Better Bioactivity, Cerebral Metabolism and Pharmacokinetics of Natural Medicine and Its Advanced Version [J]. Frontiers in Pharmacology, 2022, 13: 937075.

897.  XIE M, GU S, HONG Y, et al. Study on the mechanism of Coptis chinensis Franch. And its main active components in treating Alzheimer's disease based on SCFAs using Orbitrap Fusion Lumos Tribrid MS [J]. Journal of Ethnopharmacology, 2023, 311: 116392.

898.  XIE S, ZHAN F, ZHU J, et al. The latest advances with natural products in drug discovery and opportunities for the future: a 2025 update [J]. Expert Opinion on Drug Discovery, 2025, (just-accepted).

899.  XIE X, SONG Q, DAI C, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: a phase I/II clinical trial [J]. General psychiatry, 2023, 36(5): e101143.

900.  XIE Y, WANG Y, JIANG S, et al. Novel strategies for the fight of Alzheimer’s disease targeting amyloid-β protein [J]. Journal of Drug Targeting, 2022, 30(3): 259-68.

901.  XING H, YUE S, QIN R, et al. Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review [J]. International Journal of Molecular Sciences, 2025, 26(8): 3905.

902.  XING M, CAO Q, WANG Y, et al. Advances in research on the bioactivity of alginate oligosaccharides [J]. Marine drugs, 2020, 18(3): 144.

903.  XING M, LI G, LIU Y, et al. Fucoidan from Fucus vesiculosus prevents the loss of dopaminergic neurons by alleviating mitochondrial dysfunction through targeting ATP5F1a [J]. Carbohydrate Polymers, 2023, 303: 120470.

904.  XIU R, SUN Q, LI B, et al. Mapping research trends and hotspots in the link between Alzheimer’s disease and gut microbes over the past decade: a bibliometric analysis [J]. Nutrients, 2023, 15(14): 3203.

905.  XU J, WANG K, YUAN Y, et al. A novel peroxidase mimics and ameliorates alzheimer’s disease-related pathology and cognitive decline in mice [J]. International journal of molecular sciences, 2018, 19(11): 3304.

906.  XU Q. Probing Patchouli Alcohol as an Agent for Alzheimer’s Disease: Evaluation of Its Efficacy and Molecular Mechanisms [D]; The Chinese University of Hong Kong (Hong Kong), 2022.

907.  XU Q, WEN L, WEI G, et al. Marked response of rat ileal and colonic microbiota after the establishment of Alzheimer’s disease model with bilateral intraventricular injection of Aβ (1-42) [J]. Frontiers in Microbiology, 2022, 13: 819523.

908.  XU Y, WEN G, ASAKAWA T, et al. Acupuncture and Alzheimer’s Disease [M]. Advanced Acupuncture Research: From Bench to Bedside. Springer. 2022: 635-65.

909.  XU Z, JIANG H, FAN X, et al. Research progress in compound drugs for anti-neurodegenerative diseases [J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 967.

910.  XU-WEN L. Chemical ecology-driven discovery of bioactive marine natural products as potential drug leads [Z]. 2020: 837-8

911.  XUECHENG Z, SHAOYING Z. Enlightenment from Guiding Principle Adjustment and Corresponding Reform Practice of Chinese Academy of Sciences [J]. Bulletin of Chinese Academy of Sciences (Chinese Version), 2020, 35(5): 583-92.

912.  XUEXIU L, SIGENG C, YUNYI L. Red ginseng pine pollens improve spatial learning and memory possibly by inhibition of hippocampal neuron apoptosis in a rat model of Alzheimer’s disease [J]. Journal of Beijing Normal University (Natural Science), 2021, 57(6): 854-8.

913.  YAJING M, SUFANG L, QINGFENG Z, et al. Approved drugs and natural products at clinical stages for treating Alzheimer’s disease [J]. Chinese Journal of Natural Medicines, 2024, 22(8): 699-710.

914.  YAN C, QU H, LI X, et al. Holothurian wall hydrolysate ameliorates cyclophosphamide-induced immunocompromised mice via regulating immune response and improving gut microbiota [J]. International Journal of Molecular Sciences, 2023, 24(16): 12583.

915.  YAN M, MAN S, SUN B, et al. Gut liver brain axis in diseases: the implications for therapeutic interventions [J]. Signal transduction and targeted therapy, 2023, 8(1): 443.

916.  YAN N, SHI X-L, TANG L-Q, et al. Synthesis and biological evaluation of thieno [3, 2-c] pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer’s disease [J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37(1): 1724-36.

917.  YAN N, XIE F, TANG L-Q, et al. Synthesis and biological evaluation of thieno [3, 2-c] pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer’s disease [J]. Bioorganic Chemistry, 2023, 138: 106663.

918.  YAN P, DENG Y, SU X, et al. The molecular pathology of neurodegenerative and psychiatric disorders [M]. Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders. Elsevier. 2023: 3-43.

919.  YANG H, HAN J, WANG J, et al. Exploring the effects of combining health qigong and dance on working memory in middle-aged and elderly women: A preliminary investigation [J]. Experimental Gerontology, 2024, 194: 112515.

920.  YANG M, XUAN Z, WANG Q, et al. Fucoxanthin has potential for therapeutic efficacy in neurodegenerative disorders by acting on multiple targets [J]. Nutritional Neuroscience, 2022, 25(10): 2167-80.

921.  YANG M, ZHOU D, XIAO H, et al. Marine-derived uronic acid-containing polysaccharides: Structures, sources, production, and nutritional functions [J]. Trends in Food Science & Technology, 2022, 122: 1-12.

922.  YANG P, SUN F. Aducanumab: the first targeted Alzheimer's therapy [J]. Drug discoveries & therapeutics, 2021, 15(3): 166-8.

923.  YANG S, LIU Z, FU X, et al. Expression and characterization of an alginate lyase and its thermostable mutant in Pichia pastoris [J]. Marine drugs, 2020, 18(6): 305.

924.  YANG W. Probing Sulforaphene as an Agent for Alzheimer’s Disease: Evaluation of Its Efficacy and Molecular Mechanisms [M]. The Chinese University of Hong Kong (Hong Kong), 2020.

925.  YANG X, GAO X, JIANG X, et al. Targeting capabilities of engineered extracellular vesicles for the treatment of neurological diseases [J]. Neural Regeneration Research, 2025, 20(11): 3076-94.

926.  YANG X, ZHANGYI Z, YU A, et al. GV‐971 attenuates the progression of neuromyelitis optica in murine models and reverses alterations in gut microbiota and associated peripheral abnormalities [J]. CNS Neuroscience & Therapeutics, 2024, 30(7): e14847.

927.  YANG Y, QIU L. Research progress on the pathogenesis, diagnosis, and drug therapy of Alzheimer’s disease [J]. Brain Sciences, 2024, 14(6): 590.

928.  YANG Y, ZHOU X, WANG B, et al. Fecal fermentation of lentinan and its effect on gut microbiota and metabolites [J]. International Journal of Food Science and Technology, 2025, 60(1): vvae004.

929.  [YEO-TEH N S L, TANG B L. A review of scientific ethics issues associated with the recently approved drugs for Alzheimer’s disease [J]. Science and Engineering Ethics, 2023, 29(1): 2.

930.  YILIN Z, QIONG X, LI X, et al. Progress in Drug Development for Alzheimer's Disease [J]. Progress in Pharmaceutical Sciences, 2019, 43(2): 100-10.

931.  YIN C, SUN J, WANG H, et al. Identification and characterization of a new cold-adapted and alkaline alginate lyase TsAly7A from Thalassomonas sp. LD5 produces alginate oligosaccharides with high degree of polymerization [J]. Marine Drugs, 2022, 21(1): 6.

932.  YIN G, HU X, XIE S, et al. Clinical Observation of Sodium Oligomannate Capsules in the Treatment of Cognitive Dysfunction in Parkinson's Disease [J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85(4): 54-8.

933.  YIN T, LIU Y, JI W, et al. Engineered mesenchymal stem cell-derived extracellular vesicles: a state-of-the-art multifunctional weapon against Alzheimer's disease [J]. Theranostics, 2023, 13(4): 1264.

934.  YIN Z-H, ZHANG X-Y, LI Y-Q, et al. Effect and neuroimaging mechanism of acupuncture for amnestic mild cognitive impairment: study protocol of a multicenter randomized controlled trial [J]. European Journal of Integrative Medicine, 2023, 58: 102219.

935.  YING L, YIN W, TINGRU C, et al. Research progress of high-value comprehensive utilization of Laminaria japonica [J]. Journal of Fisheries Research, 2023, 45(2): 192-201.

936.  YONGYAN C, MIN Y, NAN L, et al. Research Progress on the Directed Enzymatic Preparation and Structure-Function Relationship of Alginate Oligosaccharides [J]. Food Science, 2024, 45(10): 320-9.

937.  YOON J H, HWANG J, SON S U, et al. How can insulin resistance cause Alzheimer’s disease? [J]. International Journal of Molecular Sciences, 2023, 24(4): 3506.

938.  YOU F-L, XIA G-F, CAI J. Behavioural Variant Frontotemporal Dementia due to CCNF Gene Mutation: A Case Report [J]. Current Alzheimer Research, 2023, 20(5): 371-8.

939.  YOU L, LIANG K, AN R, et al. The path towards FDA approval: A challenging journey for Traditional Chinese Medicine [J]. Pharmacological Research, 2022, 182: 106314.

940.  YU C-C, DU Y-J, LI J, et al. Neuroprotective mechanisms of puerarin in central nervous system diseases: Update [J]. Aging and Disease, 2022, 13(4): 1092.

941.  YU C-C, DU Y-J, WANG S-Q, et al. Experimental evidence of the benefits of acupuncture for Alzheimer's disease: an updated review [J]. Frontiers in Neuroscience, 2020, 14: 549772.

942.  YU C-C, WANG J, YE S-S, et al. Preventive Electroacupuncture Ameliorates D‐Galactose‐Induced Alzheimer’s Disease‐Like Pathology and Memory Deficits Probably via Inhibition of GSK3β/mTOR Signaling Pathway [J]. Evidence‐Based Complementary and Alternative Medicine, 2020, 2020(1): 1428752.

943.  YU H. 19. A Missed Opportunity [M]. Mind Thief. Columbia University Press. 2021: 179-89.

944.  YU T-W, LANE H-Y, LIN C-H. Novel therapeutic approaches for Alzheimer’s disease: an updated review [J]. International journal of molecular sciences, 2021, 22(15): 8208.

945.  YU Z, YANG Y, CHAN R B, et al. GV‐971 attenuates α‐Synuclein aggregation and related pathology [J]. CNS Neuroscience & Therapeutics, 2024, 30(2): e14393.

946.  YUHUI L, XIANLE B, XIN M, et al. Guidelines for drug treatment of Alzheimer's disease [J]. Chinese Journal of Alzheimer's Disease and Related Disorders, 2025, 8(1): 8-16.

947.  ZAIDI S R, BADOLA A. Recent advancement in drugs of Alzheimer's disease [J]. International Journal of Basic & Clinical Pharmacology, 2023, 12(1): 125.

948.  ZANG X, CHEN S, ZHU J, et al. The emerging role of central and peripheral immune systems in neurodegenerative diseases [J]. Frontiers in aging neuroscience, 2022, 14: 872134.

949.  ZENG H, ZHOU K, ZHUANG Y, et al. Unraveling the connection between gut microbiota and Alzheimer’s disease: a two-sample Mendelian randomization analysis [J]. Frontiers in aging neuroscience, 2023, 15: 1273104.

950.  ZENG K-W, GU M-Y. Annual advances of integrative pharmacology in 2019 [J]. Traditional Medicine Research, 2020, 5(2): 74-82.

951.  ZENG L, LI J, CHENG Y, et al. Comparison of the Values of a Novel Exolytic and Two Endolytic Alginate Lyases with Mannuronate Preference for Direct Preparation of Oligosaccharides, Action Modes, and Underlying Catalytic Mechanisms [J]. 2021.

952.  ZENG L, LI J, CHENG Y, et al. Comparison of biochemical characteristics, action models, and enzymatic mechanisms of a novel exolytic and two endolytic lyases with mannuronate preference [J]. Marine Drugs, 2021, 19(12): 706.

953.  ZENG L, LI J, GU J, et al. Alginate-Degrading Modes, Oligosaccharide-Yielding Properties, and Potential Applications of a Novel Bacterial Multifunctional Enzyme, Aly16-1 [J]. Microorganisms, 2024, 12(11): 2374.

954.  ZENG X, CHENG S, LI H, et al. Design, synthesis, and activity evaluation of novel multitargeted l‐tryptophan derivatives with powerful antioxidant activity against Alzheimer's disease [J]. Archiv der Pharmazie, 2024, 357(5): 2300603.

955.  ZHA X, LIU X, WEI M, et al. Microbiota-derived lysophosphatidylcholine alleviates Alzheimer’s disease pathology via suppressing ferroptosis [J]. Cell Metabolism, 2025, 37(1): 169-86. e9.

956.  ZHAN Y, AL-NUSAIF M, DING C, et al. The potential of the gut microbiome for identifying Alzheimer’s disease diagnostic biomarkers and future therapies [J]. Frontiers in Neuroscience, 2023, 17: 1130730.

957.  ZHANG D-F, XU M, BI R, et al. Genetic analyses of Alzheimer’s disease in China: achievements and perspectives [J]. ACS Chemical Neuroscience, 2019, 10(2): 890-901.

958.  ZHANG F, ZHONG R-J, CHENG C, et al. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease [J]. Acta Pharmacologica Sinica, 2021, 42(9): 1382-9.

959.  ZHANG G, SHEN Y, PHIPPS J, et al. Metal-organic frameworks for the diagnosis and treatment of Alzheimer’s disease: Current status and perspectives [J]. Coordination Chemistry Reviews, 2024, 518: 216059.

960.  ZHANG G, ZHANG Y, SHEN Y, et al. The potential role of ferroptosis in Alzheimer’s disease [J]. Journal of Alzheimer’s Disease, 2021, 80(3): 907-25.

961.  ZHANG J, YOU L, WU W, et al. The neurotoxicity of trichothecenes T-2 toxin and deoxynivalenol (DON): Current status and future perspectives [J]. Food and Chemical Toxicology, 2020, 145: 111676.

962.  ZHANG J, ZHANG Y, WANG J, et al. Recent advances in Alzheimer’s disease: Mechanisms, clinical trials and new drug development strategies [J]. Signal transduction and targeted therapy, 2024, 9(1): 211.

963.  ZHANG L. Progress in molecular biology and translational science: glycans and glycosaminoglycans as clinical biomarkers and therapeutics-part B [M]. Academic Press, 2019.

964.  ZHANG M, LIANG C, CHEN X, et al. Interplay between microglia and environmental risk factors in Alzheimer's disease [J]. Neural Regeneration Research, 2024, 19(8): 1718-27.

965.  ZHANG Q, GAO Z, DENG Y, et al. Current status and trends in the study of intestinal flora in cognitive disorders: a bibliometric and visual analysis [J]. Frontiers in Microbiology, 2025, 16: 1577597.

966.  ZHANG Q, YAN Y. The role of natural flavonoids on neuroinflammation as a therapeutic target for Alzheimer’s disease: a narrative review [J]. Neural Regeneration Research, 2023, 18(12): 2582-91.

967.  ZHANG Q, YAN Y. 天然黄酮类化合物靶向干预阿尔茨海默病的神经炎症 [J]. 中国神经再生研究 (英文版), 2023, 18(12): 2582.

968.  ZHANG T, OUYANG Z, ZHANG Y, et al. Marine Natural Products in Inflammation‐Related Diseases: Opportunities and Challenges [J]. Medicinal Research Reviews, 2025.

969.  ZHANG T, WU J, WANG Y, et al. Alleviating neuronal inflammation induced by Aβ42 in SH-SY5Y through interaction with polysialic acid–oligomannuronate conjugate [J]. International Journal of Biological Macromolecules, 2024, 276: 133862.

970.  ZHANG T, ZHANG S, PENG Y, et al. Food & Function d1fo01755a [J].

971.  ZHANG T, ZHANG S, PENG Y, et al. Safflower leaf ameliorates cognitive impairment through moderating excessive astrocyte activation in APP/PS1 mice [J]. Food & Function, 2021, 12(22): 11704-16.

972.  ZHANG W, GUO Y, CHENG Y, et al. Neuroprotective effects of polysaccharide from Sparassis crispa on Alzheimer's disease-like mice: Involvement of microbiota-gut-brain axis [J]. International journal of biological macromolecules, 2023, 225: 974-86.

973.  ZHANG W, XIAO D, MAO Q, et al. Role of neuroinflammation in neurodegeneration development [J]. Signal transduction and targeted therapy, 2023, 8(1): 267.

974.  ZHANG X, BAO M, ZHANG J, et al. Neuroprotective Mechanism of Ribisin A on H2O2-induced PC12 cell injury model [J]. Tissue and Cell, 2024, 87: 102322.

975.  ZHANG X, ELMANSY R, LIU J. Artificial Intelligence in Medication Management for Alzheimer's Patients in China; proceedings of the Healthcare and Medical Devices, F, 2024 [C]. AHFE International.

976.  ZHANG X, LIU J. Artificial Intelligence in Medication Management for Alzheimer's Patients [J]. 2023.

977.  ZHANG X, ZHONG S. Enlightenment from Guiding Principle Adjustment and Corresponding Reform Practice of Chinese Academy of Sciences [J]. 2020.

978.  ZHANG Y, LI Y, MA L. Recent advances in research on Alzheimer's disease in China [J]. Journal of clinical neuroscience, 2020, 81: 43-6.

979.  ZHANG Y, LIU T, PAN F, et al. Dietary Methionine Restriction Alleviates Cognitive Impairment in Alzheimer’s Disease Mice via Sex-Dependent Modulation on Gut Microbiota and Tryptophan Metabolism: A Multiomics Analysis [J]. Journal of Agricultural and Food Chemistry, 2025.

980.  ZHANG Y, ZHANG M. Neuroprotective effects of Morinda officinalis How.: Anti-inflammatory and antioxidant roles in Alzheimer’s disease [J]. Frontiers in aging neuroscience, 2022, 14: 963041.

981.  ZHANG Z. Understanding the gut-microbiota-brain axis: a biological model for analyzing the impact of microbiota on learning, memory and defensive behavior in honey bees [D]; Université de Toulouse, 2024.

982.  ZHANG Z, LV J, WANG Y, et al. Static Binding and Dynamic Transporting‐Based Design of Specific Ring‐Chain‐Ring Acetylcholinesterase Inhibitor: From Galantamine to Natural Product [J]. Chemistry–A European Journal, 2023, 29(25): e202203363.

983.  ZHANG Z, WANG S, TAN H, et al. Advances in polysaccharides of natural source of the anti-Alzheimer's disease effect and mechanism [J]. Carbohydrate polymers, 2022, 296: 119961.

984.  ZHAO H, ZHUO L, SUN Y, et al. Thiazolidinedione use is associated with reduced risk of dementia in patients with type 2 diabetes mellitus: A retrospective cohort study [J]. Journal of Diabetes, 2023, 15(2): 97-109.

985.  ZHAO H, ZHUO L, SUN Y, et al. 噻唑烷二酮的使用与 2 型糖尿病患者痴呆风险降低相关: 一项回顾性队列研究 [J]. Journal of Diabetes, 2023, 15(2): 97-109.

986.  ZHAO J, LU W, LI J, et al. Decreased serum ncam levels associated with cognitive impairment in vascular dementia [J]. Disease Markers, 2021, 2021(1): 2792884.

987.  ZHAO J, SHI Q, TIAN H, et al. TDMQ20, a specific copper chelator, reduces memory impairments in Alzheimer’s disease mouse models [J]. ACS Chemical Neuroscience, 2020, 12(1): 140-9.

988.  ZHAO M-M, ZHENG K. Marine natural products with anti-inflammation effects [J]. Tradit Med Res, 2020, 5: 252-60.

989.  ZHAO W, WANG J, LATTA M, et al. Rhizoma Gastrodiae Water Extract Modulates the Gut Microbiota and Pathological Changes of P-TauThr231 to Protect Against Cognitive Impairment in Mice [J]. Frontiers in Pharmacology, 2022, 13: 903659.

990.  ZHAO X, LI D, ZHANG L, et al. Mesenchymal stem cell therapies for Alzheimer’s disease: preclinical studies [J]. Metabolic Brain Disease, 2021, 36(7): 1687-95.

991.  ZHAO X, XIONG L, SHE L, et al. The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer’s disease [J]. Biomedicine & Pharmacotherapy, 2022, 151: 113188.

992.  ZHAO Y, LV J, YU H, et al. Dictamnine derivatives as a novel family of dual inhibitors for cholinesterase and β-amyloid aggregation [J]. Journal of Molecular Structure, 2023, 1293: 136222.

993.  ZHAO Y, ZHAN J-K, LIU Y. A perspective on roles played by immunosenescence in the pathobiology of Alzheimer's disease [J]. Aging and disease, 2020, 11(6): 1594.

994.  ZHENG C. Effect of a Canton herbal tea on the toxicity of amyloid-beta peptide in cell culture and a transgenic mouse model of Alzheimer's disease [J]. HKU Theses Online (HKUTO), 2021.

995.  ZHENG H, WANG C, CHEN J, et al. Policy evolution and analysis of characteristics and values of China’s marine seed industry development under the food security strategy [J]. Marine Policy, 2023, 155: 105681.

996.  ZHENG Q, WANG S, WANG T, et al. Efficacy of Stem Cell-derived Extracellular Vesicles in the Treatment of Alzheimer's Disease Model Mice: A Systematic Review and Meta-analysis [J]. Current Stem Cell Research & Therapy, 2025.

997.  ZHENG R, SHI S, ZHANG Q, et al. Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer’s disease by regulating microbiome via network pharmacology and molecular docking analysis [J]. Frontiers in Cellular and Infection Microbiology, 2023, 13: 1140945.

998.  ZHENG R, SHI S, ZHANG Q, et al. Molecular mechanisms of Huanglian Jiedu decoction in treating Alzheimer's disease by regulating microbiome via network pharmacology and molecular docking analysis [J]. Frontiers in Cellular and Infection Microbiology, 2023, 13: 1140945-.

999.  ZHENG X, TANG Y, YANG Q, et al. Effectiveness and safety of anti‐tau drugs for Alzheimer's disease: Systematic review and meta‐analysis [J]. Journal of the American Geriatrics Society, 2022, 70(11): 3281-92.

1000.  ZHONG S-R, KUANG Q, ZHANG F, et al. Functional roles of the microbiota-gut-brain axis in Alzheimer’s disease: Implications of gut microbiota-targeted therapy [J]. Translational Neuroscience, 2021, 12(1): 581-600.

1001.  ZHOU C, FENG X, LIU H, et al. Bidirectional modulation of Alzheimer’s disease via gut microbiota: rescue by fecal transplantation from healthy donors and aggravation by colitis-associated dysbiosis [J]. Frontiers in Neuroscience, 2025, 19: 1593854.

1002.  ZHOU G, YIN Y, HUAN X, et al. The potential role of the brain–gut axis in the development and progression of Alzheimer's disease [J]. Journal of Translational Internal Medicine, 2022, 10(2): 89-91.

1003.  ZHOU L. Using genetic and therapeutic approaches to study the role of Caspase-6 in Alzheimer disease [J]. 2021.

1004.  ZHOU X, LU J, WEI K, et al. Neuroprotective Effect of Ceftriaxone on MPTP‐Induced Parkinson’s Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota [J]. Oxidative Medicine and Cellular Longevity, 2021, 2021(1): 9424582.

1005.  ZHOU Y, MENG H, DING N, et al. Whey protein hydrolysate intervention ameliorates memory deficits in APP/PS1 mice: Unveiling gut microbe–short‐chain fatty acid–brain axis [J]. Food Frontiers, 2024, 5(5): 2171-87.

1006.  ZHOU Z, CHEN X, SHENG H, et al. Engineering probiotics as living diagnostics and therapeutics for improving human health [J]. Microbial Cell Factories, 2020, 19: 1-12.

1007.  ZHU C, MA S, ZHANG S, et al. Structural characterisation of a homogeneous polysaccharide from Gastrodia elata Bl. and its effects on two models of Alzheimer's disease [J]. International Journal of Biological Macromolecules, 2025: 143987.

1008.  ZHU C-C, FU S-Y, CHEN Y-X, et al. Advances in drug therapy for Alzheimer’s disease [J]. Current medical science, 2020, 40(6): 999-1008.

1009.  ZHU F, LI C, CHU F, et al. Target dysbiosis of gut microbes as a future therapeutic manipulation in Alzheimer’s disease [J]. Frontiers in aging neuroscience, 2020, 12: 544235.

1010.  ZHU G, GUO M, ZHAO J, et al. Integrative metabolomic characterization reveals the mediating effect of Bifidobacterium breve on amino acid metabolism in a mouse model of Alzheimer’s disease [J]. Nutrients, 2022, 14(4): 735.

1011.  ZHU M, LIU X, YE Y, et al. Gut microbiota: a novel therapeutic target for Parkinson’s disease [J]. Frontiers in immunology, 2022, 13: 937555.

1012.  ZHU X, FU B, DONG M, et al. Effects of long-term antibiotic treatment on mice urinary aromatic amino acid profiles [J]. Bioscience Reports, 2021, 41(1).

1013.  ZHU Y, WANG X, LU S, et al. Microwave-assisted synthesis of highly sulfated mannuronate glycans as potential inhibitors against SARS-CoV-2 [J]. Organic & Biomolecular Chemistry, 2024, 22(19): 3986-94.

1014.  ZHU Y, XU H, YU C, et al. Polymers for the treatment of Alzheimer’s disease [J]. Frontiers in Pharmacology, 2025, 16: 1512941.

1015.  ZHU Z, LIAO L, QIAO H. Extracellular vesicle–based drug delivery system boosts phytochemicals’ therapeutic effect for neurodegenerative diseases [J]. Acupuncture and Herbal Medicine, 2022, 2(4): 229-39.

1016.  ZHUO L, ZHANG B, YIN Y, et al. Use of sodium‐glucose cotransporter‐2 inhibitors and risk of dementia: A population‐based cohort study [J]. Diabetes, Obesity and Metabolism, 2025, 27(5): 2430-41.

1017.  ZOU C, CAI R, LI Y, et al. β-chitosan attenuates hepatic macrophage-driven inflammation and reverses aging-related cognitive impairment [J]. Iscience, 2024, 27(9).

1018.  ZOU Z, LEI D, YIN Y, et al. Frequent fecal microbiota transplantation improves cognitive impairment and pathological changes in Alzheimer's disease FAD4T mice via the microbiota-gut-brain axis [J]. Heliyon, 2025, 11(5).

1019.  ZVĚŘOVá M. 10 Metabolický syndrom a jeho vliv na kognitivní funkce [J]. Gerontopsychiatrie v klinické praxi, 2022: 42.

1020.  БАЧУРИН С, БОВИНА Е, УСТЮГОВ А. Современные тенденции в создании препаратов для лечения болезни Альцгеймера и их клинические испытания [J]. Biomedical Chemistry: Research and Methods, 2018, 1(3): 00015-.

1021.  БЕЛОУСОВА А, ПТУШКО С, ТАНАЕВ Д, et al. ВЛИЯНИЕ МИКРОБИОТЫ КИШЕЧНИКА НА ЭФФЕКТИВНОСТЬ РАБОТЫ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ, ПРИМЕНЯЕМЫХ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС [J]. 2022.

1022.  БЕРЕЗОВСКИЙ В Б. ЧИТАЙТЕ В НОМЕРЕ [J].

1023.  ВОРОБЬЕВ С, ЕМЕЛИН А, ЯНИШЕВСКИЙ С. Эволюция представлений о лечении болезни Альцгеймера: от прошлых лет до наших дней [J]. Российский неврологический журнал, 2022, 27(1): 5-15.

1024.  ЗАКЛЯЗЬМИНСКАЯ Е. Стратегическое планирование ключевых направлений науки и техники Китая в 14-й пятилетке (2021-2025 гг.); proceedings of the Новые горизонты экономики КНР в 14-й пятилетке (2021-2025 гг), F, 2022 [C].

1025.  ПОЗДНЯКОВ Д, ВИХОРЬ А, РУКОВИЦИНА В, et al. Аналоги халкона как потенциальные средства патогенетической терапии болезни Альцгеймера: in vitro-скрининг [J]. Вопросы биологической, медицинской и фармацевтической химии, 2024, 27(2): 43-7.

1026.  ПОЗДНЯКОВ Д, ЧИРЯПКИН А, КОДОНИДИ И. Новые производные 6, 7-диметоксихиназолин-4 (3H)-она как перспективные соединения для терапии болезни Альцгеймера [J]. Вопросы биологической, медицинской и фармацевтической химии, 2023, 26(4): 23-7.